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SUMMARY
Neurofibromatosis-1 is an autosomal dominant disorder with a 
prevalence of approximately 1 in 3000 individuals. Its manifestations involve 
tissues derived from the neural crest and include mainly cafe au lait spots, 
neurofibromas and Lisch nodules. The gene for NF-1 was identified in 1990 
and found to encode a protein, neurofibromin, with sequence similarity to a 
family of GTPase activating proteins (GAP). The region of homology is called 
the NF-1 GAP related domain (NF-1 GRD). Its expression has been shown to 
complement yeast strains deficient in the yeast GAP homologues IRA1 and 
IRA2 and to interact with human ras proteins and accelerate the conversion 
of active GTP bound ras to inactive GDP bound ras. Neurofibromin is also 
known to associate with cytoplasmic microtubules and the connection 
between ras mediated signal transduction and the cytoskeleton suggests that 
neurofibromin may play multiple roles in the regulation of cell division.
Neurofibromatosis type-1 is caused by mutations in the NF-1 gene. 
Mutation analysis in NF-1 is complicated due to the large size of the gene, 
which extends for over 300 kb on chromosome 17 and is made up of more 
than 49 exons, due to its high mutation rate and due to the presence of NF-1 
pseudogenes and homologous sequences.
The present study involved the characterisation of germline and somatic 
mutations within the NF-1 gene. Characterisation of germline mutations was 
carried out in 25 randomly selected, unrelated patients with 
neurofibromatosis type-1 from Scotland and included both inherited and 
sporadic cases. Characterisation of somatic mutations was carried out in 
tumours unrelated to NF-1, to assess the tumour suppressor function of the 
NF-1 gene.
The strategy for germline mutation analysis involved initial amplification 
of the NF-1 coding sequence by the polymerase chain reaction (PCR) using 
both DNA and RNA as templates. In order to do so, PCR primers were 
designed to amplify 78% the NF-1 coding sequence. Primers for amplification 
of selected individual exons from genomic DNA were also designed. After 
initial amplification by PCR, the products were electrophoresed on agarose 
gels in order to check for any abnormal alterations in size. If no alteration 
was identified, the segments amplified using DNA as a template i.e. 
individual exons of the NF-1 gene were analysed using single stranded 
conformational analysis and chemical cleavage analysis. The segments 
amplified using RNA as a template were larger in size (0.4-1 kb) and thus 
were directly subjected to chemical cleavage analysis, to precisely locate the 
presence of small alterations or point mutations within the NF-1 gene. Any 
mismatch detected by chemical cleavage was then fully characterised using 
direct sequencing by the dideoxy chain termination method, using single 
stranded DNA generated by asymmetric PCR amplification. Larger 
rearrangements within the NF-1 gene were screened by Southern blotting of 
genomic DNA.
Using the above strategy, 17 positive screening results were detected on 
analysis of 78% of the coding sequence in 25 patients. Of these, 13 have 
been characterised by direct sequencing. The mutations include three splice 
site errors responsible for exon skipping, two other gross abnormalities of the 
NF-1 mRNA resulting from a partial deletion in exon 16 and the complete 
deletion of exon 18, two insertions, a nonsense mutation, two missense 
mutations, three silent mutations and a novel intragenic polymorphism in 
intron 41.
The mutation 3113+1G to A affected the splice donor site of intron 18 
and resulted in the skipping of exon 18 from the NF-1 mRNA. This loss of 
exon 18 did not cause a shift in the reading frame and is predicted to result in 
a loss of 41 amino acids from the protein product. The 41 amino acids lost 
include two cysteine residues at positions 1016 and 1036, whose loss may 
lead to altered conformation / stability of neurofibromin. This mutation was 
identified in a familial case of NF-1.
5749+2T to G is a splice site mutation that affects the invariant GT 
dinucleotide of the splice donor site of intron 30 and was identified in a 
sporadic case of NF-1. This mutation resulted in the skipping of exon 30 and 
a shift in the translational reading frame. This is predicted to result in a 
truncation of the protein product due to the translation of a single altered 
amino acid before the termination at a premature stop codon at position 
1851.
1721+3A to G is a splice site mutation at position +3 of the donor site in 
intron 11 and was identified in a familial case of NF-1. This transition resulted 
in an error of splicing, leading to skipping of exon 11 from the NF-1 mRNA. 
This is predicted to cause a shift in the translational reading frame, resulting 
in the formation of 12 altered amino acids and the creation of a premature 
stop codon at position 560. This would result in the synthesis of a protein of 
559 amino acids instead of the normal 2818 amino acids, which would lack 
the NF-1 GAP related domain.
Two other gross abnormalities of the NF-1 mRNA were identified by RT- 
PCR and confirmed by direct sequencing. These included a 229bp deletion 
in exon 16, identified in a sporadic case of NF-1 and a complete deletion of 
exon 18 from the NF-1 mRNA, in a familial case of NF-1. Sequence analysis
of the region surrounding exon 18 revealed a novel homologous sequence to 
the NF-1 gene in this region.
Four small alterations were detected within the NF-1 gene on analysis of 
the cDNA segments. These were as follows: A missense mutation G1166D at 
codon 1166 in exon 21, caused by a G to A substitution at nucleotide 3497 
was identified in a familial case of NF-1. K1419R is a missense mutation at 
codon 1419 in exon 24, caused by an A to G transition at nucleotide 4256. 
This mutation created a Mnl I site and was identified in a sporadic case of 
NF-1. G1404G is a silent mutation at codon 1404 in exon 24, caused by a G 
to A substitution at nucleotide 4212. This mutation created an Apo I site and 
was identified in a sporadic case of NF-1. S1311S is a silent mutation at 
codon 1311 in exon 23, caused by a C to T substitution at nucleotide 3933. 
This mutation resulted in the loss of a Fok I restriction site and was identified 
in a familial case of NF-1.
Exons 28-36 and 42-44 were amplified from genomic DNA and were 
subjected to SSCP and chemical mismatch cleavage analysis. Positive 
screening results were further characterised using direct sequencing. The 
mutations identified on screening these exons were as follows: A single base 
insertion of guanine, 6519insG was detected in exon 34 that resulted in a 
shift in the reading frame and premature termination of translation at codon 
2220. This mutation was identified in a familial case of NF-1. R2496X is a 
nonsense mutation in exon 42, caused by the conversion of a C to T at 
nucleotide 7486. This transition, at a hypermutable CpG dinucleotide, 
converts an Arginine to a termination codon at position 2496. This mutation 
was identified in a sporadic case of NF-1. 7485insGG is a frameshifting two 
base insertion in exon 42, predicted to cause the translation of 5 altered 
amino acids before creating a premature stop codon at position 2502. A
consequence of this mutation will be the synthesis of a truncated protein 
product of 2501 amino acids instead of the normal 2818 amino acids. 
Interestingly, the insertion was found to affect the same codon (Arginine 
2496) which was converted to a premature stop codon in the previous patient 
(R2496X) and was identified in a sporadic case of NF-1. N1776N is a silent 
mutation at codon 1776 in exon 29, caused by a C to T substitution at 
nucleotide 5328. This mutation created a Hinf I restriction site and was 
identified in a sporadic case of NF-1.
A novel intragenic polymorphism was identified in intron 41, the change 
being that of an A to G transition, 28 bases upstream of the first base of exon 
42. 75 unrelated Caucasian individuals of Scottish origin were studied by 
heteroduplex analysis which showed three distinct electrophoretic patterns 
and an allele heterozygosity of 47% was calculated. This polymorphism will 
be useful in families where the disease causing mutation remains to be 
identified.
Four other chemical cleavage results were detected on analysis of the 
NF-1 cDNA segments and were localised to exons 2, 4, 16 and 27a. Two 
possible polymorphisms were detected, in exon 16 (as the same cleavage 
product was identified in 4 different patients) and in exon 28, where SSCP 
analysis revealed three distinct patterns.
An interesting feature presented in a case of segmental 
neurofibromatosis on RT-PCR of the NF-1 mRNA surrounding the 
alternatively spliced isoform of the NF-1 gene, NF-1 GRD II. Amplifcation and 
analysis revaled equal expression of both isoforms in this patient, while the 
other patients and normal controls showed expression of only the type I 
isoform. This may not be the cause of disease but was the only finding on 
screening 78% of the coding sequence.
The spectrum of the above 13 and other reported mutations within the 
NF-1 gene is discussed and their mechanisms of mutagenesis are presented. 
The distribution of mutations was random and in this study no additional 
mutation hotspots were identified on analysis of 78% of the coding sequence. 
However the remaining 22% of coding sequence and other regions important 
for efficient expression remain to be analysed. A genotype-phenotype 
correlation is presented, which will help in drawing conclusions regarding the 
function of the various regions within the NF-1 gene and may help in 
determining the molecular basis for the wide variation in clinical features.
Screening for somatic mutations (small alterations) in exon 24 (FLR 
exon) of the NF-1 gene (by SSCP and CCM) was carried out in the following 
nine tumour types unrelated to NF-1: colonic adenocarcinoma (2), colonic 
adenoma (2), pancreatic carcinoma (2), seminoma (2), melanoma (3), lung 
adenocarcinoma (2), thyroid carcinoma (2) and myelodysplastic syndrome 
(10). Screening for large alterations (by Southern and Northern blotting) was 
carried out in 4 neuroblastoma samples.
The role of NF-1 mutations was considered in the tumour types in which 
activated ras genes are frequently found. NF-1 mutations, considered to be 
the functional complement of ras mutations, were looked for in tumour 
samples lacking ras mutations. Initially the tumour samples were screened 
for activating mutations in the appropriate group of ras oncogenes (H-RAS, 
K-RAS, or N-RAS) depending on the tumour type. Two shifts on SSCP 
analysis were identified in the PCR products encompassing codons 12-13 of 
the K-ras oncogenes in a colonic adenoma sample and a colonic 
adenocarcinoma sample. No small or large somatic mutations in the NF-1 
gene were detected in the tumour types analysed in this study.
Thus in this study a heterogeneous group of germline mutations was 
identified in the NF-1 gene and a mutational spectrum was established. The 
majority of germline mutations identified and characterised in this study are 
predicted to cause disruption of the protein product neurofibromin. 
Correlation of genotype with the phenotype in the cases with pathogenic 
mutations characterised in this study did not show a clear correlation and a 
larger number of mutations will have to be analysed.
The strategy used in this project for characterisation of mutations in the 
gene for neurofibromatosis type-1 has proved to be useful and may be 
applied to the detection of molecular pathologies in general.
Note: Some of the data presented in this thesis have been published. 
Reprints are bound at the back.
CHAPTER: 1 
INTRODUCTION
CHAPTER 1: INTRODUCTION
1.1 HOW MUTATIONS CAUSE DISEASE
The gene is the unit of inheritance. Each gene is a nucleic acid 
sequence that carries information representing a particular polypeptide. A 
gene is a stable entity, but can acquire a change in the base sequence. Such 
a change is called a 'mutation'. When a mutation occurs, the new form of the 
gene is inherited just like the previous form. The organism carrying the 
altered gene is called a mutant and an organism carrying the normal 
(unaltered) gene is called the wild type. Mutations can be divided into two 
general classes: point mutations and rearrangements or length mutations. 
Point mutations are changes affecting a single position in a gene, 
rearrangements or length mutations affect larger regions and the simplest 
type are insertions or deletions. Mutations will be copied at subsequent 
replications unless a reverse mutation occurs.
By and large mutations that produce disease manifest in two ways: 
mutations which cause synthesis of an abnormal gene product and those 
which cause a reduction or absence of a protein product. Mutations which 
cause synthesis of an abnormal gene product comprise single base 
substitutions (missense mutations) which alter the structure of the mRNA 
such that an abnormal protein product is synthesised. The change in function 
or stability of the protein results in an abnormal phenotype. Mutations 
causing decreased output or absence of gene product are mutations 
affecting transcription or processing of mRNA or mutations that act at the 
translational level by interfering with initiation, elongation or termination.
Mutations which lead to a greatly reduced level or no protein product 
are classified by immunological protein assay methods as cross reacting
material negative, (CRM -ve), whereas those mutations which produce a 
protein product in normal amounts but with aberrant function are CRM +ve. 
Mutations can occur in the coding sequences, which are the exons, that 
comprise mature RNA and the introns or intervening sequences (IVS), which 
are transcribed but then cut out of the transcript during mRNA processing. 
Although the boundaries of the coding sequences can be precisely defined, 
other less well defined sequences such as the promoters, enhancers and 5' 
and 3' untranslated regions are required to constitute a unit which is 
transcribed efficiently in the appropriate tissues and at the proper time.
1.1.1 MUTATIONS CAUSING SYNTHESIS OF AN ABNORMAL GENE 
PRODUCT
A single base substitution or a more subtle rearrangement of a gene 
may alter the structure of the mRNA such that an abnormal protein product is 
synthesised. Point mutations can be divided into two types depending upon 
the nature of the change when one base is substituted for another. The more 
common class of mutation is the TRANSITION, comprising the substitution of 
one pyrimidine by the other or of one purine by the other. The other class is 
the TRANSVERSION, in which the purine is replaced by a pyrimidine or vice 
versa.
Mutations induced by a base substitution are often 'leaky' (the mutant 
has some residual function). This situation arises when the sequence change 
in the corresponding protein does not entirely abolish its activity. A point 
mutation that alters only a single base will change only the one codon in 
which that base is located so only one amino acid is affected in the protein. 
While this substitution may reduce the activity of the protein, it may not 
abolish it entirely.
Some single base substitutions have no apparent effect and they fall 
into two types: One group involves base changes in DNA that do not cause 
any change in the amino acid present in the corresponding protein and are 
called silent mutations. Others change the amino acid (usually with an amino 
acid of the same class-basic / acidic / neutral, hydrophilic / hydrophobic) but 
the replacement in the protein does not affect its activity and the phenotypic 
effects are small. These are called neutral substitutions, or conservative 
changes.
The results of single amino acid substitutions in proteins vary 
depending on the type of amino acid that is substituted and the site of 
substitution in a particular protein. However, many amino acid substitutions 
have no effect on function or stability. The primary amino acid sequence of a 
protein or its subunits determines the way it assumes its secondary structure. 
Some amino acid substitutions in the primary amino acid sequence go on to 
cause abnormalities of a tertiary structure and to reduce the overall stability 
of the protein or its subunit. For example, proline cannot participate in an 
alpha helix except as one of the initial three residues. Thus the substitution of 
proline by another amino acid can sometimes seriously disrupt helical 
conformation and result in protein instability. Most proteins are folded into a 
complex tertiary configuration, so that most of the charged amino acids such 
as lysine, arginine, glutamic acid and aspartic acid are found on the surface 
of the molecule, allowing their ionised groups to be in contact with water. On 
the other hand, residues oriented towards the interior of the molecule have 
non polar groups; thus the inside of the molecule is stabilised by hydrophobic 
interactions. The substitution of a charged for an uncharged residue can 
disrupt these important interactions and lead to molecular instability.
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20 amino acids are used to synthesise proteins and are classified by 
their ionic charge into four groups (Lewin, 1993):
1)Basic: lysine, arginine and histidine 2)Acidic: aspartic acid and glutamic 
acid 3)Neutral and polar amino acids: amino acids that have no net charge 
are neutral. Some of the neutral amino acids are polar i.e. electrically 
charged because of the distribution of charges within the molecule. These 
are: glycine, serine, threonine, tyrosine, cysteine, glutamine, aspargine
A
4)Neutral and hydrophobic: the apolar amino acids are hydrophobic. These 
are: alanine, valine, leucine, isoleucine, proline, tryptophan, phenylalnine 
and methionine.
Occasionally, the substitutions may involve chain termination or 
initiation codons or may disrupt the genetic code such that either elongated 
or shortened peptide chain products are produced. Extended gene products 
result from the following mechanisms: base substitution in the chain 
termination codon or preservation of the initiator methionine residue. 
Shortened gene products are due to substitutions resulting in premature 
termination of translation.
1.1.2 MUTATIONS CAUSING DECREASED OUTPUT OF GENE PRODUCT 
The second group of mutations are those that cause a reduction or 
absence of a particular protein product. These mutations can be divided into 
mutations that cause defective transcription, defective processing of 
messenger RNA and mutations that interfere with translation.
Mutations causing defective transcription
These comprise deletions, insertions, inversions, duplications, fusion genes 
and promoter mutations.
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a)Deletions: e.g. DMD, cystic fibrosis etc. Deletions are the physical 
absence of DNA sequence. Deletions can result due to non-homologous 
recombination, from faulty repair of damaged DNA, or from a skip during 
DNA replication. The effects of gene deletions are as follows:
Table 1: Effects of gene deletions
Deletion of Consequences
many genes chromosomal abnormalities
one whole gene no gene function
exon material truncated protein, often unstable, may generate a 
frameshift
intron material usually no phenotypic effect
splice site usually no functional product/ or truncated product
promoter reduced/absent gene function
b)lnsertions: e.g. Lesch-Nyhan syndrome, Haemophilia B etc. Insertions 
may be large sequence insertions, or insertion of a few bases into gene 
coding regions causing disease. These involve insertion of either novel 
bases, or of a specific DNA sequence.
conversions: e.g. Haemophilia A. The term inversion signifies that a region 
of DNA is back-to-front with respect to its normal orientation in the genome.
d)Fusion genes: e.g. red/green colour blindness. There are three separate 
genes for each of the cone pigments responsible for colour vision, blue (on 
chromosome 7) and red and green (Xq28). There is a single red gene on 
each X chromosome and 1 -3 copies of the green genes. The red and green 
genes have 96% sequence homology and unequal crossing over in the area 
can result in the formation of hybrid genes or fusion genes, which produce 
pigments of altered function.
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e)Promoter mutations: e.g. haemophilia B (Leyden), retinoblastoma.
The haemophilia B Leyden phenotype is seen in patients with different 
mutations within the promoter region of the factor IX gene.
f)Duplications: e.g. CMT1A, DMD/BMD. Duplications can be tandem or 
inverted. Duplication of a whole gene will cause dosage effects only, but 
partial duplications can result in disease in two general ways: In one, 
duplication of several amino acids of a protein may change the protein 
conformation, leading to an unstable / dysfunctional protein. In the other, the 
duplication may result in a reading frame shift in the mRNA, producing a 
truncated and usually dysfunctional protein.
Mutations causing defective processing of messenger RNA 
These comprise splice junction and consensus site mutations, mutations 
creating cryptic splice sites in exons and introns and polyA signal site 
mutations.
a)Splice junction and consensus sequence mutations: e.g. Ehler Danlos 
syndrome, a and (3 thalasaemia. Splice site mutations alter the 5' donor (GT) 
or 3' acceptor (AG) sequences at the ends of an intron which are required for 
excision of the intron during mRNA processing and usually abolish gene 
function. In addition to the GT/AG junctional sequences, there are highly 
conserved sequences at the boundaries between introns and exons that also 
must be involved in splicing of mRNA. Several forms of (3 thalassaemia are 
described, which result from the production of alternatively spliced sites 
within these sequences.
b)Cryptic splice sites in introns and exons e.g. |3 thalassaemia. In p 
thalassaemia, single base substitutions within introns may result in 
preferential alternative splicing of the precursor p mRNA molecules at the
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site of mutation. The mRNA produced as a result of the abnormal splicing 
contains intron sequences and therefore is useless as a template for globin 
chain synthesis, so more abnormal than normal mRNA is produced.
Mutations have been also found in the exons of the globin genes that seem 
to activate cryptic splice sites, e.g.: The structural haemoglobin variant 
haemoglobin E, due to a G to A transition at position 26 results in the 
activation of a cryptic spice site, which competes with the normal splice site 
and leads to a reduced output of p globin chains.
c)Polyadenylation/cleavage signal mutations: e.g. a and p thalassaemia. 
Polyadenylation signal site mutations also interfere with the normal 
processing of mRNA. For example, the single base change AATAAA to 
AATAAT, in the a globin genes of patients with a certain form of a 
thalassaemia. Due to the mutation, instead of the normal cutting and 
polyadenylation of the mRNA precursor, a long molecule is produced which 
does not appear in the cytoplasm. A small amount of polyadenylated mRNA 
is produced, but the overall effect is to almost entirely inactivate the affected 
globin gene.
Mutations causing defective translation
These comprise initiation codon mutations, termination codon mutations, 
nonsense mutations and frameshift mutations.
a)lnitiation codon mutations: e.g. phenylketonuria, Tay-Sachs disease and 
a & p thalassaemia. Several mutations have been observed in patients with a 
thalassaemia which involve either the initiation codon itself or the sequences 
immediately adjacent to it and no a chains are produced from the affected a 
globin gene.
7
b)Termination codon mutations: e.g. a thalassaemia. Termination codon 
mutations have been observed only in the a globin genes. The base 
alteration results in the insertion of an amino acid instead of chain 
termination. Messenger RNA sequence that is not normally utilised is then 
translated until another in-phase stop codon is reached, resulting in 
elongated but stable a chains (Hb Constant Spring).
c)Nonsense mutations: e.g. Haemophilia A, B, Lesch-Nyhan, OTC 
deficiency, porphyrias. Nonsense mutations replace the codon for an amino 
acid by a stop signal (UGA, UAA, UAG) leading to premature chain 
termination, with the production of a shortened and physiologically useless 
peptide fragment.
d)Frameshift mutations: e.g. Duchenne muscular dystrophy. Frameshifts 
are a consequence of the way the genetic code in the mRNA is read in 
triplets. Any change in the number of nucleotides in a coding sequence which 
does not add or remove complete triplets alters the reading frame of all the 
message downstream of the change. Frameshifts usually abolish the function 
of the protein. Sometimes the altered base sequence generates a new 
termination codon leading to premature termination of translation of the 
abnormal RNA. If the normal stop codon is thrown out of sequence, the 
scrambled mRNA is translated until another stop codon is produced, leading 
to an elongated translation product.
1.2 MECHANISMS OF MUTAGENESIS
Cytosine methylation and the role of CpG dinucleotides in disease
The methylation of mammalian DNA at the cytosine residues, is one of 
the most common forms of DNA modification and is involved in a number of 
cellular and developmental processes (Cooper and Youssoufian, 1988). The
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dinucleotide CpG is a hotspot for mutation in the human genome. This is as a 
result of the modification of the 5' cytosine by cellular DNA 
methyltransferases and the consequent high frequency of spontaneous 
deamination of 5-methylcytosine. Methylated cytosine residues are relative 
hotspots for mutations (25-35% of all point mutations) because with 
deamination they produce thymidine (with substitution of adenine for guanine 
on the complementary strand), which is not recognised by DNA repair 
mechanisms and thus results in mutation (Cooper and Krawczak, 1991).
Mechanisms of insertional mutagenesis
Insertions of either novel bases or of a specific DNA sequence into a 
gene coding region usually result in alteration of the reading frame of the 
encoded protein, which may lead to termination of translation at some 
distance downstream. Examples of the insertion of <10bp of DNA sequence 
into human gene coding regions causing genetic disease was analysed by 
Cooper and Krawczak (1991), in order to study the underlying mechanisms 
and the following observations were made: insertional mutation, involving the 
introduction of <10bp of DNA sequence into a gene coding region is not a 
random process and appears to be highly dependent on the local DNA 
sequence context. The majority of insertion type mutations are consistent 
with an explanation which involves an endogenous replication associated 
mechanism of mutagenesis and may be explained either in terms of a)direct 
repeats/runs of single bases causing slipped mispairing b)inverted repeats or
c)symmetric elements facilitating the formation of secondary structure 
intermediates.
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Mechanisms of deletional mutagenesis
Deletional events in human genes are at least in part sequence 
directed and the frequency of occurrence reflects underlying structural 
differences between genes. Human gene deletions appear to be caused by 
multiple mechanisms, whose relative importance is influenced by local 
primary and secondary DNA structure. Reports describing short (<20bp) 
gene deletions causing human disease were analysed by Krawczak and 
Cooper (1991) in order to study underlying causative mechanisms. Direct 
repeats are a feature of a number of recombination, replication or repair 
based models of deletion mutagenesis. Palindromes or inverted repeats 
could potentiate the looping out of single stranded DNA. Inverted repeats 
may promote instability by facilitating the formation of secondary structure 
intermediates. A significant excess of symmetrical sequence elements was 
found at the sites of single base deletions. These elements were seen to 
possess an axis of internal symmetry (e.g. CTGAAGTC, GGACAGG) and 
varied between 5bp and 11 bp in length. In addition a consensus sequence 
proposed to be hot-spot for deletions was drawn up: (TGA/GA/GGrTA/C).
Mechanisms of gene duplication
Tandem duplication involving parts of genes is now recognised as a 
contributor to the mutational spectrum that results in genetic disease. The 
mechanisms of duplication formation were analysed by Hu and Worton 
(1992), with special emphasis on the molecular details of the nucleotide 
sequences at the duplication junctions. Partial gene duplication can result in 
disease in two general ways. In one, duplication of several amino acids of a 
protein may change the protein conformation, leading to an unstable / 
dysfunctional protein. In the other, the duplication may result in a reading 
frame shift in the mRNA producing a truncated and usually dysfunctional
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protein. Two general mechanisms leading to duplications and deletions have 
been proposed: homologous and non-homologous recombination. In the 
former sequence homology between the two parental strands in the regions 
of cross-over is needed for strand exchange. Homologous recombination 
may involve recombination between repetitive sequences, i.e. the Alu 
elements. Non homologous recombination involves recombination between 
unrelated (non-homologous) sequences and probably the duplications may 
have been created by random chromatid cleavage and rejoining events. 
Unequal sister chromatid exchange, i.e. unequal crossing over between 
sister chromatids, rather than between non-sister chromatids of two X 
chromosomes, is the predominant event for producing duplications in the 
dystrophin gene.
Expansion of trinucleotide repeats as a mechanism of mutagenesis
The unstable expansion of trinucleotide repeats represents one of the 
previously unrecognised mechanism of mutagenesis and so far seven 
examples of triplet repeat diseases are known. These are as follows: fragile 
X syndromes (FRAXA and FRAXE) (Fu et al., 1991), myotonic dystrophy 
(DM) (Fu et al., 1992), Kennedy's disease (spinal and bulbar muscular 
atrophy SBMA) (La Spada et al., 1991), Huntington's disease (The 
Huntingtons Disease Research Collaborative Group, 1993), spinocerebellar 
ataxia (Orr et al., 1993) and the most recently discovered DRPLA 
(dentatatorubral and pallidoluysian atrophy) (Koide et al., 1994). All the 
diseases are due to a novel mutational mechanism by which normally 
polymorphic trinucleotide repeats expand beyond the normal size range and 
result in changes involving gene expression (FRAX), message stability (DM), 
or gain of function (SBMA and HD).
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1.3 MUTATION SCREENING METHODS
The spectrum of mutations found may range from cytogenetically 
visible chromosome rearrangements to large and small alterations within the 
gene, including single base changes. The mutation screening methods can 
be divided into screening methods for detection of unknown mutations (small 
and large alterations) and methods for detection of known mutations (Loss or 
gain of an RFLP, ARMS, ASO and PCR directed mutagenesis). While 
several useful techniques for detection of sequence heterogeneity exist, no 
single method is applicable for all situations. The different methods used 
have complementing strengths and a combination of methods can be used 
successfully for mutation detection. The various methods are outlined below 
and the principles, advantages and disadvantages are discussed and 
compared in to order to evaluate the screening methods available and apply 
them to screen for mutations within the NF-1 gene.
Detection of small alterations
Small alterations include deletions, insertions and single base 
substitutions which comprise nonsense, missense, silent and splice 
mutations. All the methods used are PCR based detection methods and rely 
on PCR amplification of sample DNA or RNA prior to analysis. The methods 
discussed include: 1)Single stranded conformation polymorphism analysis 
(SSCP), 2)Heteroduplex analysis (HA) 3)Denaturing gradient gel 
electrophoresis (DGGE), 4)RNase cleavage and chemical mismatch 
cleavage analysis (CCM), 5)Protein truncation test (PTT), 6)Direct 
sequencing and its modifications.
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Single Stranded Conformational Polymorphism (SSCP) Analysis
This procedure was first described by Orita et al. (1989). Single stranded 
DNA molecules assume a three-dimensional conformation which is 
dependent on the primary sequence. If a sequence difference exists between 
wild type and mutant DNA, this may result in differential migration of one or 
both the mutant strands when the products are denatured and then 
electrophoresed through a non denaturing polyacrylamide gel, under 
different sets of electrophoretic conditions. It is a simple and relatively 
sensitive technique, with no additional steps required after PCR. A large 
number of samples can be analysed simultaneously. However, SSCP 
analysis detects mutations but does not localise them within a fragment. 
SSCP analysis detects 70-95% of mutations in PCR products of 200bp or 
less and the sensitivity of the method is less than 50% when fragments 
>400bp are analysed (Grompe M., 1993). To increase the sensitivity of the 
technique, a radioactive label may be necessary, but silver staining of the 
gels also shows equally good results. Size limitations may be overcome by 
restriction digestion of a larger amplification product prior to electrophoresis. 
Occasionally there may be occurrence of additional bands which may 
correspond to different stable conformations (conformers) of the same 
sequence and whose presence may be sensitive to the temperature 
employed.
A modification of SSCP termed RNA conformation polymorphism 
analysis (rSSCP) has been described by Sarkar et al. (1992a). RNA is used 
instead of DNA, the RNA being generated by T7 RNA polymerase 
transcription, from a PCR amplified DNA template fragment. Sense and 
antisense RNA strands yielded different conformational patterns and this 
method has been claimed to be more successful than conventional SSCP
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(Sarkar et al, 1992a). A second modification is the dideoxy fingerprinting 
(ddF) method, which combines SSCP analysis and direct sequencing and 
was described by Sarkar et al. (1992b). After amplification the PCR product 
is sequenced with dideoxyCTP to generate a C-ladder (fingerprint) of bands. 
The sequencing reactions from wild type and mutant samples are then 
electrophoresed through a non denaturing polyacrylamide gel. Mutations are 
detectable as shifts of individual bands in the ladder. Another modification of 
SSCP was proposed by Lazaro and Estivill, (1992). Their assay consisted of 
generation of single stranded fragments by asymmetric PCR, which were 
then subjected to SSCP analysis and visualised by ethidium bromide 
staining.
Heteroduplex analysis
Mutant and wild-type sequences, when present simultaneously in a 
PCR reaction, form heteroduplexes during the late cycles in a PCR reaction 
(Nagamine et al., 1989). Heteroduplex molecules with a single base pair 
variance may show different mobility from homoduplexes in regular 
polyacrylamide gels (White et al., 1992), as well as other newer 
polyacrylamide based gel matrices such as Hydrolink™ and MDE™, due to 
sequence dependent conformational changes in the dsDNA (Tassabehji et 
al., 1992). The technique is very simple and is equally effective using non­
isotopic detection methods (ethidium bromide staining) and detects 80-90% 
changes in fragments less than 300bp (Grompe M., 1993). However it cannot 
be solely used as a mutation detection technique due to its inability to detect 
all types of mutations and due to the fact that there is decreased sensitivity 
when large products are analysed.
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Denaturing gradient gel electrophoresis (DGGE)
DGGE is also a technique that allows the separation of DNA 
molecules differing by single base changes due to differential electrophoretic 
migration of wild type and mutant DNA (Fischer and Lerman, 1983, Myers et 
al., 1985). The separation is based on the fact that DNA molecules differing 
by a single base change have slightly different melting properties. These 
cause them to migrate differently into discrete sequence dependent domains 
of low melting temperature, in a polyacrylamide gel containing a linearly 
increasing gradient of DNA denaturants such as urea and formamide, from 
top to the bottom of the gel. There are two types of denaturing gradient gels,
a)parallel gels which contain a linearly increasing gradient of DNA 
denaturants from top to bottom in the gel. b)perpendicular gels which contain 
a linear gradient of denaturants from left to right across the gel. The 
denaturing gradient can also be generated by temperature and this method is 
termed TGGE. The sensitivity of DGGE is greatly enhanced if heteroduplex 
DNA between wild type and mutant sequences is used for analysis (Sheffield 
et al., 1989). Wild type and mutant PCR products are denatured and 
reannealed to generate four species of hetero and homoduplexes. 
Differential melting behaviour of these heteroduplexes leads to altered 
migration in a gradient of denaturing gels compared to wild type homoduplex. 
Once the appropriate PCR primers and denaturant conditions (using 
computer programs to predict theoretical melting profiles and design PCR 
primers) have been developed for a specific region DGGE is a highly 
reliable and rapid method for mutation detection. Single base differences can 
be detected with about 95% accuracy in PCR products of up to 600bp in 
length and detection is usually carried out by non-radioactive means 
(Grompe M., 1993). However this method requires a special apparatus to
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control gel temperature and long PCR primers which include a 30-40 
nucleotide "GC clamp" at the 5' end of the primer to ensure that the amplified 
sequence has a low dissociation temperature (Sheffield et al., 1989, Myers et 
al., 1985). Also the location of the sequence difference within the fragment 
cannot be localised and has to be determined by sequencing.
RNase cleavage and Chemical mismatch cleavage analysis
The principle of heteroduplex analysis is applicable to both RNase 
and chemical mismatch cleavage and the two procedures were described by 
Myers et al. (1985) and Cotton et al. (1988), respectively.
In RNase A cleavage an RNA-DNA heteroduplex between a 
radioactive wild type riboprobe and mutant DNA generated by PCR is 
subjected to cleavage by RNase A. The enzyme will recognise and cleave 
single stranded RNA at the points of mismatch. The reaction is analysed by 
electrophoresis and autoradiography. The presence and location of the 
mutation is indicated by a cleavage band of a given size. However use of 
radiolabelled RNA is necessary and RNase A can detect only 50% of 
mismatches.
Chemical mismatch cleavage analysis (CCM) is based on the principle 
of creation of heteroduplexes between radiolabelled wild type and mutant 
DNA or RNA molecules. Chemical modification at the sites of mutation is 
then carried out using hydroxylamine and osmium tetroxide. This is then 
subjected to cleavage at the site of modification using piperidine followed by 
denaturing gel electrophoresis and autoradiography. CCM is very sensitive 
detecting > 95% of mismatches when only the wild type DNA is labelled and 
100% when both wild type and mutant DNA are labelled (Forrest et al., 
1991). PCR products of up to 1.7kb can be screened, permitting efficient
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screening of amplified mRNAs (Grompe M., 1993). Finally, the sequence 
alteration is detected reliably and the precise localisation and nature of the 
change is also indicated by the size of the cleavage band and cleaving 
reagent. However it is a relatively complex and lengthy procedure involving 
use of radioactivity and toxic chemicals.
Protein truncation test (PTT)
The above techniques, used to recognise point mutations in genetic 
disease detect all sequence differences including phenotypically silent 
changes. Consequently the methods are not convenient to analyse mutations 
in large multiexonic genes where a large fraction of pathological point 
mutations produce early termination. The technique of PTT, or protein 
truncation test is based on the combination of RT-PCR, transcription and 
translation and selectively detects translation terminating mutations and was 
first described by Roest et al. (1993). This technique does not detect 
phenotypical ly silent alterations. The site of mutation is localised, so only a 
small part of the gene needs to be sequenced. Comparatively larger (2.4kb) 
stretches of coding sequence can be screened. However this method can 
only detect translation terminating mutations.
Direct sequencing
Direct DNA sequencing refers to the direct sequence analysis of PCR 
products without prior subcloning into sequencing vectors and can be a 
primary method of mutation detection, if the coding sequence of the gene to 
be screened is relatively small (Mgone et al., 1992). Direct sequencing 
involves the synthesis of a DNA strand by a DNA polymerase in vitro using a 
single stranded DNA template (Sanger et al., 1977). Template DNA is
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purified and annealed to a synthetic oligonucleotide primer. The DNA 
synthesis is carried out in 2 steps, the first a labelling step and the second 
the chain termination step using dideoxynucleotides. A radioactively labelled 
nucleotide is included in the synthesis so the labelled chain of variation can 
be visualised by autoradiography after separation by high resolution 
electrophoresis on denaturing gels. DNA sequencing defines the location 
and exact nature of the change and therefore is the necessary final step of 
any mutation detection method.
In order to sequence PCR products successfully by the conventional 
dideoxy termination protocol, it is essential to convert the double stranded 
product into a single stranded template for sequencing. The methods 
described are:
1)Asymmetric PCR: This is a modified type of PCR to produce single 
stranded DNA of a chosen strand and utilises an unequal or asymmetric 
concentration of the 2 amplification primers.(Gyllensten and Erlich, 1988). In 
asymmetric PCR, during the initial 15-25 cycles, most of the product 
generated is double stranded and accumulates exponentially. As the low 
concentration primer becomes depleted, further cycles generate an excess of 
one of the two strands depending on which of the amplification primers is 
limited. The primer ratios used for asymmetric PCR are usually 
50pmoles:1pmol or 100pmoles:1pmol. The single stranded DNA accumulates 
linearly and is complementary to the limiting primer.
2)Biotinylation of one of the primers: In this method, one of the PCR primers 
is biotinylated. After the reaction the double stranded PCR product is 
captured on an avidin coated magnetic bead. The nonbiotinylated strand is 
separated with NaOH and the sequencing reactions are carried out on the 
immobilised single stranded template (Gibbs et al., 1990).
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3)Direct sequencing with phage promoters:
This can be done in two ways: RAWTS: RNA amplification with transcript 
sequencing and GAWTS: genomic amplification with transcript sequencing 
(Stoflet et al., 1988). In this method, the original PCR primers carry 17 RNA 
polymerase binding sites. In vitro transcription is then used to generate 
single stranded template for sequencing. These are methods of direct 
sequencing that utilise a phage promoter sequence 5' to at least one of the 
PCR primers. RAWTS is a four step procedure that involves:
a)cDNA synthesis with oligo dT random primers or an mRNA specific 
oligonucleotide primer.
b)A PCR in which one or both nucleotides contain a phage promoter 
attached to a sequence complementary to the region to be amplified.
c)Transcription with a phage polymerase and d)dideoxysequencing with a 
reverse transcriptase.
The procedure for GAWTS is identical except that genomic DNA is the input 
to step b). The advantages of this procedure are that the transcription step 
produces an additional level of amplification that obviates the need for 
purification subsequent to PCR; the amplification afforded by transcription 
can compensate for a sub optimal PCR; and the generation of single 
stranded template provides a more reproducible sequence than obtained 
from a double stranded template. The disadvantages include the fact that 
there is added expense of attaching phage promoters to the PCR primers.
Detection of large alterations:
Large gene alterations are mutations in which substantial portions of a 
gene are deleted, duplicated or otherwise rearranged. The techniques 
available for detection of large alterations can be divided into cytogenetic
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techniques and molecular techniques. Cytogenetic techniques include:
a)Cytogenetic analysis using conventional and high resolution cytogenetics,
b)Flow cytometry using FACS (fluorescence activated cell sorter) and
c)Fluorescent In Situ Hybridisation (FISH). Molecular techniques include
a)Southern blot hybridisation and b)pulsed field gel electrophoresis (PFGE). 
1 )Using cytogenetic techniques: Flow cytometry can be used to measure the 
DNA content of individual chromosomes as they pass in a fluid stream 
through the laser beam of a FACS (fluorescence activated cell sorter). This 
technique is useful in identifying chromosome aberrations in particular 
microdeletions as its lower limit of resolution is 1-2Mb compared with 4Mb for 
the light microscope used in conventional cytogenetics. FISH utilises 
fluorescently labelled DNA probes hybridised to chromosome spreads, to 
detect the presence/absence of a chromosomal region corresponding to the 
probe and its position within the genome.
2)Using molecular techniques: a)Southern blot hybridisation: this technique 
was first described by E. Southern in 1975. This a quick method to screen for 
large alterations and offers a good first step in mutation analysis. By this 
method, large deletions and insertions may be detected by the presence of 
junction fragments, or changes in band intensities (for autosomal dominant 
conditions). Point mutations may be detectable if they alter restriction sites.
b)Puised field gel electrophoresis: In contrast to routine DNA analysis 
techniques which have an upper size limit of 40kb, PFGE can separate 
fragments in the size range of 1)4-10Mb and hence large areas of a gene can 
be screened for alterations in a single experiment. PFGE involves switching 
of the voltage potential relative to the gel during electrophoresis and as the 
shorter DNA molecules can reorientate to the potential more quickly than the 
longer molecules, they migrate further into the gel. The large fragments for
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PFGE are generated using special restriction enzymes which have infrequent 
cutting sites such as Not I (8bp) and Sfi I (13bp) in length.
Methods used for detecting known mutations
Specific point mutations can be detected by several approaches 
including loss or gain of an RFLP, Allele-Specific Oligonucleotide probes 
(ASO) and the Amplification Refractory Mutation System (ARMS).
Loss or gain of an RFLP
A difference in the pattern of fragments after restriction enzyme 
digestion is called restriction fragment length polymorphism. The use of PCR 
has made it possible to amplify a short region of DNA surrounding the 
restriction site of interest which is then exposed to the relevant restriction 
enzyme. The presence of a mutation may destroy a restriction enzyme site or 
lead to creation of a site. This can be used for rapid detection of that 
particular mutation on digestion with the relevant restriction enzyme.
Allele specific oligonucleotide hybridisation (ASO)
In this method, ASO probes are used, which are short (17-30 mers) 
and have the complementary sequence to either the normal or the mutant 
DNA sequence at the point of interest. Under very stringent conditions, such 
probes will only hybridise to their perfect homologous sequences and not to 
those that vary by even a single nucleotide residue. Thus a normal gene can 
be detected using the wild type probe and the mutant gene with the probe 
containing the same mutation. In practice, for the routine analysis, dot-blot 
filter hybridisation is used and detection done by either radioactive or 
biotinylated and enzyme labelled probes. This method also allows
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simultaneous amplification and analysis of multiple polymorphic sites by 
using ASO probes of identical length and tetramethylammonium chloride 
(TMACI). When washed in 3M TMACI, perfectly matched oligonucleotides of 
the same length tend to dissociate from the hybridised test sample at the 
same temperature, thus leaving behind the mismatched probes. Alternatively, 
a "reverse dot-blot" procedure can be used in which the oligonucleotide 
probe is immobilised on a membrane and hybridised to labelled PCR 
products. In this method a panel of different probes can be used to screen 
simultaneously for several mutations in a given PCR product.
Amplification refractory mutation system (ARMS)
This technique involves PCR amplification of the target DNA with a 
normal or mutant primer and a common end primer. The normal and mutant 
primer differ at their 3' ends only by a single base which corresponds to the 
normal and mutant alleles. The technique is based on the concept that 
template amplification by PCR in which one of the amplification primers is 
mismatched at the 3' end is not possible. This is due to the lack of 3' 
exonucleolytic proof reading activity of Taq DNA polymerase. The technique 
is performed by amplifying a test DNA with a mutant amplification primer and 
a common primer. As a control, internal primers are added in the same 
reaction. Similarly another set of reactions is performed using normal and 
common primers, with internal control primers also added to the reaction. 
After amplification, the products are size fractionated in agarose gels and 
visualised by ethidium bromide staining. With the normal sample, 
amplification will only be positive in the reaction with the normal primer, but 
not in the reaction with the mutant primer. In the case of heterozygotes, it will 
be positive on amplification with both the normal and mutant primer and in
22
case of homozygous mutant samples, there will be no amplification with the 
normal primer.
All the above methods can be used in the investigation of mutations 
that have already been characterised and are useful as a means of direct 
detection of the particular mutations.
PCR directed mutagenesis
All the mutations characterised in this study, were confirmed by 
digestion with the appropriate restriction enzyme site that was created or lost. 
However not all the single base substitutions characterised in this study 
altered restriction enzyme sites and therefore were not amenable to detection 
by this method. Detection of these mutations was therefore carried out using 
the method of PCR directed mutagenesis as described by Li et al. (1992).
1.4 CLINICAL FEATURES OF NEUROFIBROMATOSIS TYPE-1
Historical Perspective
Neurofibromatosis type-1 (NF-1), also known as von Recklinghausen's 
neurofibromatosis was first described by Freidreich von Recklinghausen in 
1882, who gave the disease its full description, including the recognition that 
the tumours arose from fibrous tissue surrounding small nerves, leading to 
the recognition of these as neurofibromas. The autosomal dominant 
inheritance pattern was defined in the early twentieth century. A crucial 
diagnostic element, the Lisch nodule was defined by the Viennese 
ophthalmologist Karl Lisch in 1937. The landmark study of Crowe, Schull and 
Neel in 1956 brought together for the first time the salient clinical features of 
NF-1.
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Incidence
Neurofibromatosis type-1 is inherited an autosomal dominant 
disorder with a 98% penetrance and with an incidence of approximately 1 in 
3000 individuals. About one third of cases are new mutations and the 
mutation rate is approximately 1 per 10,000 gametes per generation.
Diagnostic criteria
The diagnostic criteria for NF-1 were established at an NIH 
'Consensus Development Conference' in 1988. The diagnostic criteria for 
NF-1 are tabulated in Table 2 and are met in an individual if two or more of 
the criteria are present.
Table 2: Diagnostic criteria for neurofibromatosis type-1
1. Six or more cafe au lait macules over 5 mm in greatest diameter in 
prepubertal individuals and over 15 mm in greatest diameter in 
postpubertal individuals
2. Two or more neurofibromas of any type or one plexiform neurofibroma
3. Freckling in the axillary or inguinal regions
4. Optic glioma
5. Two or more Lisch nodules (iris hamartomas)
6. A distinctive osseous lesion such as sphenoid dysplasia or thinning 
of long bone cortex with or without pseudarthrosis
7. A first degree relative with‘NF-1 by the above criteria
The basic disturbance in neurofibromatosis appears to be an abnormality in 
development of the neural crest cells with resulting tendency to abnormal, 
excessive growth of affected tissues and the development of multiple 
tumours.
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Defining features present in most patients
Cafe au lait spots
The cafe au lait spot is a flat evenly lightly pigmented macule that 
does not macroscopically differ from normal skin and appears in 95% of NF-1 
patients. Ordinarily they are not apparent at birth, but become visible during 
the first year of life, when at least six spots measuring from 0.5 to 10 cm are 
apparent, although the occasional patient may have fewer. Melanocytes 
within a cafe au lait spot have an increased number of macromelanosomes, 
although this is not diagnostic for NF-1. Cafe au lait spots are present from 
early infancy and their numbers (in contrast to freckling which is also a part 
of this disorder) are relatively constant until late middle age (late 40s and 
50s) when the total number of spots declines (Riccardi, 1994).
Peripheral neuro fibromas
NF-1 derives its name from its hallmark feature neurofibromas. 
Neurofibromas may be intracutaneous and are of a violet colour and soft 
consistency, or subcutaneous and presenting as firm tumours along the trunk 
of peripheral nerves. Their diameter varies from a few millimetres to 3-4 cm. 
Pathologically, these lesions are made up of a mixture of cell types, including 
fibroblasts, Schwann cells, mast cells and vascular elements. These tumours 
make their appearance in adolescence and increase in size and number with 
age, although the rate can be extremely variable. Some affected females with 
NF-1 note an increase in rate of progression during pregnancy, suggesting 
these tumours may be hormone responsive.
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Freckling
The occurrence of freckles in the axillae, groin and intertriginous areas 
is seen in NF-1. Such freckling is not apparent at birth, but often appears 
during childhood. The occurrence of such freckling in the inframammary 
areas and other skin folds may suggest that these lesions are modulated by 
the local environment.
Lisch nodules
Raised pigmented nodules of the iris pathologically representing 
hamartomas are called Lisch nodules and represent an extremely important 
diagnostic feature of NF-1. Lisch nodules are of melanocytic origin and are 
present in 30% of NF-1 patients by 6 years of age and in over 90% of adult 
patients.
Frequent but non diagnostic and non morbid features of NF-1
Macrocephaly and short stature are frequent accompaniments of NF- 
1. The macrocephaly reflects accompanying megalencephaly. Macrocephaly 
>98th centile occurs in 16-45% of patients. Individuals with NF-1 are on the 
average about 3 inches shorter than predicted by their family background. 
However more significant causes such as aqueductal stenosis due to diffuse 
or membranous gliosis of the aqueduct, leading to hydrocephalus and growth 
failure which occasionally may result from a hypothalamic involvement by an 
optic glioma should be ruled out.
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Variable but significant complications
Learning disability
Frank mental retardation is uncommon in NF-1 and such patients are 
more likely to have the disease because of a large deletion that removes the 
entire NF-1 gene and considerable flanking DNA (Kayes et al., 1994). Other 
nearby genes reduced to hemizygosity by the deletion in these patients may 
contribute to the retardation. Learning disabilities are found in 30-50% of the 
children with NF-1 and this is an important complication. The learning 
disabilities in NF-1 have a specific pattern, often involving difficulties in with 
reading and fine and gross motor co-ordination. Significance of MRI 
abnormalities in children with NF-1 was evaluated by North et al. (1994). 
Forty children were evaluated with MRI, medical, psychometric, speech 
therapy and occupational therapy assessments. The mean full scale IQ 
scores showed a left shift in comparison with the normal population and the 
distribution of the IQ scores was bimodal, suggesting that there were two 
populations of patients with NF-1, those with and without a variable degree of 
cognitive impairment. Areas of increased T2 signal intensity on MRI have 
been reported in children with NF-1 called "UBOs" or unidentified bright 
objects. It was seen that children with UBO+ had significantly lower values 
for IQ and language scores and significantly impaired visuomotor integration 
and co-ordination. Children without increased T2 signal on MRI (UBO-) did 
not significantly differ from the general population. Areas of increased T2 
signal on MRI represent dysplastic glial proliferation and aberrant 
myelination in the developing brain and may be associated with deficits in 
higher cognitive function. The presence of these signals thus can divide the 
population into two distinct groups anatomically and developmentally, (UBO+ 
and UBO-). These two groups should be considered separately in the
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assessment and management of children with learning disabilities in NF-1 
(North et al., 1994).
Plexiform neurofibromas
A group of nerves affected by numerous oval and irregular swellings is 
referred to as a plexiform neurofibroma. It may diffusely involve nerve, 
muscle, connective tissue, vascular elements and overlying skin and occurs 
in 10% of individuals with NF-1. Plexiform neurofibromas are usually 
congenital and combine cutaneous and subcutaneous elements to form 
tumours that may become huge and represent one of the most serious 
complications of NF-1. They may be continuous with intracranial or 
intraspinal tumours. Histologically these tumours are a mixture of Schwann 
cells, perineural cells and fibroblasts loosely arranged in a myxoid stroma 
with variable amounts of collagen. 3-6% of neurofibromas undergo malignant 
transformation and the plexiform neurofibroma has a greater tendency to 
malignant transformation. Severe plexiform lesions are almost invariably 
apparent by the age of 4-5, so it is possible to reassure older individuals 
without plexiform lesions, that they are not at significant risk for development 
of these lesions.
Malignancy
A particularly aggressive and often fatal malignancy is the 
neurofibrosarcoma, which commonly arises in a plexiform neurofibroma.
Optic gliomas are present in 4% of children and 2% of adults (Table 3). 
Histologically, these differ from other optic gliomas by the presence of an 
arachnoidal gliomatosis surrounding the optic nerve. They may be limited to 
the optic nerve, or involve the chiasma and the retrochiasmatic portion of the
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visual pathway. Certain forms of malignant myeloid disorders such as 
juvenile chronic myelogenous leukaemia (JCML), monosomy 7 (Mo 7), 
chronic myelogenous leukaemia (CML) and acute myeloid leukaemia (AML) 
are seen in children with NF-1 and show a male preponderance. The other 
tumours seen in NF-1 are astrocytomas, rhabdomyosarcomas, gliomas, 
ependymomas, meningiomas, acoustic neuromas, phaeochromocytomas and 
thyroid carcinomas.
Seizures
A seizure disorder develops in approximately 5% of patients with NF-1 
and the onset of this can occur at any time during life.
Scoliosis
Vertebral defects including scalloping from dural ectasia are extremely 
common in NF-1 and approximately 10% of affected individuals have 
scoliosis during late childhood and adolescence.
Pseudarthrosis
An uncommon complication of NF-1, whose pathological basis is 
unknown, is the involvement of long bones, noted first as bowing particularly 
of the tibia, in young children. This progresses to thinning of the cortex, 
pathological fracture and severe difficulties, with non-union of the fragments 
and may go on to form a false joint, rendering the limb severely 
compromised.
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Hypertension
Hypertension is extremely common in adults with NF-1, affecting one 
third of the patients. This is usually essential hypertension with no underlying 
cause, but the new development of hypertension may be due to renal artery 
stenosis which is particularly common in children, or phaeochromocytoma in 
adults.
The frequencies of the complications of NF-1 in 1000 patients was 
summarised by Birch and Freidmann (1993) from the information obtained 
from the NNFF 'CLINICAL' database, which has contributions by 47 centres 
from 12 countries (Table 3).
Table 3: Frequencies of complications of NF-1
Complication Rate in children Rate in adults
1) Plexiform neurofibromas 18% 29%
2) Proptosis 6% 3%
3) Strabismus 10% 10%
4) Pseudoarthrosis 2% 2%
5) Scoliosis 17% 31%
6) Malignant tumours (excluding brain 
tumours)
0.3% 2%
7) Symptomatic optic gliomas 4% 2%
8) Brain tumours excluding optic 
gliomas
1.5% 1.5%
9) Learning difficulties 38% ~
10) NF-1 related behavioural, emotional, 
psychological problems
33% 33%
11) NF-1 related cosmetic problems 19% 43%
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Variant forms of NF-1
NF-1 is also known to exist in association with other disorders (e.g. 
NF-1 in association with CMT1A), but most of these reports appear to 
represent the coincidental occurrence of two unrelated conditions. However 
variant forms of NF-1 have been described, which are:
Segmental NF-1
This is a spatially restricted form of NF, with symptoms localised to one 
region of the body (left or right upper quadrant and limb) not crossing the 
midline. Segmental NF patients do not have an affected parent but 
occasionally have had children with classical NF. The hypothesis for its 
causation is that these individuals may be mosaic as a result of a mutation in 
the NF-1 gene in early embryogenesis and if the mosaicism involves the 
germline, the disease can be transmitted.
Watson Syndrome
This variant of NF-1 involves multiple cafe au lait spots, dull intelligence, 
short stature, pulmonary valvular stenosis and only a small number of 
neurofibromas and Lisch nodules. Molecular analyses have shown at least 
two families that appear to fall in the Watson syndrome category and have 
mutations in the NF-1 gene (Tassabehji et al, 1993).
Neurofibromatosis-Noonan syndrome (NFNS):
The clinical features seen in Noonan's syndrome include triangular facies, 
downward slanting palpebral fissures, micrognathia, short stature and 
learning difficulty. Many of the features of Noonan syndrome seen in patients 
with NF-1, may be caused by dysgenesis or other developmental alterations
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of the central nervous system resulting in muscular hypotonia. In the 
presence of hypotonia, development of craniofacial structures will be altered 
leading to hypoplasia of the midface and micrognathia. When coupled with 
craniofacial changes known to be common in NF-1, (prominent forehead, 
ptosis, ocular hypertelorism and broad nasal tip) the resulting facial 
phenotype may suggest Noonan's syndrome (Stern et al., 1992). The 
phenotype of NF-1 can include features that overlap, but these disorders are 
probably genetically distinct. The absence of linkage of Noonan's syndrome 
to the neurofibromatosis type-1 locus was shown by Sharland et al. (1992).
Spinal neurofibromatosis
Rare families have been identified with a predominance of spinal tumours 
and relatively few peripheral neurofibromas, some of them being linked, while 
the others showing no linkage to the NF-1 locus.
Other variant forms of NF-1
Familial intestinal neurofibromatosis (NF-3), neurofibromatosis- 
Phaeochromocytoma-Duodenal carcinoid syndrome (NPDC syndrome; 
Duodenal carcinoid syndrome), neurofibromatosis type III of Riccardi (NF-III; 
neurofibromatosis, mixed central and peripheral type; Palmar cutaneous 
neurofibromatosis included) and neurofibromatosis type IV of Riccardi, (NF- 
IV; neurofibromatosis variant forms of; neurofibromatosis-atypical) are some 
of the other described variant forms of NF-1.
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1.5 GENETIC ASPECTS OF NF-1
Inheritance pattern
NF-1 is inherited as an autosomal dominant disease.
In NF-1, maternal transmission of the disease gene is associated with 
a more severe clinical phenotype (Miller and Hall, 1978) whilst the vast 
majority of new mutations are paternal in origin but do not exhibit a paternal 
age effect (Jadayel et al, 1990, Stephens et al, 1992).
In other genetic disorders that show a bias towards paternal origin of 
new mutations, there is a marked increase in the incidence of mutations with 
paternal age, consistent with the mutations arising from replication errors in 
mitosis of spermatogonial stem cells. In NF-1 however, such effects are slight 
or absent and therefore, most NF-1 mutations probably arise either at mitosis 
in a cell that is not a self renewing stem cell, or independently of mitosis, for 
example in a mature sperm. Also in NF-1, the paternal chromosomes are 
more susceptible to this mutation than maternal chromosomes and the 
reason for this is unclear, but could be related to the differences in maternal 
and paternal germ lines. The sex of the affected parent may have an impact 
on the severity of the disease a phenomenon which is referred to as parental 
imprinting. (Hall, 1990). Genomic imprinting is the term that has been used to 
refer to the differential expression of genetic material, at either a 
chromosomal or allelic level, depending on whether the genetic material has 
come from the male or female parent. Genomic imprinting may involve 
modifications of the nuclear DNA of somatic cells in order to produce these 
phenotypic differences. The term imprinting is also meant to imply that 
something happens during a critical or sensitive period in development. In 
case of genomic imprinting, the stage during which germ-line cells are 
formed may represent one critical period in which genetic information is 
marked, temporarily changing the genetic information to allow differential
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expression. Because this marking is thought to occur during germline 
formation, the term germline imprinting is sometimes used. Genomic 
imprinting appears to be a form of regulation, allowing flexibility within the 
control and expression of the mammalian genome and may explain why 
mutations in some parts of the mammalian genome function differently 
depending on whether they come from the father or the mother (Hall, 1990).
Penetrance
The penetrance of NF-1 is 98% in individuals who have reached 
adulthood and been subjected to careful examination by an experienced 
physician. Rare cases of normal parents giving rise to affected children have 
been described and could be due to germline mutations in one of the 
parents, or rarely two independent mutations.
Variable expressivity
NF-1 is notable for its variable expression and an explanation for the 
variation in phenotypic expression was put forward by Riccardi, (1994) who 
suggested that within a family with NF-1 (for whom a single allele at the 
17q11.2 locus was being dealt with), the key modifying factor is stochastic 
and the least critical is the epigenetic factor.
The phenotypic expression of NF-1 is to a large extent determined by 
the genotype at other modifying loci and the modifying genes are trait 
specific (Easton et al., 1993). The study was based on an analysis of 
variation in expression of NF-1, to determine whether the variation has an 
inherited component, using three quantitative traits and five binary traits. 175 
individuals in 48 NF families were examined including 6 monozygotic (MZ) 
twin pairs. The quantitative traits showed a high correlation between MZ
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twins and suggested a strong genetic component in the variation of 
expression. All five binary traits except plexiform neurofibromas showed 
significant familial clustering. There was no evidence of association between 
the different traits in affected individuals. Easton et al. (1993) concluded that 
the phenotypic expression of NF-1 is to a large extent determined by the 
genotype at other modifying loci and identification of putative genes when 
possible, would be candidates for evaluation in NF-1 families.
1.6 MOLECULAR BIOLOGY OF THE NF-1 GENE: CHARACTERISATION 
OF THE NF-1 LOCUS
Molecular genetic investigations into NF-1 began in the 1980s with the 
goal to localise and characterise the NF-1 gene.
Linkage and physical mapping
The first step was chromosomal localisation by family linkage studies.
The NF-1 locus was mapped to chromosome 17 by linkage with DNA
markers in families (Barker et al., 1987). Seizinger et al. (1987) presented
evidence that the NF-1 gene is linked to the locus for nerve growth factor
receptor (NFGR), a gene on the long arm of chromosome 17 (17q12-22).
However the authors found cross-overs which indicated that NFGR was not
the NF-1 gene. Goldgar et al. (1989) summarised the results reported by the
International Consortium for NF-1 linkage. 142 families with more than 700
t r
affected persons were studied using 31 markers in the pericentromic region 
of chromosome 17. The genetic analysis of these families indicated that the 
NF-1 gene lies on proximal 17q and markers on both sides of the gene were 
identified that were within 5 centimorgans of NF-1 (Goldgar et al., 1989).
35
In support of this localisation of the NF-1 gene, two unrelated patients 
with NF-1 having apparently balanced translocations involving chromosome 
17 were identified. In both instances, the chromosome 17 breakpoint was in 
band q11.2, precisely where NF-1 mapped by genetic linkage analysis. 
Schmidt et al. (1987) described a patient with the balanced chromosome 
rearrangement [46XX,t(1;17)(p34.3;q11.2)]. Ledbetter et al. (1989) described 
a patient with a balanced translocation between chromosomes 17 and 22, 
[46XX,t(17;22)(q11.2;q11.2)]. This breakpoint was cytogenetically identical to 
the case with the 1 ;17 translocation reported by Schmidt et al. (1987). These 
results were suggestive that the translocation events disrupt the NF-1 gene 
and precisely mapped the NF-1 gene to 17q11.2. This provided a physical 
reference point for strategies to clone the breakpoint and therefore the NF-1 
gene. The first step involved the construction of somatic cell hybrids from the 
cells of the two patients to add to the panel of hybrids that were in use for 
physical mapping. The hybrid derived from t(1;17) DCR-1 contained the 
translocation product carrying 17q11.2-qter as its only chromosome 17 
material (Menon et al., 1989).The t(17;22) hybrid NF13 also contained the 
translocation product bearing 17q11.2-qter (Ledbetter et al., 1989). These 
two hybrids plus two other hybrids constructed by Van Tuinen et al. (1987) 
and Leach et al. (1989), provided starting material for construction of libraries 
in an effort to clone more of the NF-1 region. Progress in the physical 
mapping included localisation of most of the markers via the somatic cell 
mapping panel and physical connections were established between several 
probes with pulsed field gel electrophoresis (PFGE) (Fountain et al., 1989a). 
New probes were being developed by a number of approaches: Fountain et 
al. (1989a) mapped a series of chromosome 17 specific Not I linking clones 
to 17q and studied them by pulsed field gel electrophoresis. One clone 17LI
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clearly identified the breakpoint in the patient with the t(1; 17) translocation 
and it was found that 17LI lay closest to the NF-1 breakpoints on the 
centromeric side. Subsequently Fountain et al. (1989b) also detected the 
t(17;22) translocation from the centromeric side using the linking clone 17L1. 
O'Connell et al. (1989) generated probes from cosmid libraries made from 
microcell hybrids. Simultaneously O'Connell et al. (1989) detected the 
breakpoints from the telomeric side using the cosmid C11-1F10. The 
combined results narrowed the translocation breakpoints to a fairly well 
mapped physical region of 600kb. A 2.3Mb pulsed field map was constructed 
by Fountain et al. (1989b) and this indicated that the NF-1 breakpoint was 
10-240kb away from 17LI. It was also seen that 17LI represented a CpG 
island. These CG rich hypomethylated regions are associated with the 5' 
regulatory sequences of active genes (Bird et al., 1986). Thus 17LI 
represented a potential candidate gene.
Cloning candidate genes
In attempting to clone the NF-1 gene, the goal was to clone cDNAs in 
the 600kb interval particularly around the translocation breakpoints and test 
each for its possibility of being the NF-1 gene. Random genomic fragments 
were also used to screen cDNA libraries including whole cosmids or YACs.
The genomic and cDNA cloning efforts in the area between 17LI and 
C11-IF10 were aided by the finding of a probe that lay between the two 
translocation breakpoints. The mouse gene evi2, involved in virally induced 
murine leukaemia was found to lie on mouse chromosome 11 (Buchberg et 
al., 1988) and showed synteny with the NF-1 region on chromosome 17 
(Buchberg et al., 1989). Mapping of this gene and its human homologue 
EVI2A showed that EVI2A lay between the two translocation breakpoints. 
This was the first candidate gene for NF-1. EVI2A allowed the translocation
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breakpoint region to be cloned in overlapping cosmids and mapped placing 
t(1 ;17) approximately 60kb closer to the centromere than t(17;22) (O'Connell 
et al., 1990a). EVI2A encoded a 1.7kb cDNA split between one small 5' exon 
and one larger 3' exon containing an open reading frame. The entire gene 
was contained completely between the two translocation breakpoints. 
However, inability to find mutations in NF-1 patients and lack of expression in 
neural crest tissues indicated that EVI2A was unlikely to be the NF-1 gene 
(Cawthon et al., 1991).
Efforts continued in trying to find additional candidate genes using 
cloned DNA from overlapping EVI2A cosmids (O'Connell et al., 1990a) and 
by chromosome jumping and YAC cloning in the EVI2A region (Wallace et 
al., 1990b). A contiguous 130kb genomic map of overlapping clones had 
been constructed by O'Connell et al. (1990a,b) that encompassed both 
translocation breakpoints. By screening cDNA libraries with these cosmids, 
two additional genes were identified, RC1 and HB36, which were similarly 
found to lie between the two NF-1 translocation breakpoints. A fourth locus, 
HB15 mapped distal to both breakpoints (Cawthon et al., 1990b). HB15 is a 
pseudogene of the adenylate kinase 3 multigene family. The predicted 
peptide from DNA sequence analysis indicated that RC1 was a 
transmembrane protein without specified function like EV12A (Cawthon et al., 
1990b, Buchberg et al., 1990). The jump clone EH1 (Wallace et al., 1990b) 
detected the second candidate gene, EV12B from the beginning of the jump 
sequences (Cawthon et al., 1991). EV12B also lay between the translocation 
breakpoints several kilobases centromeric to EV12A (Cawthon et al., 1991). 
The cDNA sequence and genomic structure was described by the authors 
and was similar to EV12A in size, structure, direction of transcription and
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tissue distribution. This gene too was eliminated as it failed to show 
mutations in NF-1 patients.
HB36 matched the sequence of the gene for oligodendrocyte myelin 
glycoprotein (OMGP) and OMGP was the third candidate gene. The 
sequence of OMGP was initially cloned by Mikol et al. (1990) and then by 
Viskochil et al. (1991). This gene also lay between the breakpoints, very 
close to the t(1 ;17) translocation. OMGP is a central nervous system cell 
surface peptide with properties of a cell adhesion molecule; potentially active 
in mediating proper cell motility and differentiation during brain development 
(Mikol 1990). However this gene, although expressed in oligodendrocytes 
was eliminated as a gene as it was not interrupted by either breakpoint and 
again did not show mutations in NF-1 patients.
Cloning the NF-1 gene
The NF-1 gene was discovered as the fourth candidate gene. The NF- 
1 gene was initially called the TBR gene (translocation breakpoint region) by 
the Utah group (Cawthon et al., 1990a, Viskochil et al., 1990) and NF1LT by 
the group in Michigan (Wallace et al., 1990a).
Wallace et al. (1990b) used chromosome jumping and yeast artificial 
chromosome technology to identify a 13kb ubiquitiously expressed transcript 
denoted as NF1LT. Two different strategies were used to derive cDNA 
clones that defined NF1LT. Initial experiments with the end of jump clone 
EH1 obtained by chromosome jumping showed that a single copy 1.4kb 
EcoR \-Hind III sub-fragment which lay just telomeric to the t(17;22) 
breakpoint was conserved across species. This probe was used to screen a 
human peripheral nerve cDNA library which resulted in the isolation of a 
clone P5, which had an insert of 1.7kb. Transcripts were also sought with the 
YAC clone A113D7, part of an overlapping contig of clones from this region.
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This YAC contained the entire breakpoint region and on direct screening of a 
cDNA B lymphoblast library with this probe, clone B3A was isolated and P5 
and B3A were seen to overlap. Using P5 as a probe, the authors showed that 
NF1LT was functionally disrupted by the translocation breakpoints. The 
above two approaches yielded 2 overlapping cDNAs that together 
represented 300bp of 3' untranslated region and 1.7kb of coding region.
The Utah group cloned a part of the same gene by initially screening a 
mouse cDNA library with a highly conserved human genomic fragment. They 
cloned the corresponding human cDNA and did several cDNA walks to 
obtain 4kb of cDNA sequence, including approximately the same portion of 
the 3' untranslated sequence. Viskochil et al (1990) used a 3.8kb (probe 
EE3.8) EcoRI fragment to screen several cDNA libraries. A 2.1 kb TBR cDNA 
clone mDVI was obtained from a murine macrophage cDNA library. The 
EcoRI insert released from mDVI was then used to screen additional human 
cDNA libraries and many human foetal brain and peripheral blood TBR cDNA 
clones were isolated and partially characterised. Viskochil et al. (1990) 
showed that the TBR gene was interrupted by four NF-1 mutations, which 
included the previously characterised t(17;22) chromosome translocation. 
Three other deletions of 11 kb, 190kb and 40kb were also shown to contain 
sequences from the TBR cDNA clones and the TBR conserved region.
Cawthon et al. (1990a) sequenced overlapping cDNA clones from the 
translocation breakpoint region (the TBR gene) which lay at the NF-1 locus 
and was interrupted by deletions and the t(17;22) translocation. The 4kb 
sequence of the transcript was compared with sequences of genomic DNA 
and a small number of exons were identified. PCR amplification of a subset 
of exons was followed by single stranded conformational polymorphism 
(SSCP) analysis and point mutations within the gene were identified.
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Thus, further crucial support came from mutation analyses in NF-1 
patients showing disruptions at the DNA level (Viskochil et al., 1990), point 
and nonsense mutations (Cawthon et al., 1990a) and a de novo insertion of 
an Alu repeat element which results in a splice error (Wallace et al., 1991). 
Both groups also determined that the cDNA originated from a large transcript 
of at least 11 kb in length and that the gene is transcribed towards the 
telomere. The genomic organisation of nine exons (initially called exons 1-9) 
now known as exons 28-36 of the NF-1 gene, was described by Cawthon et 
al. (1990a).
Embedded genes within the NF-1 gene
The three previous candidate genes EVI2A, EVI2B and OMGP were shown 
to be embedded within an intron of the NF-1 gene in the opposite 
transcriptional orientation. The cDNA sequence and genomic structure of all 
the genes has been described; EVJ2A (Cawthon et al., 1990b), EVX2B 
(Cawthon et al., 1991) and OMGP (Viskochil et al., 1991). An example of 
embedded genes, is a gene within intron 22 of the human factor VIII gene, 
also on the antisense strand (Levinson et al., 1990). There are very few 
previous examples of functional genes embedded within introns in higher 
eukaryotes and these examples raise the possibility that antisense RNA may 
regulate the expression of complex loci. Wallace et al. (1990a) proposed that 
the gene products of the embedded genes in the NF-1 gene may be 
responsible for some of the NF-1 phenotypic features.
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1.7 THE NF-1 GENE AND ITS GENE PRODUCT (NEUROFIBROMIN)
The complete coding sequence of the NF-1 gene was cloned by an 
extensive cDNA walk using five different cDNA libraries (Marchuk et al.,
1991). Walks proceeded sequentially by isolation of positive phage clones 
using the most 5' cDNA insert. The positive clones were characterised by 
restriction mapping using EcoRI and Southern blot analysis, using previously 
isolated inserts. The phage clones were sub-cloned and the ends were 
sequenced to anchor the position of the clones to the transcript map. As the 
walk neared completion, a very GC rich region of the transcript that 
contained an abnormally high concentration of the dinucleotide CpG, as well 
as rare cutting restriction endonuclease sites such as Bag I, Nar I and Sac I 
was encountered at the 5' end. These sites had been previously placed on 
the pulsed field map using the linking clone 17LI (Fountain et al., 1989a). 
The most 5' cDNA clone, KE-2 contained an in frame stop codon. 
Downstream from this codon, the first ATG fitted the rules for a proper 
translational start (Kozak, 1986). Marchuk et al. (1991) proposed that this 
ATG represented the authentic start codon, giving the protein a total of 2818 
amino acids and a predicted molecular weight of 327kD. However, Marchuk 
et al. (1991) were unable to characterise the 3' end of the NF-1 transcript as 
a polyA tail had not been found in any of the clones. The authors were able 
to clone and sequence 9kb of the message and the remainder appeared to 
be the 3' untranslated region, as previous sequence analysis had shown the 
proper position of a stop codon (Wallace et al., 1990a).
Analysis of the sequences revealed an open reading frame of 2818 
amino acids and it was shown that the gene extends for over 300kb on 
chromosome 17, with its promoter in a CpG island. The NF-1 gene is known 
to consist of at least 49 exons and the boundaries of some of the exons have
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been made available via information from the NNFF (National 
Neurofibromatosis Foundation) Mutation Analysis Consortium.
Searches of the protein database with the known amino acids 
predicted from the sequence of neurofibromin revealed striking amino acid 
sequence similarities to IRA proteins of yeast (inhibitory regulators of the ras- 
cAMP pathway) and also to mammalian GAPs (GTPase activating protein). 
The similarities were initially identified between a 360 amino acid region of 
the NF-1 protein and the catalytic domains of mammalian GAP and the 
essential domain of yeast IRA proteins. These domains modulate the activity 
of the p21-ras protein in their respective hosts by accelerating the rate of 
hydrolysis of active rasGTP to inactive rasGDP (figure 1).
The region of homology was termed as the NF-1 GAP related domain 
or NF-1 GRD (figure 2). Within the GRD, four regions, termed box l-IV, 
contain residues that are conserved among different ras-GAP proteins which 
include NF-1, p120-GAP and yeast IRA1 and IRA2 proteins. Among these, 
two regions boxes III and IV, located towards the C-terminal side of the GRD, 
contain a high percentage of conserved residues. There are fourteen 
conserved amino acids within the GRD and ten of the fourteen are found in 
these two boxes. A sequence FLR...PA located in box III is highly conserved 
(Appendix 5).
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The p21-ras cycle of ac t iva t ion  and ina c t iva t io n  
by GAP re lated p ro te ins
Figure 1
The p21-ras cycle of activation and inactivation by the GAP-related 
proteins
p21-ras is inactive in the GDP bound state and is converted into an active 
GTP bound state by guanosine nucleotide replacing proteins that substitute 
GDP for GTP. Interaction of GAP-like proteins with p21-ras accelerates the 
conversion of p21-rasGTP to p-21rasGDP by increasing the intrinsic GTPase 
activity of p21-ras and converting p21-ras to the inactive GDP bound form. In 
resting cells, the majority of the p21-ras is inactive and in the GDP bound 
form.
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Figure 2
Regions of homology between the NF-1 protein and the IRA1, IRA2 and 
GAP proteins
Unfilled boxes represent regions with little or no homology and open spaces 
are used to align the most homologous region. Hatched boxes represent 
regions homologous among only three of the proteins and the black boxes 
show the regions conserved among all four proteins (which represents most 
of the catalytic domain or NF-1 GRD, Ballester et al., 1990).
(Adapted from Wallace and Collins, 1991).
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Guanine nucleotide binding to ras proteins mediates signal 
transduction that regulates cell growth. Binding of ras to GTP activates 
signalling, while hydrolysis to GDP terminates signalling (Barbacid, 1987). A 
GTPase activating protein GAP was the first protein found to catalyse the 
hydrolysis to GDP and thereby mediate the signal termination event (Trahey 
and McCormick, 1987). In addition GAP may also function in signal 
propagation as a downstream effector of ras (McCormick, 1989; Hall, 1990). 
The GAP related domain of NF-1 (NF1-GRD), similarly stimulates the 
GTPase of ras (Ballester et al., 1990, Martin et al., 1990, Xu et al., 1990a) 
and possesses properties consistent with the functioning of neurofibromin as 
a downstream effector of ras (McCormick and Bollag, 1991). The GAP 
related domain of the NF-1 gene spans exons 20-27, exon 24 being the most 
highly conserved, also termed the FLR exon (Li et al., 1992).
The complete amino acid sequence of the NF-1 transcript showed 
three blocks of homology most conserved among the GAP family of proteins 
as seen above. There were no SH2 or SH3 (S RC-homology domains- 
elements that control interactions of cytoplasmic signalling proteins) in 
neurofibromin. SH2 and SH3 domains are homologous to the non-catalytic 
regions of the oncogene src and are thought to direct interactions with 
phosphotyrosine proteins involved in signal transduction. Their absence in 
neurofibromin implies that neurofibromin and GAP are not interchangeable in 
the cell and that neurofibromin is probably not directly modulated through 
tyrosine phosphorylation by activated growth factor receptors.
Six potential cAMP dependant protein kinase phosporylation sites and 
a single potential tyrosine phosphorylation site were found to be present in 
the NF-1 gene. The potential sites for tyrosine and serine threonine 
phosphorylation may mean that an intermediate between an activated
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receptor and neurofibromin may modulate its activity, since there is evidence 
that neurofibromin is phosphorylated on serine and threonine residues 
(Marchuk et al., 1991). The sequence of neurofibromin showed no significant 
homology to the bcr-related GAP family or rap I GAP (Marchuk et al., 1991).
To find conserved, potentially functional domains of neurofibromin 
which would allow identification of potentially significant sequence 
alterations, the complete mouse NF-1 sequence was identified by Bernards 
et al. (1993). The sequence was predicted to be approximately 12kb with a 
2841 amino acid protein, that is more than 98% identical to human 
neurofibromin, with the 3' segment being highly conserved. 45 amino acid 
differences were identified between mouse and human neurofibromin, of 
which all but 9 occur in the N-terminal half of the protein with 16 changes 
clustered just upstream of the IRA related segment. Given the high degree of 
sequence identity virtually any sequence alteration in NF-1 patients or 
tumours was thought to be potentially significant (Bernards et al., 1993).
Alternatively spliced transcripts of the NF-1 gene
Examination of the intron-exon organisation of the NF-1 gene revealed 
the presence of two alternatively spliced exons (Marchuk et al., 1991 
Andersen et al., 1993a, Nishi et al., 1991).
The first alternatively spliced exon is exon 23a. It is located within the 
GAP related domain and inserts 63 nucleotides into the NF-1 mRNA (Nishi et 
al., 1991). These are inserted just upstream from the most conserved exon 
(exon 24) in the GRD and it encodes a basic stretch of amino acids including 
6 lysines out of 21 amino acids. This isoform is termed GRDII for GAP 
related domain II and is expressed predominantly in adult brain and its 
expression is induced in neuroblastoma cells on retinoic acid treatment 
(Nishi et al., 1991). This isoform produces a protein with GAP activity but its
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ability to down regulate ras is reduced. Thus differential regulation of 
neurcfibromin isoforms may control the degree of influence p21-ras 
transduction pathways have on the overall signal for cell proliferation 
(Viskochil et al., 1993). Andersen et al. (1993a) demonstrated that because 
high lysine content could significantly alter the peptide conformation in a 
region presumably critical for p21-ras interaction, it was thought that the 
alternatively spliced form lacked function. To test this hypothesis a 
baculovirus sf/9 expressed peptide termed (NF-GRDII), identical to the NF-1 
GRD, now termed (NF-GRDI), except for inclusion of the 21 amino acid insert 
was purified and its functional properties were compared with NF-GRDI. NF- 
GRDII demonstrated decreased stimulation of H-ras as compared with NF- 
GRDI, however, its affinity for H-ras was about two fold greater. Thus the 
affinity of NF-GRDII for ras-GTP is the highest yet demonstrated between 
wild type p21-rasGTP and a GAP. This feature of the NF-GRDII could be 
significant in cells where limiting concentrations of rasGTP play a major role 
in signal transduction of physiological responses (Viskochil et al., 1993).
The other alternatively spliced exon (48a), is located in the extreme 
carboxy terminus of the NF-1 gene and inserts 54 nucleotides into the NF-1 
mRNA (Marchuk et al., 1991), 18 amino acids between residues 2771 and 
2772 (Cawthon et al., 1991). This isoform is called 3' ALT or Neurofibromin III 
for 3' alternatively spliced exon and this isoform was originally detected in a 
foetal brain cDNA library (DeClue et al., 1991). Examination of its expression 
by reverse transcribed RT-PCR demonstrated a high level of expression in 
cardiac muscle, skeletal muscle and smooth muscle (Gutmann et al., 1993). 
Additionally this isoform was also shown to be expressed in muscle tissues 
from other vertebrate species and the expression of this isoform in muscle 
suggested that the NF-1 gene may play additional tissue specific roles in
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muscle development and signal transduction. Northern blot analysis of 
human adult tissues detected faint NF-1 expression in muscle at levels 10-20 
fold lower than in brain. However it is not known whether this low level of 
expression (also seen in rat tissues) of neurofibromin in muscle compared 
with brain reflects the 3' ALT isoform or the uninserted neurofibromin protein. 
There are reports of patients with NF-1 and heart disease and although there 
is no consistent pattern of congenital heart defect in these patients, perhaps 
the timing of the 'second hit' (somatic mutation) could determine the 
phenotypic expression. There are a small number of neural crest derived 
cells that migrate into the heart during development. Some of these cells 
contribute to the orderly separation of the aorta and the pulmonary vessels, 
while others may give rise to the heart conduction system. Mice derived from 
homozygous targeted disruption of the NF-1 gene die at embryonic day 13.5 
of generalised oedema secondary to a heart defect (Gutmann et al., 1993). 
This cardiac development defect known as double outlet right ventricle has 
been described to result from neural crest ablation in the developing chick. 
Further investigation of the role of neurofibromin in muscle is necessary to 
determine the tissue specific role of this GTPase activating protein in signal 
transduction pathways and development.
Expression and tissue distribution of neurofibromin
Neurofibromin is ubiquitiously expressed in most human tissues. The 
methods used to ascertain expression are: Northern blot analysis, RNA 
reverse transcribed PCR (RT-PCR), Antibody binding and NF-1 GAP activity. 
Northern blot analysis demonstrated an 11-13kb transcript from a 
neuroblastoma, 2 melanoma cell lines, brain frontal lobe tissue and kidney 
tissue (Wallace et al., 1990a). Viskochil et al. (1990) demonstrated 
transcripts from a choriocarcinoma cell line. Using RT-PCR, the
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neurofibromin transcript was present in all tissues examined, including 
lymphoblastoid cell lines, skin fibroblasts, spleen, muscle, brain, kidney, liver 
and lung (Nishi et al., 1991, Wallace et al., 1990a, Suzuki et al., 1991).
To further elucidate the normal function of the NF-1 gene product and 
to determine the pathophysiologic basis whereby alterations in the gene give 
rise to neurofibromatosis, specific antibodies recognising the NF-1 protein 
product were developed. Identification of neurofibromin in cells by means of 
an antibody has been reported by DeClue et al., 1991, Gutmann et al., 1991 
and Daston et al., 1992. Antibodies raised against various domains of the 
protein identified a 220-280kD protein by several techniques. Gutmann et al. 
(1991) generated polyclonal antisera (antibodies) in rabbits against 3 fusion 
proteins and 2 synthetic peptides. Initial characterisation of the two anti 
peptide antibodies and one fusion protein antibody demonstrated a specific 
protein of approximately 250kD by both immunoprecipitation, immunoblotting 
in HeLa cells, NIH 3T3 cells and various murine tissues. The authors also 
stated neurofibromin was detected in all cell lines and tissues examined. In 
another study by DeClue et al. (1991), identification of the NF-1 protein was 
carried out in mammalian cells. DeClue et al. (1991) raised rabbit antisera to 
a bacterially (E.Coli fusion expression construct) synthesised 48kD peptide 
corresponding to the GAP related domain of NF-1 (NF-1 GRD). The sera 
detected specifically, a 280kD protein in 35S labelled cell lysates of mouse 
NIH 3T3, human HeLa and rat Schwannoma cell lines. The detected protein 
corresponded to the NF-1 gene product. Daston et al. (1992) used antibodies 
generated against two E.Coli fusion peptides that contained approximately 
310 amino acids of neurofibromin to detect a 220kD band from total rat spinal 
cord on SDS/PAGE Western blots. Direct Western analysis on human spinal 
cord failed to detect the protein, but immunoprecipitation of human spinal
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cord tissue lysate with one antibody followed by Western immunoblot 
analysis using the second antibody identified a 220kD protein.
Although the open reading frame of the NF-1 cDNA predicts a total 
protein of 2818 amino acids and a molecular size of 327kD, neurofibromin 
migrates at about 250kD. The size discrepancy was thought to result from 
anomalous migration due to protein folding, or the difference could reflect 
post translational modifications such as processing of a pro-protein species 
and the modification would necessarily involve cleavage of amino terminal 
sequences. These studies thus demonstrated a 220-280kD protein in cell 
and tissue lysates recognised by several different antibodies.
The expression pattern of neurofibromin during development, was 
characterised by Daston et al in 1992 and 1993, using the rat as a model 
system. Highest levels of neurofibromin using antibodies have been detected 
in brain, spinal cord, sciatic nerve and adrenal glands. Lower levels have 
been detected in liver, spleen, pancreas and cardiac tissue and none in 
skeletal muscle, lung kidney, skin (using antibody studies). Daston et al. 
(1993) also showed that neurofibromin immunoreactivity was enriched in 
neurons of the cortical plate, in the peripheral ganglia and in the developing 
CNS and PNS fibre tracts. Within the PNS the dorsal root ganglia and small 
axonal fibres associated with non-myelinating Schwann cells stain intensely 
with antineurofibromin antibodies. Transient expression of neurofibromin 
during development in many tissues suggested the importance of this protein 
in morphogenesis and organ growth. Daston and Ratner (1993) proposed a 
separate role for neurofibromin in growing axons and in the mature nervous 
system.
To determine whether the cellular and neuroanatomical distribution of 
neurofibromin revealed a possible function of neurofibromin in the brain,
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Nordlund et al. (1993) stained rat brain tissue sections with antineurofibromin 
antibodies. They found that neurofibromin was present in cell bodies and in 
axons and was highly enriched in dendrites. Immunoelectron microscope 
analysis demonstrated that neurofibromin was associated with smooth 
vesiculotubular elements and cisternal stacks, but not with the plasma 
membrane, nucleus, nuclear envelope, golgi apparatus or rough endoplasmic 
reticulum. The preferential localisation of neurofibromin to the smooth 
endoplasmic reticulum, together with evidence that neurofibromin modulates 
rasGTPase activity suggested that some of the CNS manifestations of NF-1 
may result from the altered expression of neurofibromin in neurons, perhaps 
through disruption of calcium signalling, translocation of organelles or 
endocyte pathways (Nordlund et al., 1993).
Analysis of the sequence and embryonic expression of the chicken 
neurofibromin RNA was carried out by Schafer et al., 1993. They isolated a 
partial cDNA for chicken neurofibromin. Sequence analysis revealed that the 
predicted amino acid sequence was highly conserved between chick and 
human. The chicken cDNA hybridises to a 12.5kb transcript on Northern 
blots, a molecular size similar to that reported for human and murine mRNAs. 
Ribonuclease protection assays indicated that the NF-1 mRNA was 
expressed in a variety of tissues in the chick embryo, which was confirmed by 
in situ hybridisation analysis. This pattern of expression suggested a role for 
neurofibromin during normal development including that of the nervous 
system.
mRNA expression of the NF-1 gene was studied in blood vessels in 
quiescent and proliferative conditions, by Ahlgrenbeckendorf et al. (1993) as 
vascular hypertrophic lesions are known to occur in NF-1. The expression 
and alternatively splicing pattern of the catalytic domain of NF-1 consistently
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changed in proliferating cells, supporting a role for this gene in the regulation 
of vascular smooth muscle and the vascular pathology in NF-1. Expression of 
neurofibromin is varied on comparison of expression by the RNA and 
antibody methods. By RT-PCR detection, neurofibromin was ubiquitiously 
expressed, yet Northern blot analysis revealed restricted expression 
patterns. Also, antineurofibromin antibodies recognised a 220-280kD protein 
from all tissue and cell line lysates tested. However 
immunohistocytochemistry revealed a restricted pattern of expression. This 
may be explained by the relative sensitivities in signal detection (Viskochil et 
al., 1993). RT-PCR may allow detection of a small number of cellular NF-1 
mRNAs which represent the leaky nature of housekeeping gene 
transcription, yet such a low level may not provide any specific contribution to 
cellular phenotypes. On the other hand, neurofibromin may be expressed at 
the lower limits of detection (e.g. antibody) in most cells, but still contribute to 
the cellular phenotype. The p21-rasGTPase activating function of 
neurofibromin provides an approach for further characterising expression of 
this protein with respect to cellular physiology (Viskochil et al., 1993).
The GAP related domain of neurofibromin is inhibited by some lipids, 
whereas p120GAP is not (Bollag and McCormick, 1991). Therefore total p21-
rasGAP activity from various cell lysates can be divided into p120GAP like
activity (non-inhibitable by lipids) and NF-1 GAP like activity (lipid
inhibitable). Bollag and McCormick (1991) found that all mammalian cells 
tested contained NF-1 and p120GAP like activity in varying proportions. The 
relative proportions of lipid inhibitable (NF-1 GAP) and noninhibitable
(p120GAP) rasGAP activities can be compared from each cell lysate. NF-1 
GAP accounts for 75% of total rasGAP activity from rat phaeochromocytoma 
cells, (PC12 cell line), whereas p120GAP accounts for 90% of total activity in
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human placental tissue. Both the proteins p120GAP and neurofibromin are 
widely expressed in mammalian tissues and this raised the question of 
whether or not they have different regulatory functions.
Cellular localisation of neurofibromin
Neurofibromin was localised to the non-nuclear particulate fraction of 
NIH3T3 cells by an immunodetection study that used differential 
centrifugation and no detergent in the cell lysis buffer (DeClue et al., 1991).
In functional studies in various cell lysates, Bollag and McCormick, 
1991 found NF-1 GAP activity distributed between the supernatant 
(approximately 60% of total GAP activity) and the particulate fraction 
(approximately 40% GAP activity). Neurofibromin may be less active within 
the particulate fraction of the cell and immunologically undetectable protein 
in the cytosol may be responsible for 60% of the detectable GAP activity. 
Alternatively, detergent may release loosely bound neurofibromin from the 
particulate fraction into the cytoplasmic fraction.
DeClue et al. (1991) used detergent (NP-40) in the cell lysis buffer to 
demonstrate that neurofibromin was immunoprecipitated from NIH 3T3, HeLa 
and rat schwannoma cell lines, both as a monomer and as a complex with an 
unidentified 400-500kD protein. In tissue culture cell lines, neurofibromin 
could be part of a complex associated with the particulate fraction of cells. In 
addition to the above findings, immunostaining demonstrated localisation of 
neurofibromin in the cytoplasm of cells from various tissues (Daston et al.,
1992).
Neurofibromin associates with cvtoolasmic microtubules
In separate experiments, using double indirect immunofluorescent labelling,
with antineurofibromin and antitubulin antibodies, Gregory et al. (1993)
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demonstrated that neurofibromin associates with cytoplasmic microtubules. 
Immunoblotting of microtubule enriched cytoplasmic fractions using 
antibodies generated against neurofibromin, showed that neurofibromin co­
purified with microtubules. When portions of neurofibromin are expressed in 
sf 9 insect cells, they associate with polymerised microtubules. Furthermore 
the critical residues for this interaction reside within the GAP related domain 
of neurofibromin. This association suggests that neurofibromin is involved in 
microtubule mediated intracellular signal transduction (Gregory et al., 1993).
The discovery that neurofibromin is a GAP-like molecule that 
associates with microtubules suggests several hypotheses to explain its 
function in cell growth and differentiation (Figure 3). One model which fits the 
upstream view of p21-ras-GAP interactions envisions that neurofibromin is 
regulated by serine/threonine kinases (Gregory et al., 1993). Neurofibromin 
would be active as a GAP while associated with microtubules keeping p21- 
ras in the inactive form and inhibiting cell division. After phosphorylation, 
neurofibromin would dissociate from microtubules and its GAP activity would 
be reduced or altered. Alternatively, neurofibromin could be 
compartmentalised in the microtubule compartment (perhaps performing 
some other function) until it was required for the control of p21-ras.
Phosphorylation of neurofibromin on critical serine residues would release it
j
from the microtubules to interact with p21-ras. Likewise the interaction of 
neurofibromin with microtubules may reduce its GAP like activity and its 
dissociation from microtubules may allow neurofibromin to associate with and 
downregulate p21-ras.
Further studies have demonstrated the involvement of neurofibromin 
in a in a B-lymphocyte signal transduction pathway involving microtubules 
and p21-ras. In this system neurofibromin and p21-ras co-localise during
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immunoglobulin receptor internalisation and neurofibromin becomes rapidly 
phosphorylated (Boyer et al., 1994). A second model, which falls into the 
category of a "downstream" hypothesis for p21-ras GAP interaction, is that 
neurofibromin is induced by the process of p21-rasGTP to p21-rasGDP 
conversion to transmit a signal through its influence on microtubule 
organisation.
Figure 3 (P.T.O)
Upstream versus downstream models of p21-ras neurofibromin 
interactions (proposed by Gutmann and Collins 1994).
In the upstream model, stimulation of appropriate cells expressing growth 
factor receptors leads to inactivation of neurofibromin perhaps through 
phosphorylation cascades. Inactivation of neurofibromin releases p21-ras 
from its downregulation, allowing p21-ras to predominate in the active, GTP 
bound form and signal other intracellular proteins to culminate in cell 
proliferation or differentiation. The downstream model envisions p21-ras to 
be a regulator of neurofibromin and transmits a signal via neurofibromin and 
p21-ras to culminate in cell proliferation or differentiation.
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1.8 PUTATIVE FUNCTIONS OF NEUROFIBROMIN
Neurofibromin as a GTPase activating protein
Due to the homology between a predicted peptide moiety of 
neurofibromin and the catalytic domains of mammalian GAP and yeast IRA 
proteins it was suggested that at least one role of neurofibromin might be to 
stimulate rasGTPase activity. This was confirmed using both genetic and 
biochemical assays.
cDNA segments encoding the homologous catalytic domain were 
cloned into expression vectors for E.Coli, baculovirus / sf 9 insect cells and 
yeast (Ballester et al., 1990, Martin et al., 1990, Xu et al., 1990b). In genetic 
experiments, the peptide was expressed in ira-yeast strains and studied by in 
vivo assays based on heat shock resistance and glycogen accumulation. 
Transformation with the GAP related domain of neurofibromin NF-1GRD 
reverted the ira phenotype and cells survived the heat shock and 
accumulated glycogen (Ballester et al., 1990, Martin et al., 1990, Xu et al., 
1990b).
In biochemical experiments, the in vitro rasGAP assays confirmed the 
hypothesis that the NF-1GRD can stimulate p21-ras hydrolysis of GTP. 
Ballester et al. (1990) used a cDNA construct encoding 412 amino acids that 
encompass the GRD to transform an ira-2 yeast strain. Cell lysates from that 
transformed strain stimulated hydrolysis of H-rasGTP but not of the 
oncogenic mutant H-rasGTPVal12. Xu et al. (1990b) purified a glutathione S- 
transferase/NF-1GRD protein expressed in E.Coli and demonstrated GTPase 
stimulating activity on both RAS2GTP and HRASGTP. The same 
investigators also showed that like the GAP and IRA2 proteins, the NF-1GRD 
fusion protein could not stimulate GTPase activity of H-rasVal12, Ras2val19, 
or RAS2Ala42 mutant protein.
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Martin et al. (1990) purified an epitope tagged 474 amino acid peptide 
which encompassed the NF-1GRD from the baculovirus/s/9 expression 
system. This peptide stimulated the GTPase activity of N-ras, but not the 
oncogenic mutants of N-rasAsp12 and N-rasVal12. NF-1GRD also stimulated 
GTP hydrolysis of the N-rasAla38 effector mutant, but at a level less than 
10% of the wild type activity.
In vitro assay results have been able to biochemically distinguish NF- 
1GRD from p120GAP. At high concentrations of N-rasGTP, GAP stimulates 
the GTPase to a much higher specific activity than does NF-1GRD. At low N- 
ras concentrations, the GAP and NF-1GRD activations are comparable 
(Martin et al., 1990). This demonstrated that NF-1GRD might have a higher 
affinity for N-rasGTP. In a competition binding assay, NF-1GRD 
demonstrated a 30 fold higher affinity for N-rasGTP than did GAP (Martin et 
al., 1990). Further studies demonstrated several differences between 
p120GAP and NF-1GRD, both in their affinities for various ras proteins and 
in their respective activations of p21-rasGTPase (Bollag and McCormick, 
1991).
NF-1GRD and p120GAP also show differences with respect to their 
interaction with p21-ras in the presence of various lipids. The activity of lipid 
derived mitogenic agents depends on cellular p21 activity (Yu et al., 1988). 
Arachidonic acid at 100pg per ml inhibits stimulation of H-rasGTPase by 
GAP catalytic fragment and NF-1GRD, whereas high concentration of 
phosphatidic acid (p-arachidonoyl^y-stearoyl) only partially inhibited NF- 
1GRD and did not inhibit GAP (Golubic et al., 1991). Other studies confirmed 
the inhibition by arachidonic acid and also demonstrated that GAP 
stimulation of H-rasGTP was increased by prostaglandins PGF2a, or PGA2 
and decreased by PGI2, whereas NF-1GRD activity was not affected by the
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prostaglandins (Han, 1991). Further comparisons of p120GAP and NF-1GAP 
with respect to lipid inhibition responses on N-rasGTP showed that 
phosphatidate, arachidonate and phosphatidylinositol 4,5 biphosphate inhibit 
NF-1GAP to a much greater extent than p120GAP (Bollag and McCormick,
1991). Furthermore, n-dodecyl-p-D-maltoside which did not inhibit p120GAP 
was identified as a stable inhibitor of NF-1GAP activity. This selective 
inhibition was used to differentiate the two GAP activities in cell lysates. 
Inhibitable GAP activity is due to NF-GAP and noninhibitable GAP activity is 
due to p120GAP. The potential physiological significance of the in vitro 
interactions of lipid moieties on GAPs raised the possibility that 
neurofibromin may play a key role in signal transduction pathways within the 
ras-dependant mitogenic response of many cell types (Viskochil et al., 1993).
Tumour suppressor function of the NF-1 gene
Neurofibromatosis type-1 represents a disease caused by disruption 
of a tumour suppressor gene, which encodes a protein involved in the proper 
regulation of cell differentiation and proliferation and its disruption 
predisposes to tumour formation. The NF-1 gene is established as a tumour 
suppressor gene (Legius et al., 1993 Andersen et al., 1993b, The et al., 
1993, Johnson et al., 1993 and Legius, 1994 (NNFF newsletter), whose loss 
of function appears to be associated with typical NF-1 related tumours and 
with a variety of unrelated tumours in the general population. The genetic 
mechanisms through which aberrations in the NF-1 gene may contribute to 
tumourigenesis involve a two-hit model of tumourigenesis in which both 
copies of the tumour suppressor locus need to be deleted or inactivated in 
order to lead to tumour formation. The clinical variability of NF-1 symptoms 
affecting multiple organ systems and cell types suggested that the NF-1 gene
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may play an important role in regulating growth and development not only in 
neural crest derived tissues.
The NF-1 gene has been shown to be a recessive tumour suppressor 
gene and the relationship between genomic imprinting and tumourigenesis is 
thus considered. Genomic imprinting has also been suggested as an 
important factor in the occurrence of certain cancers (Hall, 1990). Knudson 
(1991) presented a model for tumourigenesis based on two successive "hits" 
on the genome. This was speculated to result in inactivation of homologous 
alleles encoding a tumour suppressor locus, leading to cellular deregulation. 
In familial cancers, the first insult was inherited and the second event 
occurred somatically. In sporadic cases of cancer, it was suggested that both 
events occurred somatically. Sapienza (1991) was the first to incorporate 
genetic imprinting into this model. If an imprinted gene was involved, the first 
hit may actually be explained by non-expression of one of the alleles due to 
the imprinting process. An imprinted gene by definition is not expressed, 
leaving a hemizygous phenotype. The second hit may be mutational, or may 
result from a loss of all or part of the chromosome carrying the remaining 
functional suppressor allele. Loss of function is only one of the mechanisms 
proposed for tumourigenesis. Hochberg et al. (1994) suggested that the 
activation of imprinted protoncogenes and growth factors may also play a 
vital role in tumourigenesis. This is proposed to occur when the gene is 
removed (translocated) from its imprinted sequence area, it escapes 
repression and overexpression then leads to abnormal cellular proliferation 
and cancer.
The NF-1 gene however may be mutant in typical NF-1 tumours as 
well as in a variety of unrelated neoplasms. Li et al. (1992) have detected 
amino acid substitutions altering the codon Lys1423 of neurofibromin in an
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NF-1 family as well as in a sporadic anaplastic astrocytoma, a sporadic colon 
carcinoma and myelodysplastic syndrome, the latter two of which are not 
known to be associated with NF-1. Lys1423 is one of the 14 amino acids in 
the NF-1 GRD which are absolutely conserved across all members of the 
GAP family of proteins, suggesting the mutations were significantly functional 
alterations.
The mechanism of action of neurofibromin may be distinct for the 
different types of tissues involved. Dramatically elevated levels of active GTP 
bound ras were found in malignant neurofibrosarcomas from NF-1 patients 
by DeClue et al. (1992) and Basu et al. (1992). To the contrary, The et al. 
(1993) found only moderately elevated rasGTP levels in neurofibromin 
deficient sporadic neuroblastoma cells.
Johnson et al. (1993) saw no correlation at all between the level of 
neurofibromin and the proportion of active GTP bound ras in neuroblastomas 
and sporadic melanoma cell lines. Previously it was seen that in 
Schwannoma cell lines from patients with neurofibromatosis, loss of 
neurofibromin was shown to be associated with impaired regulation of 
rasGTP on overexpression of cHras. However the above neuroblastoma and 
melanoma cell lines have greatly reduced or absent levels of neurofibromin 
with appropriate regulation of GTP ras, even when cHras was overexpressed 
in these lines. These results suggest that some neural crest tumours not 
associated with neurofibromatosis have acquired somatically inactivated NF- 
1 genes and suggest a tumour suppressor function of neurofibromin 
independent of its rasGTPase activation i.e. its GAP like activity. 
Neurofibromin may be involved in ras mediated differentiation pathways and 
loss of neurofibromin may inhibit this pathway (Seizinger, 1993). Indeed in 
some neural crest derived cell types p21-ras activation may actually result in
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cell cycle arrest rather than in mitogenic stimulation depending on the 
physiological status of the cells.
The ras group of oncogenes, activating mutations and relationship with NF-1 
somatic mutations
The ras gene family encodes membrane associated, guanine 
nucleotide binding proteins (p21) that are involved in the control of cellular 
proliferation and differentiation. Similar to other guanine binding proteins, the 
ras proteins cycle between the active guanosine triphosphate bound form 
(GTP) and an inactive guanosine diphosphate bound form (GDP). The weak 
intrinsic GTPase activity of ras proteins is greatly enhanced by the actions of 
GTPase activating proteins (GAPs). Both p120ras (protein product of the ras 
genes) and neurofibromin greatly stimulate p21 mediated GTP hydrolysis.
Point mutations in the ras genes, (activating or oncogenic mutants) 
have been detected in many human tumours and mice transgenic for mutant 
ras proteins develop tumours at a higher frequency than control mice. The 
ras genes acquire transforming potential when due to a point mutation, a 
single amino acid of the protein product at one of the critical codon positions 
12, 13, or 61 is altered. The ras genes appear to be finely balanced at the 
edge of oncogenesis. Almost any mutation at codon position 12 or 61 can 
convert them to active oncogenes. Position 12 is occupied by glycine in exon
1. If it is replaced by any other of the 19 amino acids except proline it can 
transform cultured cells. Position 61 is occupied by glutamine in wild type 
genes in exon 2. Its change to another amino acid usually creates a gene 
with transforming potential. However conversion of the glutamine to proline 
or glutamic acid has no effect. Ras mutations have been detected in many
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human malignancies and their incidence in various tumour types is shown in 
Table 4: Incidence of ras gene mutations in human malignancies
Tumour type % of tumours 
harbouring a 
mutant ras gene
ras gene
preferentially
activated
Colon adenocarcinoma 50 K-ras
Colon adenoma 50 K-ras
Pancreatic
adenocarcinoma
90 K-ras
Seminoma 40 K-ras, N-ras
Melanoma 20 N-ras
Neuroblastoma <5
Lung adenocarcinoma 30 K-ras
Thyroid follicular 
carcinoma
50 N,K, & H-ras
Myelodysplastic syndrome 30 N-ras
Biochemically, nearly all of these activating mutations decrease the 
intrinsic GTPase activity of the encoded ras and are insensitive to stimulation 
by GAPs (Ballester et al., 1990). Normally only a small proportion of cellular 
p21-ras is GTP bound. Mutations in ras can dramatically increase its 
biological activity by encoding mutant p21-ras, that accumulates much higher 
levels of the GTP bound form. These observations led to the hypothesis that 
at least some of the transforming activity of mutant ras is conferred by the ras 
protein being constitutively activated in the GTP bound state. Mutations in 
ras that render it insensitive to GAP regulation, result in tumour formation. 
Therefore mutations in GAP (C-terminal portion or the catalytic domain) and 
NF-1 (NF-1 GAP related domain) that alter their ability to down regulate ras 
might result in a similar phenotype. Thus if a tumour phenotype can be 
related to the ras protein being in the active, GTP bound state, then perhaps 
a similar phenotype can be induced by an inactivation of the catalytic domain 
of GAP, or NF-1 which are the contributors to ras-GTP hydrolysis.
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This was the hypothesis that was tested by undertaking somatic 
mutation analysis in the GAP related domain of the NF-1 gene in various 
tumour types. Before screening for mutations within the NF-1 gene, the same 
panel of mutations was analysed for mutations in the appropriate ras group of 
oncogenes. Somatic mutations that activate ras genes may contribute to 
tumourigenesis in up to 30% of human tumours (Bos, 1989). It was proposed 
that NF-1 mutations should be considered in any tumour type in which 
activated ras genes are frequently found and perhaps in these tumour types, 
NF1 mutations are the functional complement of ras mutations and will be 
found in those tumour samples lacking ras mutations. NF-1 mutations were 
also screened for in tumour types in which activated ras is shown to inhibit 
growth (e.g. medullary thyroid carcinoma) and it was proposed that in these 
tumour types, mutations would be found in those tumour samples composed 
of cells that continue to proliferate when activated ras is introduced (Li et al.,
1992).
Treatment of NF-1
The cloning of the NF-1 gene has helped in understanding the 
pathobiology of neurofibromatosis and the eventual goal is to design specific 
nonsurgical treatments for affected patients. The finding of elevated p21-ras­
GTP levels in tumours from NF-1 patients suggests that drug therapies 
directed at upregulating neurofibromin GAP activity or down regulating p21- 
ras activity might have some beneficial growth on neurofibromas. A number 
of groups have been studying the lipid sensitivity of neurofibromin GAP 
activity and find that specific lipids preferentially alter neurofibromin GAP 
activity as opposed to mammalian p-120 GAP activity. The discovery of a 
compound capable of up-regulating or replacing neurofibromin, or drugs that 
interfere with p21-ras activity, such as pharmaceutical events that block
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farnesylation (a reaction necessary for p21-ras membrane localisation) might 
have a therapeutic potential in NF-1.
Animal models of NF-1
Three early models of NF-1 were reported. In the bicolour damselfish, 
spontaneous neurofibromas and hyperpigmented spots develop, but the 
disorder appeared to be transmissible and these tumours were more 
aggressive and malignant than human neurofibromas (Schmale et al., 1988). 
Hinrichs et al. (1987) reported a murine model resulting from overexpression 
of the HTLV-tat gene in mice. However other phenotypic features of NF-1 
were absent and the neurofibromas lacked Schwann cells unlike human NF-1 
neurofibromas. Also the relationship between HTLV-I and human NF-1 
disease is unclear, as there is no increased incidence of HTLV-I expression 
or infection in NF-1 patients. Nakamura et al. (1989) described a third model 
of NF-1 by injecting N-nitros-N-Ethylurea into pregnant Syrian golden 
hamsters. The progeny developed neurofibromas histologically identical to 
those observed in NF-1 lesions, as well as pigmented lesions similar to cafe 
au lait spots. However these hamsters also had Wilms tumours and other 
malignancies not seen in typical NF-1 patients. Point mutations in the n- 
protoncogene were identified in these tumour cells but no mutations were 
identified in the NF-1 gene.
Recent efforts have been directed at generating a mouse NF-1 
knockout by homologous recombination. Brannan et al. (1994) used gene 
targeting in ES cells to generate mice carrying a null mutation at the mouse 
NF-1 locus. However heterozygous mutant mice did not exhibit obvious 
abnormalities. The homozygous mutant embryos died in utero, due to severe 
malformation of the heart and also displayed hyperplasia of neural crest 
derived sympathetic ganglia.
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Jacks et al. (1994) created a mouse model by successfully disrupting 
the mouse homologue of exon 31. This was done by the insertion of a 
neomycin cassette to produce a truncated NF-1 mRNA. Mouse embryonic 
stem cells carrying this abnormal NF-1 gene, were introduced into 
blastocysts and viable offspring were selected that carried a copy of the 
mutated NF-1 gene. The heterozygous animals did not exhibit the classic 
symptoms of the disease, but were highly predisposed to the formation of 
different tumour types, notably phaeochromocytoma and myeloid leukaemia, 
both of which occur with increased frequency in human NF-1 patients. The 
wild type NF-1 allele was lost from approximately half of the tumours from 
heterozygous animals. In addition homozygosity for the NF-1 mutation led to 
abnormal cardiac development and mid-gestational embryonic lethality.
1.9 GERMLINE AND SOMATIC MUTATIONS IN NF-1
£
IMPORTANCE OF MUTATION DTECTION WITHIN THE NF-1 GENE
A
Identification of mutations in this large and complex gene is important for the 
following reasons:
1. By isolating a large number of independent mutations within the NF-1 
gene a mutational spectrum for the NF-1 gene can be established. By 
determining the type and site of each mutation, delineation of mutational 
hot-spots, if any, within the gene can be carried out.
2. Identification of mutations within the gene will allow many variant forms of 
the protein to be compared. A detailed analysis of the mutations can be 
used to identify regions of neurofibromin responsible for specific 
functions.
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3. Mutation analysis is necessary to assess the role of the three embedded 
genes EV12A, EV12B and OMGP within the NF-1 gene and to determine 
unique molecular mechanisms for disease. An example for this is seen in 
Haemophilia A, where the embedded gene (F8A) within intron 22 of the 
factor VIII gene was found to be responsible for the causation of 
mutations (inversions) in 50% of the severe cases. (Naylor et al., 1993, 
Lakich et al., 1993).
4. The existence of mutations allows comparison of properties of the wild- 
type gene with a defective gene. By analysing the type of changes that 
occur, an effort can be made to correlate the phenotype with the genotype 
and perhaps, associate certain domains of the gene with specific 
manifestations of the disorder.
5. Mutation detection within the NF-1 gene may help in creating a molecular 
classification for the clinically variant forms of NF-1 e.g. Watson 
syndrome, segmental NF, etc.
6. Detection of somatic mutations within the NF-1 gene in NF related and 
unrelated tumours will further establish the tumour suppressor function of 
the NF-1 gene.
DIFFICULTIES IN MUTATION ANALYSIS IN THE NF-1 GENE
Mutation analysis within the NF-1 gene is complicated due to the 
following:
1)The large size of the gene:
The NF-1 gene extends for over 300 kb on chromosome 17 and has at least 
49 exons, whose intron exon boundaries have not yet been fully 
characterised. The NF-1 gene produces a transcript of 11-13 kb, of which 8.5 
kb is the coding sequence, encoding 2818 amino acids. Screening for
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mutations in a large gene, for which the coding sequence of only 9 exons 
(28-36) had been initially reported (Cawthon et al., 1990a) and whose 
complete characterisation is still awaited, created initial difficulties.
2)The high mutation rate:
When mutations are considered in terms of inactivation of the gene, most 
genes within a species show rates of mutation relative to their size. However 
it is seen that the spontaneous mutation rate in NF-1 is even higher (Huson 
et al., 1989), estimated at 1 X 10-4 mutations per gamete per generation.
Up to 30-50% of cases are due to new mutations. The prevalence and 
mutation rate for NF-1 from various studies are listed in Table 5.
Table 5: Prevalence and mutation rate in NF-1
Study (year) Methods of ascertainement Prevalence Mutation rate
Crowe et al. 
(1956)
Surveys of general hospital 
admissions & state mental 
institutions
1/2500-3000 1.4-2.6x1 O’4
Sergeyev (1975) Population sample of 16 year 
old Russian youths
1/7800 4.4-4.9x1 O’4
Samuelsson & 
Axelson (1981)
Population based 1/4600 4.3x10-5
Huson et al. 
(1989)
Population based 1/2500-4590 3.1-10.5x10-5
Adapted from Huson et al. (1989).
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3) Presence of the normal allele:
NF-1 is an autosomal dominant condition and during mutational analysis, the 
presence of the normal allele has always to be taken into account, on 
analysis of the directly sequenced PCR products. This may sometimes 
complicate analysis of complex sequences. This can be seen in the case of 
insertions and deletions within the NF-1 gene (e.g. sequence analysis of a 
single base insertion 6519insG -Figure 39).
4) Presence of NF-1 homologous sequences and pseudogenes
The presence of NF-1 homologous sequences has been detected (Marchuk 
et al 1993) and some of these have been characterised by Legius et al 
(1993) and Gasparini et al (1993). The presence of homologous sequences 
should be taken into account during amplification and analysis of mutations.
NF-1 mutations that have been detected in the constitutional DNA of 
NF-1 patients include translocations, medium to large sized deletions and 
insertions and nonsense and missense mutations. Most of the above 
mutations would be expected to inactivate neurofibromin by truncating the 
protein and/or drastically changing its overall shape. Mutant alleles with 
mutations lying 3' to the NF-1 GRD might produce stable neurofibromin with 
intact functioning GRD. For mutations within the GRD of NF-1 patients the 
mutant neurofibromin predicted even if stable, would not be expected to bind 
to rasGTP and stimulate the GTPase. It was seen that most NF-1 germline 
mutations lead to neurofibromatosis by inactivating the gene and suggested 
that NF-1 was a tumour suppressor gene. If so, the remaining allele would be 
expected to undergo inactivation during development of at least some of the 
tumours which arise in NF-1 patients.
Loss of allele is one mechanism of inactivation and one way of 
detecting loss of an allele is to examine benign and malignant tumours from
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NF-1 patients for loss of heterozygosity (LOH) on chromosome 17 in the 
region of the NF-1 gene (Figure 4). Extensive analyses by various groups 
have failed to detect LOH along chromosome 17 in the benign tumours of 
NF-1 neurofibromas. This suggested that events other than inactivation of 
the second NF-1 allele, or inactivation of the second NF-1 allele by 
mechanisms more subtle than allele loss i.e. point mutations, were involved 
in the development of these tumours.
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LOSS OF HETEROZYGOSITY IN NF-1
Figure 4: Loss of heterozygosity in NF-1
A given DNA marker polymorphism, denoted by the filled squares, is present 
in a normal NF-1 chromosome 17. A germline mutation found in all cells in an 
NF-1 patient would alter the NF-1 gene to result in loss of one of the DNA 
markers. Because the patient has one normal chromosome 17 DNA 
polymorphism and one mutated chromosome 17 DNA polymorphism, the 
patient is heterozygous with respect to that DNA marker. Mutation of the one 
remaining normal NF-1 gene in a tumour would result in loss of both copies 
of the gene and loss of heterozygosity with respect to that DNA marker 
polymorphism.
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Analysis of some malignant tumours from NF-1 patients have shown LOH for 
DNA markers on 17p or along the entire length of chromosome 17 (Skuse et 
al., 1989, Glover et al., 1991, Menon et al., 1990). These findings were 
ambiguous because loss of a normal allele of the p53 tumour suppressor on 
17p could contribute to tumour progression and drive chromosome loss. 
However other malignant tumours from NF-1 patients have shown LOH 
specific to 17q. Xu et al. (1992) reported allele losses with markers flanking 
the NF-1 region in each of the 7 phaeochromocytomas they examined and in 
3 tumours the loss involved the wild-type chromosome. These results 
provided evidence that in cells of the adrenal medulla at least, the NF-1 gene 
may act as a tumour suppressor.
In total allele losses that were shown unequivocally to span the NF-1 
region have been reported in 6/19 neurofibrosarcomas from NF-1 patients in 
the series of Xu et al. (1992), Glover et al. (1991) and Menon et al. (1990). 
Studies of neurofibrosarcomas in NF-1 patients by Basu et al. (1992) and 
DeClue et al. (1992) showed drastically diminished levels of neurofibromin by 
immunoassay with elevated levels of rasGTP. This suggested that the 
development of the tumours was due to nearly complete loss of 
neurofibromin function.
Andersen et al. (1993b), The et al. (1993) and Johnson et al. (1993) 
have shown aberrations in the NF-1 gene in sporadic malignant melanomas 
and neuroblastomas. Some of the melanomas and neuroblastomas were 
found to be associated with homozygous deletions at the NF-1 locus, i.e. 
both copies of the NF-1 gene were aberrant or deleted. Legius et al. (1993) 
also detected a homozygous deletion in a neurofibrosarcoma from an NF-1 
patient. Loss of marker alleles in the vicinity of NF-1 or encompassing the 
NF-1 locus leaves open the possibility that some other gene in the region
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and not NF-1 itself may be a relevant contributor to tumour progression in 
NF-1 associated malignancies.
The other mechanism of inactivation of the second allele could be due 
to small alterations within the NF-1 gene. Li et al. (1992) used the 
polymerase chain reaction and single stranded conformational polymorphism 
method to screen rapidly for point mutations and small alterations within the 
NF-1 gene. They initially screened exon 24 or the FLR exon, which is the 
most conserved exon in the NF-1 GRD. The three consecutive amino acids 
FLR are completely conserved across all 4 proteins and FLR occurs only 
once in the entire 2818 amino acid sequence of the predicted NF-1 protein. 
The relatively high degree of conservation of amino acid sequence across 
these different proteins and between species suggested that somatic 
mutations in this region of the gene would be likely to alter amino acid 
residues crucial to the function of the gene and so to the clinical pathology. 
The initial screening revealed an amino acid substitution altering Lys1423, 
that occurred in three tumour types: colon adenocarcinoma, myelodysplastic 
syndrome and anaplastic astrocytoma and in one family with 
neurofibromatosis-1. The GAP activity of the mutant GRD was shown to be 
200-400 fold lower than that of wild type, whereas binding affinity was 
unaffected. Thus it was shown that point mutations seen in the germline and 
causing NF-1 also occur in somatic cells and contribute to the development 
of sporadic tumours, including tumours not associated with NF-1.
The above study reported the conversion of lysine 1423 to glutamine 
in a colon cancer sample and conversion to glycine in an anaplastic 
astrocytoma sample. An alteration of this lysine residue to methionine has 
been reported to affect stability of the protein (Weismuller and Wittinghoffer, 
1992).
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To further understand the significance of the lysine 1423 residue of 
neurofibromin and its role in NF-1 function, Poullet et al. (1994) mutated it to 
all possible amino acids. Functional assays using yeast ira complementation 
revealed that lysine was the only amino acid that produced functional 
neurofibromin. Quantitative analysis of different proteins suggested that their 
GAP activity is drastically reduced due to decrease in their ras affinity. Such 
a requirement for a specific residue was not observed in the case of other 
conserved residues within the GRD. The authors also reported that another 
residue phenylalanine 1434 plays an important role in NF-1 function. This 
was indicated by the finding that the defective neurofibromin due to an 
alteration of lysine 1423 to other amino acids could be rescued by a second 
mutation at residue 1434. The mutation partially restored GAP activity in the 
lysine mutant. Thus the above work demonstrated the importance of the 
lysine 1423 for NF-1 function.
Legius (NNFF newsletter-June 1994) recently identified a point 
mutation (L2317P) in exon 38 of the NF-1 gene. This mutation was detected 
in a patient whose neurofibrosarcoma was studied and found to show loss of 
heterozygosity for all of chromosome 17 (Glover et al., 1991) and lack of 
neurofibromin expression (DeClue et al., 1992 and Basu et al., 1992). With 
the finding of the germline mutation in this patient, it was shown that the 
normal allele was the one lost in the tumour, in accordance with the tumour 
suppressor hypothesis (NNNF International NF-1 Genetic analysis newsletter 
vol. 2, no 3). Thus the results further contributed to the fact that inactivation 
of both NF-1 alleles may contribute to the development of several NF-1 
associated and non associated malignancies and that the NF-1 gene 
appears to follow the pattern of a recessive tumour suppressor gene.
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1.10 AIMS OF THE STUDY
1. To amplify the NF-1 coding sequence by designing oligonucleotide 
primers for amplification using both DNA and RNA as templates for 
PCR.
2. To develop an efficient screening strategy for the detection of mutations, 
utilising techniques such as single stranded conformational 
polymorphism (SSCP) and chemical cleavage of mismatches (CCM).
3. To completely characterise the mutations identified by the above 
techniques, by direct sequencing of single stranded template generated 
by asymmetric PCR amplification.
4. To identify the mutational spectrum of the germline mutations affecting 
the NF-1 gene.
5. To analyse the distribution of mutations detected within the NF-1 gene 
and detect areas with a high mutation frequency (mutational hot-spots).
6. To assess the tumour suppressor function of neurofibromin by analysis 
of somatic mutations in tumours unrelated to NF-1.
7. To correlate the genotype with the phenotype by predicting the effect of 
the characterised mutations on the protein product.
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CHAPTER: 2 
MATERIALS AND METHODS
CHAPTER 2: MATERIALS AND METHODS
2.1 PATIENTS AND TUMOUR TISSUE USED FOR ANALYSIS
Twenty-five Caucasian patients including both sporadic and familial 
cases were screened for mutations in the NF-1 gene. 78% of the coding 
sequence was screened, of which 50% was screened using RNA as a 
template and 28% using DNA as a template.
The tumour samples studied were:
Melanoma: 3 samples (F-2564, B-5530, P-2852)
Neuroblastoma: 4 samples (S-1, B-2, C-3, M-4).
Myelodysplastic syndrome (MDS): 10 samples (922363, 921492, 921406, 
921508, 921822, 922161, 922404, 921919, 921821, 921572)
Pancreatic carcinoma: 2 samples (9020, 2063)
Colonic adenocarcinoma: 2 samples (8496, 8278)
Colonic adenoma: 2 samples (8549, 8284)
Lung adenocarcinoma: 2 samples (0019, 2575)
Seminoma: 2 samples (0187, 0907)
Thyroid follicular carcinoma: 2 samples (7830, 3505)
2.2 EXTRACTION OF DNA
DNA was extracted from peripheral leukocytes, paraffin embedded 
tissue and cultured cell lines.
Extraction of DNA from whole blood
Genomic DNA was extracted from peripheral blood leukocytes (fresh 
and frozen) using a variation of the method described by Kunkel et al. (1977).
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10ml of whole blood was put in a 50ml Falcon centrifuge tube, to 
which 40ml of lysis mix was added. Tubes were left on ice for 10 minutes and 
then centrifuged at 2500 r.p.m. for 10 minutes at 4°C in an IEC DPR-6000 
centrifuge. The resulting pellet was resuspended in 3ml of nuclei lysis mix, 
200pl of 10% SDS and 100pl proteinase K (100 mg/ml). Tubes were 
incubated overnight at 37°C. After incubation, 1ml of 6M sodium chloride 
was added with vigorous shaking and the tubes were spun at 2500 r.p.m. for 
a further 10 minutes. The supernatant was then transferred to a fresh 50ml 
Falcon centrifuge tube and 3ml of phenol:chloroform was added and spun at 
2500 r.p.m. for 15 minutes. The upper aqueous phase was transferred to a 
fresh tube and DNA was precipitated by addition of two volumes of ethanol. 
The DNA was then spooled out, washed in 70% ethanol, allowed to air dry 
and suspended in 500pl of T.E buffer. DNA extractions were also carried out 
from bone marrow samples (in patients with myelodysplastic syndrome) that 
were stored at -20°C in fixative (methanol:acetic, acid 3:1). In order to get rid 
of the fixative the cells were given 3 washes with PBS and the method used 
was the same as for the extraction from blood samples, except that the initial 
lysis step was omitted since the starting material was solely nucleated cells.
Extraction of DNA from paraffin embedded tissue
DNA extraction was carried out from tumour tissue embedded in 
paraffin blocks (Rolfs et al., 1992). 10pm sections were cut from the paraffin 
blocks, taking care to exclude surrounding normal tissue and only sections 
having tumour tissue were taken as far as possible. One 10pm section was 
placed in a 1.5ml microfuge tube. To remove the paraffin, 400pl of xylene 
was added. The tube was vortexed vigorously and centrifuged at full speed in 
a bench top centrifuge (IEC Centra 4X) for 5 minutes at room temperature.
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The xylene was carefully removed with a pipette and the residual xylene was 
removed by gently mixing the tissue pellet with 400pl of absolute ethanol. 
This was again centrifuged at full speed in a bench top centrifuge for 5 
minutes at room temperature. The ethanol was removed with a pipette and 
the remaining ethanol was allowed to evaporate off by incubating in an oven 
at 37°C for 10-15 minutes.
The tissue pellet was resuspended in 50pl of proteinase K buffer and 
this mixture was incubated at 50°C in a water bath for 24 hours. An 
additional aliquot of proteinase K was added after 12 hours, to ensure more 
complete protein digestion. The tubes were removed from the water bath and 
centrifuged briefly to remove any condensed water in the lid. To the tubes 
was added one volume phenol/chloroform/isoamyl alcohol (25:24:1). The 
tube was vortexed vigorously and then centrifuged at full speed in a bench 
top centrifuge for 10 minutes at room temperature, to separate the organic 
phase from the aqueous phase. The upper aqueous phase was then 
transferred to a clean 1.5ml microfuge tube. The organic phase was re­
extracted by addition of 100pl T.E buffer. This was vortexed and spun at full 
speed in a bench top centrifuge. This aqueous phase was then added to the 
previously collected aqueous phase. The DNA from the aqueous phase was 
precipitated by addition of 1/10 volume of 3M sodium acetate (pH 5.2) and 
2.5 volumes of pure ethanol. The mixture was mixed well and incubated at - 
20°C overnight. This was then centrifuged for 30 minutes at 4°C at full 
speed in a bench top centrifuge. The supernatant was removed and the 
pellet was washed with 200pl of 70% ethanol. The pellet was then allowed to 
dry and resuspended in 20pl of T.E buffer. Approximately 400ng of DNA can 
be recovered from a 10pm section and 5pl (100ng) of the above extracted 
DNA dissolved in T.E buffer was used for a PCR reaction.
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Extraction of DNA from cultured cell lines
DNA was extracted from cultured cell lines using a modified procedure 
described by Laird et al. (1991).
Cells were grown in 80cm2 flasks at 37°C (LTE incubator), in a closed 
system using Ham's F10 with Hepes (Gibco BRL) supplemented with 10% 
foetal calf serum, 10% new-born calf serum and 1% penicillin streptomycin 
until confluent (Boyd, I.). An 80% confluent flask contained about 2X106 
cells. The flasks were washed with 10ml of PBS (Gibco BRL) thrice to get rid 
of the medium. To the flask was added 5ml of lysis buffer. The flasks were 
incubated at 37°C for 3-4 hours. The flasks were then taken out of the 
incubator and an equal volume of isopropanol was added. This was kept on 
a shaker and agitated for 15-20 minutes. The DNA obtained was spooled out 
and washed in 70% ethanol. This was then dissolved in 200pl of T.E buffer 
and stored at -20°C until further use.
Determination of concentration of DNA
The concentration of each DNA sample was determined by measuring 
the optical density at 260nm in a dual beam spectrophotometer. An O.D. 
reading of 1 corresponds to 50pg/ml of DNA.
2.3 EXTRACTION OF RNA
RNA was extracted from peripheral lymphocytes and cultured cells by 
the modified acid-guanidinium thiocyanate method described by 
Chomczynski and Sacchi (1987).
Extraction of RNA from peripheral lymphocytes
The extraction of RNA from peripheral lymphocytes involved the initial 
separation of lymphocytes from whole blood, followed by the acid
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guanidinium thiocyanate phenol-chloroform extraction. All the solutions used 
(except organic solutions) and the tubes and tips required for handling of the 
RNA were treated with a solution of 0.1% DEPC (diethyl pyrocarbonate), to 
prevent degradation of the RNA by RNases.
a)Separation of lymphocytes from whole blood:
5ml of whole blood was layered over 5ml of Histopaque (Sigma) in a 
Universal. The tube was then centrifuged for 30 minutes at 1400 r.p.m. at 
room temperature. The opaque interphase (buffy coat) was transferred into a 
fresh tube. The cells were then washed twice with 5ml of cold PBS (Gibco 
BRL). The supernatant was discarded after centrifugation at 1400 r.p.m. for 
10 minutes.
b)The Acid guanidinium thiocvanate phenol chloroform extraction:
To the cells in the Universal, 500|il of solution D was added and the 
cells were thoroughly mixed with the solution D until viscous. This was then 
transferred to an autoclaved and DEPC treated 1.5ml microfuge tube. To this 
was added 50pl of 2M sodium acetate (pH 4.0), 500pil phenol and 100pl of 
chloroform-isoamyl alcohol (49:1). The microfuge tube was then vortexed for 
10 seconds and placed on ice for 15 minutes. The tube was then centrifuged 
in a bench top centrifuge for 20 minutes. After centrifugation there was 
separation into an upper aqueous phase. This was transferred to a fresh 
microfuge tube, to which an equal volume of isopropanol was added. The 
tube was then vortexed and precipitated at -20°C for a minimum of one hour. 
The tube was then centrifuged at full speed in a bench top centrifuge and the 
supernatant was discarded. The resultant RNA pellet was then dissolved in 
300pJ of solution D to which an equal volume of isopropanol was added. 
The mixture was kept at -20°C for one hour. The tube was then centrifuged 
at full speed for 10 minutes. The supernatant was discarded and the pellet
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was washed in 70% ethanol and air dried. The pellet was dissolved in 50pl of 
DEPC water and stored at -20°C until required.
Extraction of RNA from cultured cells
Human tumour (neuroblastoma) lines were cultured in 80cm2 flasks 
until confluent. The cells were washed twice in PBS (Gibco BRL) and the 
flask drained. 1ml of solution D was added to the flask and the flask was 
agitated. A further 2ml of solution D was added and the viscous mixture was 
collected in a sterile 30ml polypropylene tube. The following reagents were 
added to this: 1/10th volume 2M sodium acetate (pH 4.0), 1ml unequilibrated 
phenol and 0.6ml chloroform:isoamyl alcohol (49:1). The sample was gently 
mixed after the addition of each reagent and incubated on ice for 15 minutes. 
The RNA was pelleted down by centrifugation at 10,000 r.p.m. for 20 minutes 
at 4°C in a Sorvall rotor. The aqueous phase was transferred to a fresh tube 
and 3ml of isopropranol was added. The solution was mixed and incubated 
at -20°C for 60 minutes. The RNA was pelleted at 10,000 r.p.m. for 20 
minutes at 4°C and the supernatant discarded. The pellet was resuspended 
in 0.6ml solution D and an equal volume of isopropanolol was added. The 
RNA was precipitated by incubation at -20°C for 60 minutes followed by 
centrifugation at 10,000 r.p.m. for 10 minutes. The pellet of RNA was washed 
twice in 70% ethanol and resuspended in DEPC treated water. The method 
yielded 200-300pg of RNA per 5X106 cells.
Visualisation of the RNA
The RNA checking gel was prepared by boiling 0.45g agarose in 22ml 
dH20 and cooled to 55°C. To this was added 5ml of 37% formaldehyde and 
10 x MOPS to make up a total volume of 30ml. The gel was poured in a fume
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hood. The RNA sample was prepared as follows: 1pl total RNA, 1.3pl dH20, 5 
pi formamide, 1.65pl (37%) formaldehyde solution and 1pl 10XMOPS made 
up to a total volume of 10pl. This was heated in a 55-60°C water bath for 10 
minutes and quenched on ice. To this was added 2pl 10XRNA loading buffer 
and the sample was loaded immediately. The gel was run in 1XMOPS buffer 
at 70-80 volts for 40-60 minutes. After electrophoresis was complete, the gel 
was rinsed in water to wash out the formaldehyde and stained for 5 minutes 
in 5pg/ml ethidium bromide. The gel was destained in water overnight and 
viewed under UV light to check for integrity of ribosomal bands and to 
estimate concentrations. The concentration was also determined by 
measuring the optical density at 260nm. The integrity of the RNA was 
assesed by comparing the ratio of the O.D at 260/280. A good quality 
preparation should give a value of 2 (Gurr and McPherson, 1991).
2.4 DESIGN OF OLIGONUCLEOTIDES
The following guidelines were followed for primer design:
1)Where possible, primers were selected with an average G+C content of 
around 50% and a random base distribution.
2)The rule of thumb calculation of 2°C for A or T and 4°C for G or C (Thein 
and Wallace, 1986) was used in calculation of the Tm of both the primers 
such that they ranged from 50-75°C.
3)Most primers were designed to be about 20-30 bases in length and runs of 
C's or G's at the 3' ends of the primers and palindromic sequences within 
primers were avoided.
The primers used in this study were designed using the program OLIGO™ 
version 3.4 and in addition to the above, the following rules were considered: 
-Self complementarity within the primers was avoided.
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-3' end complementarity at the end of both primers was avoided, as this 
reduces the incidence of primer-dimer artefacts.
-Primers were designed such that there was not much difference between 
their melting temperatures (Tm) as calculated by the program.
-Duplex stability i.e. the strength of the bond the primer makes with the 
template was usually kept to >400 kcal/mol and was similar in both primers.
2.5 PURIFICATION OF OLIGONUCLEOTIDES
Oligonucleotides used in this study were synthesised on an ABI 391- 
DNA synthesiser. These oligonucleotides were phosphoramidite synthesised 
and require a final reaction step with concentrated ammonia to effect their 
complete deprotection. Ammonia was used for primer elution and 
deprotection and this needed to be removed from the oligonucleotides before 
the latter was used in various enzymatic processes. Primers were stored in 
their ammonia eluant at -20°C. Before use 10pl of this stock was heated to 
95°C for 3 minutes to drive off the ammonia (Taylor G. 1991) cooled, diluted 
and used for amplification.
Another method described by Sawadago and VanDyke (1992) 
involved oligonucleotide purification through extractions with n-butanol. This 
method obviated the need for prior NH3 removal and resulted in a high yield 
of oligonucleotides for use in PCR amplification and sequencing.
The procedure was carried out as follows: 100pl of deprotected 
oligonucleotide solution in NH4OH was vortexed vigorously in a 1.5ml 
microfuge tube with 10OOpI n-butanol for 15 seconds and then centrifuged for 
10 minutes (minimum 1 minute) at 12,000 r.p.m. The H20  containing n- 
butanol phase was removed and discarded. Following n-butanol extraction, 
the pellet was dried and resuspended in 50pl distilled H20  and used for PCR
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amplification. In this study both methods described were used as appropriate 
for the oligonucleotides used for PCR amplification or sequencing.
2.6 PCR USING GENOMIC DNA AS A TEMPLATE (DNA-PCR)
PCR reactions were performed in a 100pl PCR reaction mix containing 
50mM KCI, 10mM Tris-HCI (pH 8.4), 1.5mM MgCl2, 100pg/ml gelatin, 200p 
mol of each dNTP and 500 ng of each primer This mixture was then 
subjected to 10 minutes of UV irradiation to minimise contamination. To this 
mixture was added 2.5 units of Taq DNA polymerase and 1pg of DNA. The 
mixture was vortexed, centrifuged, overlaid with 40pl of mineral oil and 
subjected to PCR. The primers used for amplification of the individual exons 
and the conditions for amplification were as described in Tables 6 and 7.
2.6.1 Primers and conditions used for amplification of exons
Exons 2, 4, 11, 18, 28-36, 42, 43 and 44 were amplified from genomic DNA. 
The primer sequences used are listed in Table 6.
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TABLE 6: Primer sequences for amplification of exons
EXON PRIMER SEQUENCE REFERENCE
2F 5'TTT TAA GGA TAA ACT GTT TAC GTG 3' designed for this study
2R 5'GAA AAG AAA GCA AAT TCC CCA AAA C 3' i i
4F 5'AGG TGG TGT GTA TGT AAG GTG TTC 3' i i
4R 5’ TTT TAA TAC CAG AGA GGT TGT AAC 3’ i t
11Fe 5'ATA AGT ACT CCA GTG TTA TGT 3' i i
11 Ri 5'CAA AAT AAA ATT TAA AGT TGA AAG 3' i i
11 Re 5'AAT GAA TAC AAG TTT AGA GAA GCT 3' i i
18Fe 5' CCC CTA CAC ACT GAT ACT GGT AGT 3' i i
18F 5'TGC CTT CTC TTT TGT CTA TAT CTG 3' i t
18R 5' ATT AAA ATT TAC AAA ACC CTA CAT 3' i i
28 f-a 5'AAT GAA TCC AGA CTT TGA AGA ATT G 3' Cawthon (pers.comm)
28 r-a 5'GCT ACC TTT GAG GCC AGT CAG 3' i i
28 f-b 5'GGG AGT ACA CCA AGT ATC ATG AG 3' i i
28r-b 5'GCC AGG ATA TAG TCT AGT TAG TC 3' i t
29F 5'TTC CTT AAA TGG CAT AGT GTT TTG T 3' i i
29R 5'AAA CCC CAA ATC AAA CTG AAG AGA 3' i i
29Fi 5' AGC AGA GCG AAC AAA AGT CC 3' designed for this study
29Ri 5' GGG GAT AGA GTC GGG CTG TG 3' i i
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Table 6 (continued)
EXON PRIMER SEQUENCE REFERENCE
30F 5'AAC TTA TAA GGA TCG TTT AAA ACA ACT 3' Cawthon (pers. comm)
30R 5'AAA GGG TTT TCT TTG AAT TCT CTT AG 3' t i
31F 5'ATA ATT GTT GAT GTG ATT TTC ATT G 3' VI
31R 5'AAT TTT GAA CCA GAT GAA GAG 3' 19
32F 5'ATC TAG TAT TTT TGA GGC CTC AG 3' Cawthon et al. (1990)
32 R 5'CAG ATA TGC TAT AGT ACA GAA GG 3' i f
33F 5'CAT ATC TGT TTT ATC ATC AGG AGG 3' VI
33R 5'AAG TAA AAT GGA GAA AGG AAC TGG 3' i i
34F 5'CAA AAT GAA ACA TGG AAC TTT AGA 3' VI
34R 5'TAA GCA TTA AGT ACA AAT AGC ACA 3' I I
35.36F 5'TAT GTA TTC AGA GTA TCC CCT T 3' designed for this study
35.36R 5'ATA AAT GCT AGA ATG ATT TCT CAT GCT 3' Cawthon et al. (1990)
42F 5'TAG GAC AGC CAC TTG GAA GGA 3' Shen et al (1993)
42R 5'ACA TAA TTT AGA TAA ACT AAC 3' IV
43F 5' ATA GAC ACT GTA GTT AAT GAA 3' IV
43R 5'ATC AAT ACT TTG TTT CTC AC 3' VI
44F 5' CAC GTT AAT TCC CTA TCT TGC 3' M
44R 5' TGA GAA GTA GAA GAC TGT ATC C 3' VI
F/f-forward, R/r-reverse, e=external reaction, i=internal reaction, 35,36f/r are 
the primers for amplification of exons 35 and 36 together
Primers for exons 2 and 4 were designed in order to characterise the positive 
chemical cleavage results obtained on CCM analysis of segment I which 
spans exons 2-4. Primers for exons 11 and 18 were designed to characterise 
the splice site mutations.
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TABLE 7:Conditions for amplification of exons
EXON DENATURATION ANNEALING EXTENSION CYCLES
2 94°C- min 50°C- min 72°C- min 35
4 94°C- min 56°C- min 72°C- .30 min 35
11 94°C- min 48°C- min 72°C- min 35
18 94°C- min 54°C- min 72°C- min 35
28 94°C- min 58°C- min 72°C- min 30
29 94°C- min 58°C- min 72°C- min 30
30 94°C- min 58°C- min 72°C- min 30
31 94°C- min 58°C- min 72°C- min 30
32 94°C- min 58°C- min 72°C- min 30
33 94°C- min 58°C- min 72°C- min 30
34 94°C- min 58°C- min 72°C- min 30
35-36 94°C- min 60°C- min 60°C- min 35
42 94°C- min 50°C- min 72°C- min 35
43 94°C- min 50°C- min 72°C- min 40
44 94°C- min 54°C- min 72°C- min 40
Identification of PCR products
After completion of the 100jil PCR, 10^ 1 of the PCR product was 
resolved on a 1% agarose minigel prepared in 1X TBE buffer. 
Electrophoresis was carried out at 100 volts for 45-60 minutes and the 
products were visualised on a UV transilluminator. After confirmation of size, 
each band was excised from the gel and covered with 50pl of T.E. buffer and 
stored in a labelled microfuge tube at 4°C, after overnight incubation at 
37°C. The DNA thus eluted into the buffer and this was the template for
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asymmetric PCR reactions (if necessary for that product). The remaining 90pl 
of PCR product was utilised as follows: 50pl was subjected to 'Geneclean' 
and the 'Genecleaned' products were stored separately at 4°C. 40jil of the 
remaining PCR product was stored at 4°C.
2.7 REVERSE TRANSCRIPTASE PCR: RT-PCR
RNA cannot serve as a template for PCR so RNA has to be converted 
to a complementary DNA which is amenable to PCR. The combination of 
reverse transcription and PCR was referred to as RT-PCR. Reverse 
transcription was carried out using MoMLV reverse transcriptase and using 
specific oligonucleotides to prime selectively the mRNA of interest. The 
procedure was carried out as follows: 1-2pg of RNA diluted in DEPC treated 
water was heated at 95°C for 5 minutes for denaturation. 10-50pM of the 
downstream primer used to prime reverse transcription was added and the 
mixture was heated at 65°C for 5 minutes to open up the regions in the RNA 
template that were rich in secondary structures. To the mixture was added 
reverse transcriptase buffer, dNTPs (1pl of a 10mM solution), 2pl 0.1M DTT 
(dithiothreitol) and 200U of MoMLV reverse transcriptase. Reverse 
transcription was carried out at 42°C for 45-60 minutes. After reverse 
transcription the mixture was heated at 95°C for 5 minutes to inactivate the 
enzyme, as reverse transcriptase is known to inhibit Taq polymerase, 
(Sellner et al., 1992} and to disrupt the mRNA:cDNA hybrid.
Table 8 lists the primers used for amplification of the seven RNA segments.
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2.7.1 Primers and conditions for amplification of RNA segments l-VII
TABLE 8: Primers used for amplification of RNA segments l-VII
SEGMENT PRIMER SEQUENCE
l-F* 5' GCA GCC GCT TCG ACG AGC A 3'
l-R* 5' CTA ACT GCG AAC CTT CTT TAG G 3'
I l-F 5' TGC CTT GTT TCT TGC TTT CG 3'
I l-R 5' TTC TAT CTG CCT GCT TAT TT 3'
lll-Fe 5' CCT GAT GCT CCT GTA GAA AC 3'
lll-Re 5' ATT TTG GCT TTT GGA TAG TT 3'
lll-Fi 5' AAC ATT TTG GGA GAT TAG CT 3'
lll-Ri 5' GCT TTG TTG CTT GTT CCC AT 3'
IV-Fe 5' GAA ACA CTG AGG CTT GGG AA 3'
IV-Re 5'AAA AAC TTG CTG ATG GTA TT 3'
IV-F-i 5' GCA AAA TGG GAA CAA GCA AC 3’
IV-Ri 5'ACT TGC TGA TGG TAT TCT TC 3'
V-Fe 5' CCT GCT CTG TAT CCA ATG CT 3'
V-Re 5' CCC ACT GAG AAC AAG GAA CCA CAT 3'
V-Fi 5' GCT CTG TAT CCA ATG CTA TTT AAC 3'
V-Ri 5' TTC CAC CAA TCT CTC AAA CC 3'
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SEGMENT PRIMER SEQUENCE
Vl-Fe 5' AGT ATT GGC TGA TCG GTT TGA GAG 3'
Vl-Re 5' AGG TCG TCT TCC AAC AGC TTT ATG 3’
Vl-Fi 5' CGG TTT GAG AGA TTG GTG GA 3'
Vl-Ri 5' CTG TTG CTG GAA AGA TAC TG 3'
Vll-Fe 5' GTG CTT GCT TTA CAT CGT CTA CTC 3’
VI 1-Re 5' GTC GTA AGC AAA GCC AGG AAA AAC 3'
Vll-Fi 5' ACA TCG TCT ACT CTG GAA CAA TCA 3'
Vll-Ri 5' CAG GAA AAA CAA CAA ACC ACT TAG 3'
29-Fe * 5' TCA GCA GAG CGA ACA AAA GTC CTA 3'
33-Re* 5' GCG GAC CTG TGG CTA CTA AGA AAG 3'
29-Fi* 5' TCA CAG CCC GAC TCT ATC CCC CAA 3’
33-Ri* 5' AAA GTA GGA GTT GGA GAT AAG CAT 3'
' e '  denotes the external reaction and ' i '  the internal reaction of the nested 
PCR reaction.
All the primers described in this table, except the primers for segment-1 were 
designed for this study using the sequence information supplied by the NNFF 
International Mutation Analysis Consortium. The primers used for 
amplification of segment I were described by Guttmann et al. (1993).
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TABLE 9: Conditions for amplification
SEGMENT DENATURATION ANNEALING EXTENSION CYCLES
1 94°C for min 56°C for min 72°C for 2 min 30
II 93°C for min 53°C for min 72°C for 2 min 35
lll-e 94°C for min 52°C for min 72°C for 2 min 30
lll-i 94°C for min 56°C for min 72°C for 2 min 30
IV-e 94°C for min 52°C for min 72°C for 2 min 30
IV-i 94°C for min 56°C for min 72°C for 2 min 30
V-e 94°C for min 52°C for min 72°C for 2 min 30
V-i 94°C for min 56°C for min 72°C for 2 min 30
Vl-e 94°C for min 52°C for min 72°C for 2 min 30
Vl-i 94°C for min 56°C for min 72°C for 2 min 30
Vll-e 94°C for min 56°C for min 72°C for 2 min 30
Vll-i 94°C for min 56°C for min 72°C for 2 min 30
29-33-e 94°C for min 52°C for min 72°C for 2 min 30
29-33-i 94°C for min 58°C for min 72°C for 2 min 30
'e1 denotes the external reaction and 'i' the internal reaction of the nested 
PCR reaction.
Other primer sets were designed internal to Segment IV, V and 
Segment VI for specific further characterisation or as primers for sequencing. 
They were as follows:
Segment IV was subdivided into 2 parts and 2 new primer sets (A-R and B-F) 
were designed for use with IVF-e and IVRe: (IVF-e and IVA-R) and (IVB-F 
and IVRe).
IVA-R 5' CCT GAT GCT CCT GTA GAA AC 3'
IVB-F 5' CGG AAG GGA AAA GGG AAC TC 3'
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A forward sequencing primer internal to IV (IV-Fseq) was as follows:
IV-Fseq 5' TGT TAA GAG GCG AAT GTC CCA T 3'
Segment VI was further divided into two segments (a and b) after 
amplification using Vl-Fe and Vl-Re. The primer sets used to amplify 
segment a and b were:
Vl-Fa 5' TTA CTC TAC CAA CTG CTC TG 3’
Vl-Ra 5' GAG GAG GAA CTG ATG ATG GC 3'
Vl-Fb 5' ATC ATC AGT TCC TCC TCA GA 3'
Vl-Rb 5' ATG AAG GAA AGA CTA TGA TT 3'
PCRs using these primers was performed for 30 cycles of denaturation for 1 
min at 94°C, annealing of 56°C for 1 min, extension of 72°C for 1.30 minutes 
and a final extension of 72°C for 10 minutes.
Identification of PCR products
The products of amplification (10pl) were electrophoresed on 1% 
agarose gels and visualised by ethidium bromide staining, to confirm the size 
and detect any abnormal alterations in size. The bands were then excised 
from the gels and covered with 40pl of T.E. buffer and stored at 4°C. In the 
case of RT-PCRs with nested segments all the RT-I products (external 
reactions) were stored for later use and the remaining 90pl of RT-PCR 
product (RT-2) (internal reaction) was subjected to 'Geneclean' and stored.
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2.8 AMPLIFICATION OF THE RAS GROUP OF ONCOGENES
Point mutations in codons 12, 13 and 61 in the ras group of 
oncogenes were screened for using primers for amplification of the sequence 
surrounding codons 12 and 13 (in exon 1) and a second set of 
oligonucleotides for amplification of the region surrounding codon 61 (in exon
2). The primers used for amplification of these regions in the H-ras (H), K-ras 
(K) and N-ras (N) group of oncogenes were as follows (Lyons, 1990).
Table 10: Primers used for amplification of the regions surrounding codons 
12-13 and codon 61 of the H,K,and N ras group of oncogenes
Primer Sequence 5' to 3'
N (12-13) F CTT GCT GGT GTG AAA TGA CT
N (12-13) R ACA AAG TGG TTC TGG ATT AG
K (12-13) F TTT TTA TTA TAA GGC CTG CT
K (12-13) R GTC CAC AAA ATG ATT CTG AA
H (12-13) F GAG ACC CTG TAG GAG GAC CC
H (12-13) R CGT CCA CAA AAT GGT TCT GG
N 61-F GTT ATA GAT GGT GAAA ACC TG
N 61-R AAG CCT TCG CCT GTC CT CAT
K61-F ACC TGT CTC TTG GAT ATT CT
K61-R TGA TTT ACT ATT ATT TAT GG
H 61-F CCG GAA GCA GGT GGT CAT TG
H 61-R ACA CAC ACA GGA AGC CCT CC
Amplification conditions for all 6 PCR reactions were as follows: 30 cycles of 
94°C for 1 min, 52°C for 1 min and 72°C for 1 min followed by a final 
extension of 72°C for 5 min.
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2.9 PCR OF THE TETRANUCLEOTIDE REPEATS (AAAT)
A highly polymorphic (AAAT) Alu-repeat sequence located in intron 27 
of the NF-1 gene (Xu et al., 1991) was analysed in 5 families, where the 
causative mutation had not been characterised. This repeat sequence 
(AAAT) was used to track the NF-1 gene through the family. The primer 
sequences used were:
Alu I : 5' CAA GAA AAG CTA ATA TCG GC 3'
Alu II :5' GGA ACC TTA AGT TCA CTT AG 3'
PCR was carried out with 300ng of DNA, 200pmol each dNTP, 20pM of 
primer Alu I and 1.5pM of end labelled and 18.5pM of cold primer Alu II in a 
total volume of 25pl.
20pM of Alu II was end labelled using 20^Ci [y-32P] ATP (3000Ci/mmol) and 
5U of polynucleotide kinase (nbl).
2pl of amplification products were mixed with 10pil of formamide stop 
solution and loaded onto a 6% polyacrylamide gel and electrophoresed at 
1500V for 5 hours. The gel was dried and exposed to radiographic film for 
10-15 hours.
95
2.10 METHODS FOR MUTATION DETECTION
2.10.1 SINGLE STRANDED CONFORMATION POLYMORPHISM (SSCP)
SSCP analysis allows the detection of single base changes in short 
DNA fragments, due to mobility differences of single stranded molecules 
(Orita et al., 1989).
In PCR-SSCP analysis, the DNA sequence of interest was first 
amplified by PCR. For efficient detection of the product, isotopic label was 
coupled to the PCR primers or was incorporated into the PCR product itself. 
The PCR product was then heated to dissociate the strands and analysed by 
non-denaturing polyacrylamide or MDE™ gel electrophoresis.
Radiolabelled PCR
Radio labelled PCR was carried out using two different methods:
1)The first method involved labelling of oligonucleotides by T4 polynucleotide 
kinase and either one or both the primers were radio labelled and used for 
amplification. Synthetic oligonucleotides were synthesised without a 5' 
phosphate group and therefore can be marked quickly at the 5' OH end by 
the transfer of [y-32p] ThjS was supplied by [y-32pj a t p  and catalysed by 
the T4 kinase enzyme. The procedure for labelling was as follows:
1)50pM of the oligonucleotide was taken in- a microfuge tube, to which was 
added 1.0p,l of T4 kinase buffer (500mM Tris-HCI pH 7.6, 0.1M DTT, 0.1M 
MgCI2), 1 0(j.l of [y-32p] ATP (10nCi of 3000 Ci/mmol, 10 mCi/ml) and 1.5pl 
(15U of 10U/jal) of T4 polynucleotide kinase enzyme and the mixture was 
made up to 10pil with sterile distilled water.
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2)The mixture was mixed thoroughly centrifuged and incubated at 37°C for 
30-60 minutes. The 10pl mixture was used for a 50|xl PCR which was made 
up as follows:
10 pi of the above mixture containing the labelled oligonucleotide, 50pM of 
the other primer, 5pl of 10XPCR buffer, 1pl dNTPs (250pM), 0.5pl of Taq 
polymerase and 0.5pl DNA (20-200ng) was made up to a total of 50pl, 
overlaid with mineral oil and subjected to PCR under the appropriate 
conditions.
For the radio labelling using [a32-p] dCTP incorporation, a 10pl PCR 
was performed, using a master mix prepared for 40 tubes which contained: 
IXreaction buffer (50mM KCI, 10mM Tris-HCI pH 8, 1.5mM MgCy, 20pCi [a- 
32P] dCTP, 100pM of the appropriate primers and 20U Taq polymerase in a 
total volume of 380pl. Reactions were assembled on ice by mixing 9.5pl 
master mix with 0.5pl DNA (20-200ng) and overlaid with mineral oil and 
subjected to PCR.
Larger PCR products were analysed by SSCP after digestion with 
restriction endonucleases to obtain DNA fragments of 100-400 bp. The 
advantage of this approach was that the length of the primary PCR product 
was not limitative as long as appropriate restriction sites were available. In 
addition, using small restriction fragments for SSCP, the sensitivity of the 
technique may be enhanced. The PCR product containing exons 35 and 36 
of the NF-1 gene was also amplified from genomic DNA as a single fragment. 
This PCR product was first non radioactively amplified by PCR. This was 
then digested using two restriction enzymes Rsa I and Xba I and the 
products were electrophoresed on a 1 % agarose gel to identify the sizes of 
the digested products. 1Opl of the digested product was radioactively end- 
labelled and subjected to SSCP analysis.
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Preparation of samples and conditions for gel electrophoresis
1pl of the PCR product was diluted in 10pl loading buffer (95% 
formamide, 10mM NaOH, 0.1% bromophenol blue, 0.1% xylene cyanol) and 
denatured for 5 minutes at 90°C. After quick cooling on ice, 5-1 Opl of each 
sample was loaded onto non denaturing polyacrylamide gels, or on a MDE™ 
gel, which is a modified polyacrylamide based vinyl polymer solution.
For preparation and electrophoresis of the SSCP gels, the Sequigen 
sequencing gel apparatus (Biorad) was used. The spacers and well forming 
comb used were 0.4 mm in thickness. The glass plates were thoroughly 
cleaned using soapy water, dried and wiped with 100% ethanol. The spacers 
were kept in place and the apparatus assembled. The bottom of the gel was 
sealed using the sealing apparatus, a wick of 3MM Whatmann paper and 
30ml of a 10% polyacrylamide solution, after addition of TEMED and 
ammonium persulfate (20%) which allowed polymerisation and sealing. The 
gel forming solution using either acrylamide or MDE™ was prepared and 100 
pi of ammonium persulphate (20%) and TEMED was added. The gel was 
carefully poured between the two glass plates and allowed to polymerise for 
a minimum of 1 hour before electrophoresis. After the gel had set, the sealing 
apparatus and the well forming comb were removed. The buffer chambers 
were filled with 0.6XTBE or 1XTBE depending on the type of gel matrix used 
and the wells were washed with buffer. The prepared samples were then 
loaded onto the gel and electrophoresis was carried out under the following 
conditions:
Non denaturing polyacrylamide gels:
1)At room temperature, 6% polyacrylamide, 10% glycerol at 8 watts for 14-16 
hours in 1X TBE buffer. 2)At 4°C 6% polyacrylamide, without glycerol, at 30 
watts for 4-5 hours.
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MDE™ gels: only one electrophoretic condition was used, 10% glycerol at 6- 
8 watts for 16-18 hours in 0.6XTBE buffer at room temperature.
Autoradiography
After electrophoresis, the glass plates were separated and the gel was 
transferred to a pre-cut piece of Whatmann 3MM paper. The gel was covered 
with Saran wrap or cling film and dried under a vacuum for 20-40 minutes at 
80°C on a gel dryer (model 583 Biorad) and subjected to autoradiography. 
Alternatively, the gel was autoradiographed without drying for 10-16 hours, 
using X-Omat diagnostic AR imaging film.
2.10.2 CHEMICAL CLEAVAGE OF MISMATCHES (CCM)
The technique for chemical mismatch cleavage identifies sequence 
mismatches in heteroduplexed molecules, by chemical modification of the 
single strand causing a break or cleavage at the site of mismatch (Cotton et 
al., 1988).
The protocol involved five steps; (i)preparation of labelled probe and 
unlabelled test DNA, (ii)formation of heteroduplexes, (iii)chemical 
modification, (iv)chemical cleavage of mismatches and (v)electrophoresis 
and autoradiography.
Preparation of the labelled probe and unlabelled test samples
The DNA or cDNA required for CCM was obtained by amplification of 
the required segment by PCR. PCR was carried out for all the test samples 
and a couple of control samples, against which the sequence variants were 
detected. The PCR products were checked on a 1% agarose gel. If non­
specific products of amplification were seen, the entire PCR product was
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electrophoresed on a low melting (NuSieve) agarose gel and the required 
band was cut out after visualisation on a UV transilluminator. The DNA from 
the gel slice was obtained by subjecting the band to purification using the 
'Geneclean' kit. If the PCR product was well defined and did not require 
separation from other non-specific products of amplification, Geneclean was 
carried out directly on the PCR product (without excision). The 'Geneclean' 
kit was used to remove and purify DNA from agarose, thus removing ethidium 
bromide, primers and dNTPs from PCR reaction products. By this method, 
15-20pl of a DNA solution with a concentration of 100ng/pl was obtained. 
The purified PCR product served as the unlabelled test DNA to be used in 
the preparation of heteroduplexes. The 'Geneclean' procedure was carried 
out as follows:
To the required band (excised from the agarose gel) or the PCR 
product was added 3 volumes of Nal stock solution. This was incubated at 
45-55°C to dissolve agarose. To this was added 10pl glassmilk and the 
tubes were vortexed and kept on ice for 10 minutes. The glassmilk-DNA 
complex was pelleted for 5 seconds. The pellet was then washed 3 times in 
NEW wash buffer. The DNA was then eluted into T.E. buffer by incubation at 
65°C for 5 minutes. The tube was then centrifuged and the supernatant was 
transferred to a fresh tube.
Preparation of radiolabelled probe
50pM of each PCR primer was end labelled at the 5' ends using T4 
polynucleotide kinase and [y^-p ] ATP. This was carried out in two separate 
reactions of 1Opl each for each primer.
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50pM of the oligonucleotide was taken in| a microfuge tube, to which was 
added 1.0pl of T4 kinase buffer. 1.0|xl of [y -32p j a tp  (10|iCi of 3000 
Ci/mmol, 10 mCi/ml) and 1.5pl (15U of 10U/pl) of T4 polynucleotide kinase 
enzyme were added and the mixture was made up to 1 0jj,I with sterile distilled 
water. The mixture was mixed thoroughly, centrifuged and incubated at 37°C 
for 30-60 minutes.
The PCR reaction was prepared containing all the components 
excluding the primers and including 0.5fil of the 'Geneclean' product of the 
control DNA PCR (as previously described) as the template. 5^ 1 of each end 
labelled reaction mixture was directly added to the PCR mix. The mixture was 
layered with mineral oil and subjected to PCR under the appropriate 
conditions. The wild-type PCR product, which was the radiolabelled probe 
was directly mixed with 3 volumes of the Nal solution and the same method 
(Geneclean) was followed.
Formation of heteroduplexes
15ng of labelled probe (10^ cpm) was mixed with 150-200ng of each 
test DNA in a 20jxl volume of IXannealing buffer. Heteroduplex formation 
was carried out in 0.5ml microfuge tubes. 50^1 mineral oil was layered onto 
the mixture and it was heated to 99°C for 10 minutes and then placed in a 65 
°C water bath for two hours. The heteroduplexes were transferred to 1.5ml 
siliconised microfuge tubes to be precipitated. To each tube was added 3jil 
of glycogen (20 mg/ml) and 750|xl of precipitation mix and the mixture was 
incubated at -70°C for 15 minutes. The tubes were centrifuged at 12,000 
r.p.m. for 10 minutes, the pellet was rinsed with 70% ethanol, air dried and 
resuspended in 14|il T.E. buffer.
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Chemical modification using hydroxylamine and osmium tetroxide
Each heteroduplex was split between two tubes (7pl each) i.e. one 
tube each for the hydroxylamine and osmium tetroxide reactions.
Preparation of hydroxylamine and the hydroxylamine reaction: 1.39G 
of hydroxylamine hydrochloride was mixed in 1.6ml of pre-warmed (37°C) 
distilled water. The pH of the solution was adjusted to 6.0 by the addition of 
diethylamine (about 1.5ml) and the solution was stored at 4°C for upto 7-10 
days. 20pl of this solution was added to the heteroduplex and incubation 
carried out at 37°C for 2 hours.
Preparation of osmium tetroxide (OSO4) and the OSO4 reaction: A 
commercially available 4% solution (which was stored at 4°C for up to 3 
months) was used. A 10Xreaction mix was prepared by adding 1.5pl osmium 
tetroxide, 6.75pl pyridine and 154pl T.E. buffer on ice. 18pl of this mix was 
then added to the other half of the heteroduplex. The mixture was incubated 
at 37°C for 1 - 2 hours.
Both the hydroxylamine and osmium tetroxide reactions were stopped 
by transferring the tubes onto ice which was followed by the addition of 750pl 
of precipitation mix. The DNA was precipitated at -70°C for 15 minutes and 
centrifuged at 12,000 r.p.m. to obtain a pellet, which was rinsed and briefly 
air dried.
Piperidine cleavage of the chemically modified mismatch
50pl of a 10% piperidine solution was added to each pellet and the 
tubes were vortexed for up to a minute. They were then incubated at 90°C for 
30 minutes. The tubes were chilled on ice and the DNA was precipitated as 
before and the pellet was resuspended in 15pl formamide loading buffer
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(95% formamide, 10mM EDTA, 10mg/ml bromophenol blue, 10mg/ml xylene 
cyanol).
Gel electrophoresis and autoradiography
The resuspended pellet was heated to 95°C for 10 minutes and 
applied to an 8% denaturing polyacrylamide gel containing 7M urea. The gel 
mixture was prepared and polymerised in between the plates of a sequencing 
gel apparatus (Sequigen; Biorad) as previously described. A labelled 1Kb 
DNA ladder (Gibco BRL) was denatured and electrophoresed on the gel, in 
order to permit accurate size estimation of the cleavage products. 
Electrophoresis was carried out at 35 watts constant power till the 
bromophenol blue reached the end of the gel. The gel was transferred onto a 
pre-cut piece of Whatmann 3MM paper and autoradiographed using Kodak 
X-Omat AR film for a period of 12-16 hours.
2.11 DIRECT SEQUENCING
Direct sequencing of the NF-1 DNA and cDNA was carried out using 
dideoxy chain termination method using Sequenase version 2.0 (USB) 
(Sanger et al., 1977).
Generation of single stranded template
To perform sequencing under optimal conditions, it was necessary to 
obtain a well purified single stranded DNA template, to avoid the 
reassociation of the two amplified strands. Two methods were used:
1 )Unequal primer ratios were used right from the beginning (Mgone et 
al., 1992). The template used for asymmetric amplification using unequal 
ratios of primers, was the PCR product of the corresponding region. 50pl of
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the PCR product was resolved on a 1.0 % agarose gel and the appropriate 
ethidium bromide stained band was excised and eluted by soaking in 100pl 
T.E. buffer overnight. A 10pl aliquot of the eluted DNA or cDNA was used in 
a 100pl asymmetric PCR mixture containing 50mM KCI, 10mM tris-HCI (pH 
8.3), 1.5mM MgCl2 and a primer ratio of 100:1 (50pM:0.5pM). A second 
asymmetric PCR was performed with the primer ratio reversed, so that both 
strands could be generated. Another method of elution was electrophoresis 
on a 8% polyacrylamide gel and visualisation and excision of the appropriate 
band. The band was then covered with 10Opil of T.E buffer and the tube with 
the excised band was incubated at 37°C overnight. 10pil of this was then 
subjected to asymmetric amplification as above.
2)One primer only was used to reamplify one DNA strand, of the pre­
existing double stranded PCR fragments (Rolfs et al 1992). This was the 
other method used for production of single stranded DNA and involved taking 
a small amount (1-2%) of a PCR product (0.5-1 pi of PCR product from a 50p 
I reaction) and repeating the temperature cycling process using one primer 
only (50-1 OOpM) for between 15-30 cycles.
Visualisation of single stranded DNA
At the end of the asymmetric PCR, 10pl of the PCR product was 
fractionated on a 1.0% Seakem agarose gel, along with the double stranded 
control and a suitable marker to monitor the amount of single stranded 
products. When a high proportion of single stranded products were observed 
these were used in dideoxysequencing reactions.
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Purification of the template for sequencing
Prior to sequencing, the PCR products were purified by removing the 
excess dNTPs, salts and primers. This was accomplished by precipitation at 
room temperature for 10 minutes, by addition of an equal volume of 4M 
ammonium acetate and 2 volumes of isopropanolol. The template was 
recovered by centrifugation in a microcentrifuge at room temperature for 10 
minutes, washed in 70% ethanol and allowed to dry. The pellet was then 
dissolved in 7pl of distilled water and used in the sequencing reaction.
Annealing of template and primer
7|il of purified asymmetric PCR product was mixed with 2pl 
5Xsequencing buffer giving a final concentration of 40mM Tris-Hcl pH 7.5, 
20mM MgCI2 and 50mM NaCI and 1pM of sequencing primer, either limiting 
or nested and complementary to the synthesised single stranded DNA. 
1.0pM of primer was used for each set of sequencing reactions. The 
concentration of the primer was determined by reading the optical density at 
260 nm. If the primer has N bases, the approximate concentration (pM/pl) 
was given by the following formula:
Concentration (pM/pl) = O.D. at 260 / (0.01 x N)
Formula obtained from 'step-by-step protocols for sequencing with 
Sequenase version 2.0' 5th edition USB.
The template-primer mixture was annealed by heating to 65°C for 2 minutes 
and then allowed to cool slowly, to less than 35°C over a period of 30 
minutes.
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Labelling reaction
The mixture was then placed on ice and 1 pi of 0.1 M DTT, 2jiM of each 
dNTP except dATP, 0.5pl [a35-S] dATP (1000 Ci/mmol;10 pCi/pl) and 2\i\ 
(1.5u/|ul) of a 1:8 dilution of T7 DNA polymerase (Sequenase version 2.0) 
were added and incubated at room temperature for 2-5 minutes.
Termination reaction
The termination mixes contain 80pM of each dNTP and 8pM of the 
appropriate dideoxyribonucleoside triphosphate. The 4 labelled (A,T,G,C) 
microfuge tubes containing 2.5pl of the appropriate termination mix were 
prewarmed at 37°C. Once the labelling reaction was complete, 3.5pl was 
transferred to each tube and the incubation reaction was continued for a 
further 5 minutes at 37°C. The reactions were terminated by addition of 4pl 
of formamide dye stop solution. The samples were stored at -20°C until 
further required.
Sequencing gel electrophoresis and autoradiography
The samples were heated at 75°C, quenched on ice and loaded on a 
8% polyacrylamide gel containing 7M urea. The sequencing gels were 
poured and run on a Sequigen sequencing gel apparatus (Biorad) as 
previously described. The gels were run at a temperature of 50°C for 2-4 
hours. On completion of electrophoresis the apparatus was dismantled and 
the plates were gently pulled apart. The gel was then treated with a solution 
of 10% methanol/10% acetic acid for 10 minutes and then dried in a vacuum 
gel dryer. The gel was then exposed for 16-18 hours to Kodak X-Omat AR 
film in a cassette using intensifying screens.
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2.11.1 Variation in sequencing protocols
The sequencing reactions and electrophoretic conditions were usually 
carried out as described. However some variations were carried out in the 
following cases:
1 Elimination of compressions: Some DNA sequences, especially 
those with dyad symmetries containing dG and dC residues, were not fully 
denatured during electrophoresis. When this occurs, the regular pattern of 
migration of DNA fragments was interrupted; the bands were spaced closer 
than normal (compressed together), or sometimes further apart than normal. 
In this case the substitution of a nucleotide analogue for dGTP, dITP was 
used. Using dITP, the bands were sharper and most compressions were 
eliminated. The reactions containing dITP were run in conjunction with 
reactions containing dGTP, since the overall quality of the reactions 
containing dITP was lower.
2)Reading sequences close to the primer: For reading sequences 
close to the primer, two methods were used: One method was to use less 
dinucleotide in the labelling step. This meant a further dilution of the labelling 
mix to a 1:10 or 1:20 of the stock reagent instead of the usual 1:4 and both 
reaction times were 3-5 minutes. When reading sequences within 20 
nucleotides of the 3' end of the primer, it was essential that sufficient 
template was present and so the amount of DNA template used and the 
primer for annealing was doubled. The other alternative was to use Mn 
buffer, which affects reactions in the termination step. The addition of Mn 
buffer which was a buffered solution of MnC^, reduces the average length of 
DNA synthesised in the termination step, intensifying bands corresponding to 
sequences close to the primer.
3)Extending sequences farther away from the primer: For extending 
sequences farther from the primer, two different methods were used: One
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method involved using more nucleotide in the labelling step. This meant use 
of undiluted labelling mix and the labelling reaction was lengthened to 5 
minutes. Excess dATP was also added and this resulted in a sequencing 
ladder that emphasised the bands in the 200-800 nucleotide range, at the 
expense of bands in the 20-100 nucleotide range. The other method involves 
alteration of the nucleotide mixture used in the termination step. This was 
achieved by using the sequence extending mix and the usual volume of 
termination mix was replaced by a mixture of termination mix (1pl) and 
sequence extending mix (1.5^1). The gels on which the sequences 
(sequenced using the extension mix) were loaded were electrophoresed for 
4-10 times longer and cooler at 40°C instead of 50°C for the best resolution.
2.12 PLASMID TECHNIQUES
The cDNA probe P5 was obtained as a plasmid DNA sample from 
ATCC and was transformed, grown up and stored as a glycerol stock. The 
details of the probe were as follows: The probe contains part of the 3' region 
of the NF-1 cDNA. The vector used was pBluescript SK-, the total size being 
4.7 kb and the insert size being 1.7 kb. Restriction digests of the clone with 
EcoRI give the following sizes: 3.0, 1.2 and 0.5 kb (ATCC), which were 
confirmed on restriction digestion. The complete insert detects human 
genomic EcoRI fragments of 15, 6.5, 4.0, 2.3, 2.0, 1.8 and 1.3 kb (Wallace et 
al., 1990).
Transformations
The competent cells used were subcloning efficiency DH5a™ (Gibco 
BRL). The competent cells were removed from the freezer and thawed on 
ice. The required number of autoclaved 1.5ml microcentrifuge tubes were
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placed on ice. The cells were gently mixed and 50pl were aliquoted into each 
chilled tube. 1-1 Ong of DNA was added to the tube and the tube was gently 
tapped to mix. The cells were incubated on ice for 30 minutes. The cells were 
then heat shocked for 20 seconds at 37°C and then placed on ice for 2 
minutes. 950jil of prewarmed L-Broth was added to the cells and the cells 
were incubated in Universals at 37°C in a shaker at 225 r.p.m. for 1 hour. 
The control Universal contained only 950pl of L-broth. 200pl of the reaction 
was spread onto LB plates (1.5% L-agar with ampicillin added to a final 
concentration of 100 pg/ml) and the plates were incubated at 37°C.
Preparation of Glycerol stocks
The agar plates were removed from the incubator and a single colony 
was picked and grown overnight in 15ml of L-broth containing ampicillin at 
37°C. After incubation glycerol stocks were made in 15% glycerol and stored 
at -20°C.
Preparation of probe
a) Using Circle-prep method:
i)Plasmid growth and cleared supernatant preparation:
Cultures were set up with 100pl glycerol stock in 50ml L-broth containing 
ampicillin and incubated overnight with vigorous shaking. The next day, the 
cultures were centrifuged at 1200 r.p.m. at 4°C for 10 minutes. The 
supernatant was removed and the tube was drained for 1-2 minutes. 4ml of 
prelysis buffer from the kit was added and the pellet resuspended. 4ml of 
alkaline lysis reagent was then added and the solution mixed well for 1-5 
minutes, until the cells were uniformly lysed. The cell suspension at this point 
was very viscous. The suspension was then centrifuged at 1200 r.p.m. for 5
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minutes at 4°C. The supernatant was then transferred through a sieve to a 
fresh tube. One volume of isopropyl alcohol was added and mixed well 
producing a fine precipitate. The tube was centrifuged for a further 5 minutes 
at 4°C at 1200 r.p.m. The supernatant was removed to a fresh tube. The 
pellet obtained, was dissolved in 0.5ml of water.
ii)Lithium chloride precipitation of RNA and single stranded DNA:
The cleared supernatant, which was transferred to a microcentrifuge tube, 
was incubated at 100°C in a hot block for 3-5 minutes and cooled in an ice 
bath for at least 1 minute. 300pl of lithium chloride was added and after 
mixing was allowed to stand at room temperature for 5 minutes. The solution 
was then centrifuged for 2 minutes. The supernatant was transferred to a 
new tube and 600-700pl of isopropanolol was added, the solution was mixed 
and then centrifuged for 2 minutes. The drained pellet was then dissolved in 
0.5ml of water and 300pl of lithium chloride was added.
iii)Purification of plasmid DNA on Circle-prep glassmilk:
The Circle-prep glassmilk vial was vortexed until homogenous and then 75pl 
was added to the tube. After mixing, this was incubated for 5 minutes and 
then centrifuged for a few seconds. The supernatant was removed and the 
pellet washed twice with 1ml of binding buffer. The tubes were spun for a few 
seconds to remove traces of liquid. The pellet was then washed with wash 
solution, the tube spun for a few seconds and the supernatant discarded. 
The pellet was resuspended in 150pl of water and incubated for 5 minutes in 
a 60°C water bath. The tube was then spun for 30 seconds to form a tight 
pellet and the supernatant containing plasmid DNA transferred to a fresh 
tube.
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b) Using the Insta-Mini-Prep ™:
The unopened Insta-prep-mini tube was centrifuged at 12000g for 10 
seconds to pellet the gel. The bacterial culture was prepared as previously 
described and 1.5ml was transferred to a separate microfuge tube (not insta- 
prep mini tube) and spun at 12000g. After centrifugation all the supernatant 
was aspirated and care was taken not to disturb the bacterial pellet. To the 
pellet was added 50pl of STE buffer and the pellet was vortexed briefly to 
resuspend the bacterial cells. 300pl of shaken PCI solution was added to the 
tube containing the resuspended cells and the tube was mixed by repeated 
inversion. The entire contents of this tube were then carefully transferred to 
the pre-spun Insta-prep-mini tube. This tube containing the bacterial lysate 
was then centrifuged at 12000g for 1 minute. To the spun tube, 300pl of Cl 
solution was added and the two upper liquid phases were mixed by repeated 
inversion. The tube was then centrifuged at 12000g for 1 minute. The 
plasmid DNA was recovered by pipetting the topmost phase to a fresh 
microcentrifuge tube and stored at -20°C until further use.
c)Using RT-PCR:
The PCR product was visualised on a 1% agarose gel and the size and 
specificity was confirmed. The PCR product was then purified using 
'Geneclean' (BIO 101) as previously described. The optical density of the 
'Genecleaned' product was measured and depending on the concentration, 
2-4pl was used for labelling.
Releasing insert from plasmid
Plasmid concentrations were determined by measuring the optical 
density of each sample at 260nM in a dual beam spectrophotometer (LKB
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Biochem Ultrospec 4050). An O.D. reading of 1 corresponds to approximately 
50pg/ml of DNA. 50pl digests were set up containing 7.5|nl of the plasmid 
DNA obtained using Circleprep and 15pl of plasmid DNA obtained using 
Insta-prep respectively, along with 4pl of the enzyme EcoRI and 5pl of the 
enzyme buffer. The digests were incubated at 37°C for 2 hours. A 1 % low 
melting agarose gel (Seakem agarose, FMC bioproducts) was made and the 
digests were run at 100 volts for 2 hours, alongside a 1 kb ladder (Gibco 
BRL). The gel was visualised on a UV illuminator and the 1.2 kb band (insert) 
was excised using a sterile scalpel blade and placed in a weighed Sarstedt 
tube. The weight of the insert was determined and a volume of sterile distilled 
water 3 times the weight of the insert was added. The probe was boiled for 
10 minutes and stored at -20°C until further use.
2.13 SOUTHERN BLOTTING
Digestion of genomic DNA
A 10pig aliquot of genomic DNA was digested using the appropriate 
restriction enzyme in a concentration of 4U/pg of DNA in a total volume of 40 
pi. The digests were incubated overnight at the suppliers recommended 
temperature, for optimal enzyme activity.
Agarose gel electrophoresis
The digests were resolved on 0.8% agarose gels (FMC bioproducts) 
containing 0.05% ethidium bromide (10 mg/ml). 4pl of loading mix containing 
0.05% bromophenol blue was added to each digest which was loaded onto 
the gel. The gels were electrophoresed at 60-70mA for 12 hours. The gels 
were visualised on a UV transilluminator and photographed. After 
photographing the gel, the gel was treated in the depurination solution
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(0.25M HCI) for 20 minutes, then transferred to denaturation solution (0.5M 
NaOH, 1.5M NaCI) to denature the DNAs for 20 minutes and finally 
transferred to neutralisation solution (1M Tris-HCI pH 8.0, 1.5M NaCI) for 30 
minutes.
Southern Transfer
The blotting apparatus comprised a plastic tray containing about 500- 
1000ml of 10-20XSSC with a raised platform for the gel. The platform was 
covered with 3MM Whatmann paper whose ends had been dipped into the 
10XSSC to form a wick. The gel was removed from the neutralisation solution 
and placed on the wick on the platform. Any air bubbles were smoothed out. 
The edge of the gel was surrounded by Saran-Wrap. The blotting membrane 
(Hybond-N) and 2 sheets of 3MM paper which have been cut to the size of 
the gel were wet in 2XSSC and placed on the gel one by one, the Hybond-N 
being laid first on the gel without any air bubbles. Finally a pack of dry paper 
towels was laid on the top and covered with a plate and some weight. The 
transfer was carried out overnight at room temperature. After the transfer was 
complete, the Hybond-N membrane was dried between two layers of 3MM 
paper and the DNA was fixed onto the membrane by placing it on the UV box 
with the DNA side down for 4 minutes. The membrane was then wrapped in 
cling film (or Saran wrap) and stored at -20°C until hybridisation.
Prehybridisation
Prehybridisation was carried out to prevent non-specific binding of 
radiolabelled probe to the filter. The filters were soaked in 2XSSC and placed 
onto a mesh. The mesh was rolled up and placed in a hybridisation bottle 
containing 30ml 2XSSC. The bottle was laid flat and gently rolled to unfold
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the mesh and filter against the inner surface of the bottle. The 2XSSC was 
poured off and replaced with 15ml of prewarmed prehybridisation solution 
containing 1 OOjj.1 of denatured salmon sperm DNA (10 mg/ml). The bottle was 
placed in the hybridisation oven for a minimum of 6 hours at 65°C.
Labelling of the probe
The probe was labelled using the random primed DNA labelling kits 
(Boehringer Mannheim) according to the method of Feinberg and Vogelstein 
(1984) and were used for both Southern and Northern Blotting. 25pl of the 
probe (using Circleprep and Insta-prep) or 2|il of the RT-PCR product 
subjected to 'Geneclean' and made up to 25jil with distilled water was boiled 
for 10 minutes and incubated at 37°C for 2 minutes. 2pl each of dATP, dGTP 
and dTTP, 4|il of the reaction mix, 1.5^1 of Klenow enzyme and 50pCi (5jj,I) of 
[a-32P] dCTP (Amersham International) were added. The mixture was 
incubated for 1-2 hours and the reaction was stopped by addition of 2\x\ of 
0.5M EDTA.
Separation of the labelled probe from unincorporated [a-32P] dCTP
This was done using NICK™ columns from Pharmacia Biotech, which 
were prepacked columns containing Sephadex G-50 DNA grade. The top cap 
of the column was removed and the excess liquid poured off. The tube was 
rinsed with 1XSSC and the bottom cap was removed. The column was 
supported over a suitable receptacle and to the column was added 3ml of 
1XSSC which was allowed to drip through. The labelled probe (40pl) was 
then added to the column and immediately 400|il of 1XSSC was added to it, 
which was allowed to drip through. A further 400pl of 1XSSC was added to 
the column and this was collected.
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Hybridisation of filters
The collected probe was denatured by boiling for 10 minutes and 
placed on ice for 2 minutes. The prehybridisation solution from the bottle was 
poured into a Universal and the probe added to it. The contents of the 
Universal were mixed gently and transferred back into the bottle. 
Hybridisation was carried out at 65°C in a Hybaid oven overnight.
Post-hybridisation washing
The hybridisation solution was poured off from the bottles and the 
filters were washed in 2XSSC/0.1%SDS for 20 minutes at 65°C. The filters 
were then transferred to a box and washed for a further 20 minutes with 
shaking in a 65°C water bath with fresh 2XSSC/0.1%SDS for 20 minutes. 
The filters were monitored using a series 900 minimonitor and if a signal 
greater than 10cpm was seen the filters were washed at an increased 
stringency at 65°C. The solutions used were: 1XSSC/0.1%SDS,
0.5XSSC/0.1 %SDS, 0.1XSSC/0.1 %SDS.
Autoradiography
After washing the filters, they were placed between a layer of Saran 
Wrap and placed in autoradiography cassettes with intensifying screens and 
exposed to Kodak Diagnostic AR Imaging film. The cassettes were stored at - 
70°C and the films were developed after 5-7 days.
2.14 NORTHERN BLOTTING
Northern blotting consists of separation of total cellular RNA by size 
on an agarose gel. The RNA molecules in the gel are transferred to a 
nitrocellulose or nylon membrane and detected using an appropriate probe.
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In this study, Northern blotting was used to examine neurofibromin 
expression from 4 neuroblastoma cell lines.
Gel and sample preparation
To make a 20 cmX20 cm gel, 4.5g agarose was boiled in 220ml dH20  
and cooled to 55°C. To this was added 50ml of formaldehyde solution (37%) 
and 30ml 10XMOPS to make a total volume of 300ml. The gel was then 
poured in the fume hood.
10-20pg total RNA was used in a volume up to 4.7pl, to which was 
added 10pl formamide, 3.3pl formaldehyde solution (37%) and 2.0pl 
10XMOPS in a total volume of 20pl. This was heated at 55-60°C in a water 
bath and quenched on ice. To this was added 5pl 6XRNA loading buffer, or 2 
pi 10XRNA loading buffer. The gel was run in 1XMOPS buffer at 50-100 volts 
for 4-8 hours.
Northern transfer
After electrophoresis, the gel was washed in dH20  for 20 minutes, to 
get rid of the formaldehyde. The marker and control RNA lanes were cut for 
staining before the gel was blotted onto Hybond-N membrane, as described 
in the procedure for Southern transfer.
Northern hybridisation
After the transfer was complete, the membrane and the hybridisation 
mesh were wet in 2XSSC. The membrane was laid onto the mesh and these 
were rolled up together. This was then inserted into a Hybaid bottle which 
contained 30ml 2X SSC. The bottle was then laid flat on a flat surface and 
gently rolled, such that the membrane and mesh become gently unrolled
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against the inner surface of the bottle. The 2XSSC was then poured off and 
replaced with hybridisation solution. The bottle was then placed into the 
hybridisation oven and prehybridised for at least 1 hour at 42°C. The 
prehybridisation solution was then poured off and replaced with the 
hybridisation solution containing the labelled probe and hybridised overnight 
at 42°C.
Posthybridisation washing
Posthybridisation washing was carried out using 2XSSC, 0.1% SDS in 
the bottle at 42°C for 10 minutes. The next wash was carried out at 
0.2XSSC, 0.1% SDS in a sandwich box at 65°C for 10-15 minutes with 
shaking. The membrane was wrapped in Saran wrap and autoradiographed 
at -70°C in a cassette with an intensifying screen and exposed initially for 2 
days.
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RESULTS
CHAPTER 3: RESULTS
3.1 STRATEGY FOR AMPLIFICATION OF THE NF-1 CODING SEQUENCE
25 unrelated patients with NF-1, including both sporadic and inherited 
cases were analysed for mutations within 78% of the NF-1 coding sequence. 
NF-1 cDNA obtained by reverse transcription of mRNA was amplified by RT- 
PCR to yield a set of seven segments (RNA segments l-VII) spanning mRNA 
positions 39-632 and 1135-4773. Genomic DNA was used for amplification of 
selected exons of the NF-1 gene, which spanned positions 4773-6756 and 
7395-7806 of the coding sequence (Figure 5).
Amplification of exons from genomic DNA
Exons 28-36 and 42-44 were amplified from genomic DNA using 
flanking intronic primers. The sizes of all the DNA-PCR products ranged from 
200-400bp. Exons 35 and 36 were amplified together (due to the small size 
of exon 36).
Amplification of the NF-1 cDNA by RT-PCR
Part of the NF-1 coding sequence was amplified to yield a set of 7 
segments, which were amplified from NF-1 mRNA. The amplified segments 
ranged from 0.4 - 1 .Okb and were amplified either as a single amplification 
product, or by using nested PCR.
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6756 7395 7806 8457
Figure 5a Diagrammatic representation of the NF-1 coding sequence. The 
filled box spans cDNA positions 39 - 632 (Segment I) and 1135 - 4773 
(Segments ll-VII) and is amplified in seven segments using the NF-1 mRNA 
as a template for RT-PCR. The two hatched boxes span exons 28-36 and 
exons 42-44 respectively and are amplified from genomic DNA.
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3.2 STRATEGY FOR DETECTION OF GERMLINE MUTATIONS
After initial amplification by PCR, the products were electrophoresed 
on 1% agarose gels to check for any abnormal alterations in size. If no 
alteration was seen, the amplification products of DNA-PCR were analysed 
using SSCP analysis. The amplification products of RT-PCR and eventually 
all DNA-PCR products were subjected to chemical mismatch cleavage 
analysis, to detect and locate the presence of small alterations or point 
mutations within the NF-1 gene. Any mismatch detected was then subjected 
to asymmetric PCR and direct sequencing by the Sanger dideoxy chain 
termination method. Each change found on sequencing was confirmed by 
sequencing the complementary strand. If a change was found on sequencing 
the cDNA, amplification of the corresponding exon from genomic DNA 
followed by direct sequencing was carried out. Every sequence change seen 
was analysed to see if it created or abolished a restriction enzyme site. 
Alteration of a restriction site was checked for using the GCG package "MAP" 
program. Digestion of the PCR product with the appropriate restriction 
enzyme, was then used as a further confirmation of the change in sequence. 
For missense and silent mutations, the restriction digests were used to 
screen normal controls, to find if the mutations were polymorphic. Restriction 
analysis with the appropriate enzyme was also used to analyse other 
affected and unaffected members of the family.
In cases where the mutation did not affect a restriction site, assays using 
PCR directed mutagenesis were designed to confirm the presence of the 
sequence change. A simple non-radioactive method of detection, such as 
heteroduplex analysis, was also made use of in screening for already 
characterised mutations (for segregation analysis & population studies).
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Using the above strategy, 17 positive screening results were obtained, of 
which 13 were characterised. In addition a novel intragenic polymorphism in 
intron 41 was identified. The mutations and the methods they were detected 
and further screened by are tabulated below and each mutation is discussed 
in detail in the following pages.
Table 11:Summary of mutations characterised within the NF-1 gene
Mutation Location Method detected by Further screened by
1721+3A to G intron 11 RT-PCR, sequencing PCR-directed
mutagenesis
patial del exon 16 exon 16 RT-PCR, sequencing RT-PCR
3113+1G to A intron 18 RT-PCR, sequencing direct sequencing
deletion exon 18 exon 18 RT-PCR, sequencing RT-PCR
G1166D exon 21 CCM, sequencing CCM
S1311S exon 23 CCM, sequencing restriction analysis (Fok I)
G1404G exon 24 CCM, sequencing restriction analysis (Apo I)
K1419R exon 24 CCM, sequencing restriction analysis (Mnl I)
5749+2T to G intron 30 SSCP, sequencing, 
RT-PCR
SSCP
6519insG exon 34 SSCP,sequencing SSCP
-28 A to G intron 41 CCM, sequencing heteroduplex
7485insGG exon 42 CCM, sequencing heteroduplex
R2496X exon 42 CCM, sequencing CCM
All the sequence numbering is in accord with that provided by the NNFF 
Mutation Analysis Consortium.
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3.3 LARGE ALTERATIONS OF THE NF-1 CODING SEQUENCE
Upon electrophoresis of the amplification products of RT-PCR five 
abnormal sized products were seen in addition to the normal sized product in 
segments II, IV, V (in two cases) and VI. The altered sized fragments could 
either be due to deletions or insertions of the NF-1 coding sequence or errors 
of splicing. Each alteration was characterised and is now considered 
separately.
Splice donor mutation in intron 11:1721+3A to G
The first altered segment was detected upon amplification of segment 
II in a 30 year old female patient, who is a familial case of NF-1 with an 
affected son. Upon electrophoresis on a 1% agarose gel, followed by 
visualisation by ethidium bromide staining, a smaller sized fragment of 644bp 
was seen in addition to the normal sized fragment of 724bp (Figure 6). 
Segment II covers exons 8-12a of the NF-1 gene. To confirm the specificity of 
the altered band, the gel was subjected to Southern blotting using segment II 
as a probe (Figure 7). The altered fragment lacked 80bp, which corresponds 
to the size of exon 11. This was confirmed on sequencing the NF-1 mRNA 
(Figure 8). The loss of 80bp from the NF-1 mRNA could either be due to a 
deletion or an error of splicing causing the skipping of exon 11. In order to 
rule out a deletion the patient's genomic DNA was digested with five different 
restriction enzymes and subjected to Southern blotting using segment II as a 
probe. No altered fragments or dosage differences were seen. Primers were 
designed to flank exon 11 (using intronic sequence information provided by 
the NNFF Mutation Analysis Consortium), the upstream primer in intron 11 
and the downstream primer in the coding region of exon 12, to rule out a 
deletion. This allowed the determination of the size of intron 11 which had 
not previously been reported/published. After ruling out the presence of a
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deletion, this mutation was suspected to be splice site mutation. Using 
primers immediately flanking exon 11 for amplification and sequencing the 
splice sites, an A to G transition was seen at the splice donor site of exon 11 
(nt 1721+3A to G). This transition resulted in an error of splicing, which 
caused the skipping of exon 11 from the NF-1 mRNA (Figure 9). This 
mutation was shown to be present in the affected son, who showed the same 
pattern of cleavage products as his affected mother, on CCM analysis of his 
NF-1 mRNA. (Figure 10).
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Figure 6
Amplification of NF-1 cDNA (segment II) showing a smaller sized transcript of 
644bp in addition to the normal sized fragment of 724bp (marked by arrows) 
in lane M = mutant. Lane N = normal control and lane L = 1kb ladder (Gibco 
BRL).
Figure 7
Southern blotting of the product of amplification of RNA segment II, in order 
to confirm specificity of the altered band, using segment II as a probe. Both 
the normal and altered bands in lane 1 are marked by arrows, lane 2 is the 
control.
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Figure 8
mRNA sequence analysis surrounding exon 11. Beyond the point marked by 
an arrow, a parallel sequence is seen along with the normal sequence. After 
analysis, this sequence was shown to correspond to the sequence from the 
normal allele and the mutant allele which lacks exon 11 running together.
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Figure 9
Sequence of the mutant DNA across the intron-exon boundary, showing the 
intron 11 splice donor site mutation, A to G at position +3, marked by an 
arrow.
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Figure 10
Deletion mapping using chemical mismatch cleavage analysis of RNA 
segment II. The proband and her affected son show cleavage products in 
lanes 3 and 4. L indicates the 1 kb ladder. The remaining lanes show CCM 
analysis in controls.
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In cases where the mutations did not affect a restriction site and where it was 
necessary to screen normal controls and the remaining members of the 
family, PCR directed mutagenesis was used to introduce part of the 
recognition sequence of the enzyme in the primer used for amplification (Li et 
al 1992). In this study this strategy was used in the case of the above splice 
donor mutation in intron 11, (nt 1721 +3A to G). The presence of a normal 
adenine (A) nucleotide at the site of transition (1721+3A) allows cutting on 
digestion with the restriction enzyme Acc I. The appearance of any other 
nucleotide destroys the recognition site of this restriction enzyme. A PCR 
primer covering the sequence immediately preceding the site of transition 
was used in combination with an upstream intron based primer for 
amplification. By designing the downstream primer to have a non-template C 
nucleotide at its 3' terminus, the PCR product derived from the normal allele 
had a part of its sequence to be GTAITAC, in which the T comes from the 3' 
base in the downstream primer and the A comes from the adjacent base in 
the template (Figure 11). This is the recognition sequence for the enzyme 
Acc I. Conversion of A to G causes loss of the restriction site for Acc I and 
prevents cutting in the mutant allele, whose sequence is GTGTAC instead of 
GTATAC.
Figure 11: The schematic representation of the mutant and normal PCR 
products is presented and the Acc I restriction site and its loss due to the 
mutation is indicated. Visualisation of Acc I digested PCR products by 
electrophoresis on a 3% MetaPhor™ (FMC) gel is shown in the lower half of 
the figure. Lane 1: Undigested control, lane 2: PCR product from the patient 
who is heterozygous for the mutation and shows the digested normal allele 
(185bp) and the undigested mutant allele (161 bp), lane 3: Normal control 
showing complete digestion of the PCR product.
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Therefore on digestion of the amplification product of the patient, the 
presence of the digested normal allele (161 bp) and the undigested mutant 
allele (185bp) is seen, while the normal control shows complete digestion of 
the PCR product.
This analysis was used to confirm the mutation and to screen 30 controls, 
none of which were shown to have this mutation. Thus segregation of the 
mutation with disease and absence of this mutation in controls, thus shows 
that mutation is responsible for disease in this family.
Splice donor mutation in intron 30: 5749 +2T to G
The second splice site mutation was detected on analysis of exon 30 
and the flanking sequences, in a 29 year old male patient, who is a sporadic 
case of NF-1. The mutation was seen as a shift on SSCP analysis of exon 30 
(Figure 12), which was confirmed on chemical cleavage analysis. CCM 
analysis showed an altered cleavage product on modification with osmium 
tetroxide (Figure 13). DNA sequencing of the sequence flanking exon 30 
revealed a T to G substitution at position +2 (nt 5749 +2T to G) at the 
invariant GT dinucleotide of the splice donor site of intron 30 (Figure 14). 
After confirmation of the mutation by sequencing the opposite DNA strand, 
analysis of the corresponding mRNA region by RT-PCR of transcripts derived 
from peripheral lymphocytes was carried out. This amplification showed the 
presence of a smaller sized transcript of 504bp in addition to the normal 
sized PCR fragment of 707bp. This corresponds to the skipping of exon 30, 
which is approximately 203bp in size (Figure 15). Sequence analysis of the 
amplified cDNA fragments confirmed that the transcript lacked exon 30. This 
patient is a sporadic case of NF-1 and analysis of his unaffected parents and 
brother was carried out and none of them had this mutation. In addition 30
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normal controls were screened and none of them were found to have this 
mutation.
1 2 3 4 5 6 7
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Figure 12
SSCP analysis of exon 30 showing an altered pattern in lane 4, as compared 
with lanes 1-7.
Figure 13
Chemical mismatch cleavage analysis of exon 30, showing the presence of a 
cleavage product marked by an arrow in lane 2, on modification with osmium 
tetroxide. In normal controls only the uncleaved probe is seen.
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Figure 14 and 15
Amplification of a segment of the NF-1 cDNA encompassing exon 30. A 
smaller transcript (504bp) is seen in addition to the normal sized transcript 
(707bp) in lane M (mutant). Lane N = normal control showing only the normal 
sized product and lane L = 1kb ladder (Gibco BRL).
Sequence of the mutant DNA across the intron-exon boundary, showing the 
intron 30 splice donor site mutation, T to G at position +2 marked by an 
arrow. The intron-exon boundary is indicated.
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Splice donor mutation in intron 18: 3113+1G to A
The third splice site mutation was identified when amplification of 
segment V showed the presence of an altered fragment of approximately 
750bp in addition to the normal sized fragment of 860bp (Figure 16a, 16b). 
This mutation was seen in a 41 year old female patient, who has an affected 
son. Chemical mismatch cleavage analysis was carried out to confirm the 
boundaries of the deletion (Figure 17a). Upon analysis, the altered fragment 
appeared to be approximately 120bp shorter than the normal sized fragment. 
To rule out the presence of a deletion, Southern blotting of the patient and 
control DNA was carried out using five different restriction enzymes using 
segment V as a probe. The results did not show the presence of a deletion, 
which would be seen as a junction fragment or a dosage effect. Exonic 
primers were designed such that a forward primer was in exon 17 (17F) and 
the reverse primer in exon 19 (19R). This product of amplification would span 
intron 17, exon 18 and intron 18, thus confirming or ruling out a deletion if 
any. Analysis of this product of amplification showed no deletion. Therefore 
the splice sites of intron 17 and 18 were sequenced. On sequencing, a G to 
A transition was seen at the splice donor site of intron 18 (nt 3113+1G to A) 
(Figure 17b). The splice mutation was characterised using primers 
immediately flanking exon 18 (18F, 18R), as well as the primers in exon 17 
and 19 (17F, 19R).
Using a combination of primers 17F, 19R, 18F and 18R also allowed the 
determination of the size of introns 17 and 18 which were shown to be 0.2kb 
and 0.7kb respectively.
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Figure 16a
Amplification of NF-1 cDNA (segment V) showing a smaller sized transcript of 
750bp in addition to the normal sized fragment of 860bp (marked by arrows) 
in lane M = mutant. Lane N = normal control and lane L = 1kb ladder (Gibco 
BRL).
Figure 16b
Southern blotting of the product of amplification of RNA segment V, using 
segment V as a probe, in order to confirm specificity of the altered band. Both 
the normal and altered bands are marked by an arrow in the patient and her 
affected son, in lanes 1 and 2, in comparison with only the normal band in 
lane 3 (control).
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Figure 17a
Deletion mapping using chemical cleavage analysis in segment V in the 
patient in lane 1 and her affected son in lane 3. Lanes 2 and 4 are the 
controls showing only the presence of the uncleaved product. Lanes 1 and 3, 
show the presence of the two cleavage products marked by arrows.
Figure 17b
Sequence of the mutant DNA across the intron-exon boundary, showing the 
intron 18 splice donor site mutation, G to A at position +1 marked by an 
arrow.
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This mutation caused an error t of slicing and resulted in the skipping 
of exon 18 from the NF-1 transccript. The skipping did not alter the 
translational reading frame, but resultlted n the exclusion of 41 amino acids 
from the predicted protein product. Thhis nutation was seen in a familial case 
of NF-1 and was shown in her affeccted son. 10 other controls were also 
screened by sequencing their splice isites and none of them were shown to 
have this mutation.
An interesting feature was seen on amplification of the region using 
the primers in exon 17 and exon 19 (1I7F, I9R). Upon sequencing this region, 
a number of sequence variants were icdentfied in 10 individuals in the coding 
region of exon 18 and in intron 17 (Fiigure 19). The changes were not seen 
when the same region was amplified uising primers immediately flanking exon 
18. These changes, thus did not appeiar to be solely amplified from the NF-1 
locus. Using primers 17F and 19R, amplification occurred from the NF-1 
locus as well as a homologous locus. But by using primers 18F and 18R, 
(which were used for amplification! and characterisation of the splice 
mutation), the altered sequence was mot seen. Therefore, this means that the 
regions on which 18F and 18R prime were not conducive to PCR 
amplification on the homologous region. This appeared to be an as yet 
unreported sequence which was homologous to exon 18 of the NF-1 gene.
Figure 18
Partial sequence analysis of exon 18, amplified using the primers 17F and 
19R which are in exons 17 and 19 respectively. Four of the seven changes 
detected in the coding sequence and intronic sequence are shown in this 
figure, the remaining lie at the other end of the exon. The positions marked 
by arrows show the substitutions. These were not seen on amplification of 
the same region using primers immediately flanking exon 18 (18F, 18R), 
indicating dual amplification from the NF-1 gene and a homologous locus.
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Partial loss of exon 16 from the NF-1 mRNA
Amplification of segment IV in a 12 year old male patient, who was a 
sporadic case of NF-1 showed an altered sized band in addition to the 
normal sized amplification product. The altered band appeared to be shorter 
by approximately 220-230bp (Figure 19). Direct sequencing of the mRNA 
revealed a deletion of 229bp, which began exactly at the first base of exon 
16 and an altered sequence ran in parallel with the normal sequence beyond 
this point (figure 20).
L  M  N
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Figure 19
Agarose gel electrophoresis showing an altered band shorter by 229bp in 
addition to the normal sized product in lane 1 (mutant). The control shows 
only the normal sized product of approximately 500bp in lane 2. L indicates 
the 1 kb ladder.
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Figure 20
Partial sequence analysis of the NF-1 mRNA surrounding the junctions of 
exon 15 and 16 in the mutant (Segment IV). Up to the junction between 
exons 15 and 16 (2409/2410), normal sequence is seen and beyond this 
point, a complex sequence is seen. This corresponds to a sequence 229bp 
away, indicating that the mutant allele running in parallel with the normal 
allele has 229 nucleotides missing.
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Insertion in exon 23
The second large alteration was seen on amplification of a part of segment 
VI, using internal primers in a case of segmental neurofibromatosis. Upon 
amplification, a larger fragment of approximately 60bp was seen in addition 
to the normal sized fragment. This region spans the alternatively spliced form 
of the NF-1 gene, called NF-GRD II, which has a 63bp insertion. This patient 
therefore is expressing equal amounts of the two neurofibromin isoforms NF- 
GRD-I and II (with the 63 base insertion), in comparison with the normal 
control who expresses only the NF-GRD I, which is the 390bp product.
N M
Figure 21
Agarose gel electrophoresis of the RT-PCR surrounding exon 23 (segment 
VI). The presence of a larger product of 450bp is seen in addition to the 
normal sized product of 390bp in lane M (Mutant), in comparison with only 
the normal sized product in lane N (Normal wild-type). The unmarked first 
lane is the 1 kb ladder.
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Loss of exon 18 from the NF-1 mRNA
Another interesting alteration was seen in a familial case who showed an 
altered fragment in the region surrounding exon 18 (segment V) on RT-PCR, 
which corresponded to shortening of approximately 120bp of the NF-1 mRNA 
(Figure 22). On sequencing of the same region this was seen to be due to 
loss of exon 18 (123bp) from the NF-1 mRNA (Figure 23).
L1 N M L2
Figure 22
Agarose gel electrophoresis of amplification product of segment V, showing 
the presence of an altered product smaller than the normal sized product by 
about 120bp in the mutant lane (marked by arrows). Lanes L1 and L2 are the 
1 kb ladder and 100bp ladder respectively.
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/Figure 23
Partial mRNA sequence analysis surrounding exon 18. The normal sequence 
is seen up to the point marked by an arrow (beginning of exon 18), beyond 
which a complex sequence is seen. On analysis, the parallel sequence is 
due to a mutant allele which has skipped exon 18 and the normal allele with 
exon 18, which run together.
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Large alterations within the NF-1 gene were screened for using Southern 
blotting with restriction enzyme EcoR I and probe p5 (ATCC). Analysis 
showed no dosage effect or junction fragment indicative of a large alteration 
using this probe-enzyme combination. However detection of large alterations 
using other probe-enzyme combinations have not been carried out.
24a 24b
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Figure 24a
Agarose gel electrophoresis of Eco Rl restriction digested DNA. The smear 
indicates digestion of the DNA into various sized fragments. Lanes 1 and 4 
show incomplete digestion.
Figure 24b
Southern analysis using probe P5.
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3.4 SMALL ALTERATIONS WITHIN THE NF-1 GENE
3.4.1 Characterisation of single base substitutions and small 
rearrangements in products of RT-PCR, using chemical mismatch 
cleavage (CCM) and direct sequencing.
Amplification of the RNA segments in the remaining patients showed 
PCR products of the expected size after electrophoresis on 1% agarose gels. 
However chemical cleavage analysis revealed the presence of cleavage 
products in these segments. The mutations identified on analysis of these 
RNA segments l-VII are presented below.
Missense mutation in exon 21: G1166D
A cleavage product was seen on modification with hydroxylamine in 
RNA segment V (Figure 25a) in an 11 year old male patient, who was a 
familial case of NF-1. This mutation was localised to exon 21, which is the 
first exon of the GAP related domain. Direct sequencing revealed a G to A 
transition at nucleotide position 3497 (Figure 25b), which is the first base of 
exon 21. This mutation caused the conversion of Glycine to Aspartate at 
amino acid position 1166 (G1166D). The mutation was seen in the proband 
and in his mother who also has NF-1.
Silent mutation in exon 24: G1404G
Two different sized cleavage products on modification with both 
hydroxylamine and osmium tetroxide were seen in Segment VI in a 19 year 
old male patient who is a sporadic case of NF-1 (Figure 26a, Figure 26b). 
These were localised to exon 24 of the NF-1 gene. Direct sequencing 
demonstrated the hydroxylamine modification to be to be a G to A transition
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in nucleotide 4212 (Figure 27) and the mutation creates an Apo I restriction 
site. This transition maintains a Glycine at position 1404 (G1404G) and is 
thus a silent mutation. Digestion of the 400bp PCR product by Apo I results 
in two bands of 220 and 180bp from the mutated allele, in addition to the 
undigested 400bp band from the normal allele in the patient (Figure 29a). 
Digestion of 30 controls was carried out to find out whether this mutation was 
polymorphic, but the mutation was not seen in any other control. Thus this is 
a rare sequence variant, within the coding region of the NF-1 gene.
Missense mutation in exon 24: K1419R
The cleavage product seen on modification with osmium tetroxide was due to 
a missense mutation. Direct sequencing demonstrated this mutation to be a 
A to G transition at nucleotide 4256 (Figure 28), causing the conversion of 
Lysine to Arginine at position 1419. This mutation creates an Mnl I restriction 
site (Figure 29b). The product of amplification contains another normally 
present Mnl I site which serves as an internal control. Digestion of the mutant 
PCR product clearly shows a different pattern from normal, which 
corresponds to the bands created due to the already present and the newly 
created Mnl I enzyme site.
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Figure 25a
Chemical cleavage analysis of RNA segment V on modification with 
hydroxylamine. The cleavage product due to the missense mutation G 1166D, 
caused by the G3497 to A substitution is seen in lane 2, indicated by an 
arrow.
Figure 25b
Partial mRNA sequence analysis surrounding exon 21 in wild type (normal) 
and mutant, showing the G3497 to A substitution in exon 21, indicated by an 
arrow.
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Figure 26a
Chemical cleavage analysis of RNA segment VI, on modification with 
hydroxylamine. The cleavage product due to the silent mutation G1404G, 
caused by the G4212 to A substitution, is indicated by an arrow.
Figure 26b
Modification of segment VI with osmium tetroxide showing a cleavage 
product due to the missense mutation K1419R, caused by an A4256 to G 
substitution and is indicated by an arrow.
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Figure 27
Partial mRNA sequence analysis of segment VI (exon 24) in wild type and 
mutant. The G4212 to A substitution, due to the silent mutation G1404G is 
indicated by an arrow.
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Figure 28
Partial mRNA sequence analysis of Segment VI (exon 24) in wild type and 
mutant, showing the A4256 to G substitution due to the missense mutation 
K1419R, indicated by an arrow.
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Figure 29a
Restriction analysis with the enzyme Apo I, the site being created due to the 
mutation G1404G in exon 24. Agarose gel electrophoresis showing digestion 
of the mutant allele into two smaller products of 240 and 160bp, indicated by 
arrows.
Figure 29b
Restriction analysis with the enzyme Mnl I. An additional Mnl I site is created 
due to the missense mutation K1419R in exon 24. Agarose gel 
electrophoresis showing digestion of the product in normal controls (N) due 
to a normally present Mnl I site. Lane M in the mutant shows a different 
pattern in the digested product, due to creation of an additional Mnl I site at 
200bp due to the mutation and is indicated by an arrow.
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Silent mutation in exon 23: S1311S
Analysis of segment VI in a 30 year old female who is a familial case 
of NF-1, showed a cleavage product on treatment with hydroxylamine (Figure 
30). This mutation is a C to T substitution at nucleotide 3933, maintaining a 
Serine at amino acid position 1311 (S1311S). This mutation causes loss of a 
Fok I restriction site and restriction analysis was used to screen 30 controls, 
none of whom were shown to have this mutation.
Upon direct sequencing, only the altered allele (T) was seen instead 
of both C from the normal allele and T from the mutant allele at the same 
level (Figure 31a).
Similarly, only the presence of the allele with the silent mutation 
(undigested, due to loss of a the Fok I site) was seen on digestion of the 
product of amplification (Figure 31b). Partial or incomplete digestion was 
ruled out as the same result was seen on three different attempts at 
digestion.
In order to rule out a deletion, Southern analysis was performed on the 
patients genomic DNA, using segment VI as a probe and 5 different 
restriction enzymes. However the results from Southern analysis were 
inconclusive and a deletion could not be ruled out. Amplification of this 
region using PCR did not show an altered product, probably because the 
deletion boundaries extended outside the amplified PCR fragment.
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Figure 30
Chemical cleavage analysis of RNA segment VI on modification with 
hydroxylamine. The cleavage product due to the silent mutation S1311S, 
caused by a C3933 to T substitution is seen in lane 5 and is indicated by an 
arrow.
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Figure 31a and b
a)Direct sequence analysis showing only the mutant allele T at the point of 
alteration marked by an arrow, instead of a C and T at the same level.
b)Restriction enzyme analysis using enzyme Fok I. Agarose gel 
electrophoresis of digested PCR products. Lane M (mutant) shows the 
undigested mutant product (S1311S abolishes a Fok I restriction site), while 
the other lanes N (normal wild type) show complete digestion in normal 
controls. The unmarked lane represents the 1kb ladder. It is seen that in lane 
M, only the undigested mutant allele is seen, when there should have been a 
digested band from the normal allele and an undigested band from the 
mutant allele.
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The remaining positive results of chemical cleavage analysis were 
seen in the following RNA segments: (These have not yet been characterised 
by direct sequencing).
In Segment I, a cleavage product of 500bp in addition to the normal 
sized fragment of 600bp (Figure 32), was seen in a 22 year old female 
patient, who is a sporadic case of NF-1.
Segment I also showed two cleavage products in a 12 year old female 
patient who is a sporadic case of NF-1, at 150bp and 450bp respectively 
(Figure 33). These mutations were mapped to lie in either exon 2 or exon 4 of 
the NF-1 gene.
A cleavage product was seen on modification with hydroxylamine in a 
3 year old female sporadic patient. The cleavage product appeared to be 
220bp in addition to the normal sized fragment of 500bp (Figure 34). This 
was seen in segment IV.
A cleavage product of 180bp was seen in addition to the normal sized 
fragment of 500bp (Figure 35) in a 36 year old female patient of NF-1, with a 
family history of NF-1 and cancer. The cleavage product was seen on 
modification with osmium tetroxide, in segment VII spanning exons 26 and 
27a and 27b, which covers part of the GAP related domain of the NF-1 gene.
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Figure 32
Chemical cleavage analysis of segment I, showing a cleavage product of 
500bp in addition to the normal sized fragment of 600bp, on modification with 
osmium tetroxide, in lane 7 marked by an arrow.
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Figure 33
Chemical cleavage analysis of segment I, showing cleavage products of 
150bp and 450bp in addition to the normal sized fragment of 600bp, on 
modification with osmium tetroxide, in Lane 6 marked by an arrow.
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Figure 34
Chemical mismatch cleavage analysis of segment IV, showing a cleavage 
product of 220bp in addition to the normal sized fragment of 500bp, upon 
modification with hydroxylamine, in lane 6 marked by an arrow.
Figure 35
Chemical mismatch cleavage analysis of segment VII showing a cleavage 
product of 180bp in addition to the normal sized fragment of 500bp on 
modification with osmium tetroxide, in lane 5 marked by an arrow.
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3.4.2 Characterisation of single base substitutions and small 
rearrangements in the products of DNA PCR using SSCP analysis, 
chemical cleavage of mismatches and direct sequencing.
Silent mutation in exon 29: N1776N
Chemical mismatch cleavage analysis of exon 29 in a 19 year old male, 
sporadic case of NF-1 showed a cleavage product on modification with 
hydroxylamine (Figure 36a). Direct sequencing revealed a C to T transition at 
position 5328, changing the third base of codon AAC to AAT (Figure 37). 
This transition maintains an Asparagine at position 1776 and is thus a silent 
mutation (N1776N).
The C to T transition results in creation of a Hint I restriction site which upon 
digestion of the 230bp PCR product produces two bands of 190 and 40bp 
(Figure 36b). The digested PCR products were resolved on an agarose gel 
and visualised by ethidium bromide staining. 100 controls were screened 
using restriction analyses and none were found to have this mutation. This is 
therefore a rare sequence variant within the coding region of the NF-1 gene.
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Figure 36a
Chemical mismatch cleavage analysis of exon 29. The presence of a 
cleavage product is seen on modification with hydroxylamine in lane 2. Lanes 
1 and 3 are the control lanes on modification with hydroxylamine and osmium 
tetroxide respectively. Lanes 2 and 4 are the patient lanes on modification 
with hydroxylamine and osmium tetroxide respectively. L indicates the 1kb 
ladder.
Figure 36b
Restriction analysis with the enzyme Hinf I. The C5328 to T transition creates 
a Hinf I restriction site, showing digestion of the 230bp PCR product into two 
bands of 190 and 40bp resolved on a 1% agarose gel and visualised by 
ethidium bromide staining.
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Figure 37
Partial sequence analysis of exon 29 showing the C5328 to T transition 
marked by an arrow in the mutant lane. Only the normal allele (C) is seen in 
the wild type.
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Single base insertion of guanine in exon 34: 6519insG
The next mutation was identified on SSCP analysis of exon 34 in a 34 year 
old female patient with four affected children and a family history spanning 
three generations. An altered pattern was seen on SSCP analysis of exon 34 
(Figure 38a). This product was then subjected to chemical mismatch 
cleavage, which showed a cleavage product of the same size (165bp) on 
modification with both hydroxylamine and osmium tetroxide in comparison 
with the uncleaved probe at 400 bp (Figure 38b). Direct sequencing 
demonstrated a single base insertion of guanine at position 6519 (6519insG) 
(Figure 39).
Figure 38a
SSCP analysis of exon 34, showing a shift at the level of the single strands in 
lane 4, compared with the level of the single strands in the control lanes.
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Figure 38b
Autoradiograph of the chemical cleavage analysis of exon 34 with 
hydroxylamine (Hy) and osmium tetroxide (Os) in patient (lanes 1,3) and 
control (lanes 2,4). The control shows only the presence of the uncleaved 
probe at 400bp, while the patient shows a cleavage product of 165bp on 
modification with both hydroxylamine and osmium tetroxide. L is the 1kb 
ladder.
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Figure 39
Sequence analysis of exon 34 in the patient and a normal control. The 
sequence surrounding position 6519 and the point of insertion of guanine 
(indicated by an arrow) is shown. As the patient is heterozygous for the 
mutation, both the normal and the mutated sequences run together beyond 
the point of insertion.
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Insertion of two guanine bases in exon 42: 7485insGG
Amplification of exon 42 and flanking intronic sequences, followed by 
chemical cleavage analysis showed a cleavage product of the same size on 
modification with both hydroxylamine and osmium tetroxide (Figure 40). This 
went in favour of the mutation being a small insertion or deletion and was 
detected in a 8 year old male patient, who is a sporadic case of NF-1.
Direct sequencing of this exon demonstrated the presence of an insertion of 
2 guanine bases at position 7485 of the published sequence (Figure 41). 
This mutation creates the following restriction enzyme sites: Msp I, Sma I, 
Nla IV, BsaJ I and Nci I. Electrophoresis on MDE™ (BIOCHEM) gel matrices 
revealed an altered pattern due to slower migrating heteroduplexes (Figure 
42).
Nonsense mutation in exon 42: R2496X
Chemical cleavage analysis of exon 42 also detected a cleavage product on 
modification with hydroxylamine (Figure 43a) in a 23 year old female patient, 
who is a sporadic case of NF-1. Direct sequencing showed this to be due to a 
C to T conversion at position 7486 (Figure 43b). This transition at a 
hypermutable CpG dinucleotide converts the codon for Arginine (CGA) to a 
premature stop codon (TGA) at position 2496 (R2496X). This nonsense 
mutation was identified in the same codon (Arg 2496) in which the 2 base 
insertion 7485insGG was identified.
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Figure 40
Chemical cleavage analysis of exon 42, showing cleavage products 
2 and 4 in the mutant on modification with hydroxylamine (HY) and 
tetroxide (OS) respectively (marked by arrows). Lanes 1 and 3 
respective controls.
in lanes 
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Figure 41
Partial sequence analysis of exon 42 showing normal sequence up to a point 
marked by an arrow. Beyond this point a complex sequence is seen, due to 
the insertion of two guanine bases at position 7485. Beyond the level of 
insertion, the sequence from the normal allele and the sequence from the 
mutated allele (whose sequence has been pushed forward two bases due to 
the insertion) are seen running in parallel.
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Figure 42
Heteroduplex analysis of exon 42. Lane 2 shows a distinct pattern with the 
formation of slower migrating heteroduplexes. More than one heteroduplex 
pattern is seen and a possible explanation for this is as follows: This patient 
was shown to be heterozygous for a polymorphism in intron 41, which itself 
generates a specific heteroduplex pattern (Figure 44). This product of 
amplification thus has two changes, heterozygosity for the intron 41 
polymorphism and a two base insertion. The various combinations of 
sequence alterations within this product could be responsible for formation of 
more than one heteroduplex.
1 2 3
NORMAL MUTANT
A G C T  A G C T
ESS I  > to
■I < -
Figure 43a
Chemical cleavage analysis of exon 42 on modification with hydroxylamine 
showing the presence of a cleavage product in the mutant lane (lane 1). 
Figure 43b
Partial sequence analysis of exon 42, showing the C to T transition at 
position 7486 marked by an arrow in the mutant lane.
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3.5 IDENTIFICATION OF A NOVEL POLYMORPHISM IN INTRON 41 OF
THE NF-1 GENE
An intragenic polymorphism was detected in intron 41 by chemical 
cleavage analysis. While screening for mutations in exon 42, this was seen 
as a constant cleavage product. DNA sequence analysis demonstrated this 
to be a transition of Adenine 'A' to Guanine 'G', in intron 41, 28 bases 
upstream of the first base of exon 42 (Figure 44). The sequence analysis was 
carried out initially in 4 individuals and it was seen that this region was 
polymorphic (2/4 individuals were heterozygous on initial sequence 
analysis).The mutation results in the loss of the following restriction enzyme 
sites: Mse I, Pac I, 7sp509 I and Vsp I. Analysis on an MDE™ gel matrix was 
carried out in an attempt to develop an easy screening strategy to find out 
the frequency of this polymorphism. It was seen that three distinct patterns 
were seen on electrophoresis (Figure 44). Correlation of the sequence 
analysis with the patterns detected on the gel permitted the following 
conclusions to be made: Pattern 1 is produced by alleles homozygous for A, 
pattern 3 is produced by alleles homozygous for G and pattern 2 
heterozygous for A and G. 75 unrelated Caucasian individuals of Scottish 
origin were studied and the genotype prevalences for the total group (n=75) 
were as follows: 36% (27/75) for A allele homozygotes, 12% (9/75) for G 
allele homozygotes and 52% (39/75) for A/G heterozygotes. The individual 
frequencies of the A and G alleles were 62% and 38% respectively. 
Autosomal codominant segregation was observed in one family with three 
generations and two families with two generations.
When the observed heterozygosity (52%) was compared with that calculated 
from the homozygous allele frequencies (42%), a discrepancy is apparent
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due to the small sample number. The average of these numbers gives an 
allele heterozygosity of 47%.
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Figure 44
Heteroduplex analysis of the intron 41 polymorphism 7395 -28 A to G, 
showing three distinct heteroduplex patterns. Lane 1 pattern for alleles 
homozygous for A, lane 2 pattern for alleles heterozygous for A/G and lane 3 
pattern for alleles homozygous for G.
Sequence analysis surrounding the intron 41 polymorphism 7395 -28 A to G 
Tracks 1: Alleles homozygous for G 
Tracks 2: Alleles heterozygous for A/G 
Tracks 3: Alleles homozygous for A
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The other two possible polymorphisms which have not been characterised by 
direct sequencing are as follows: Three distinct patterns were seen on SSCP 
analysis of exon 28 and could be due to a polymorphism in exon 28.
1 2 3 4 5 6 7 8
Figure 45 shows lanes 1,2,4 and 6 with one pattern, lanes 3 and 8 with 
another pattern and lanes 5 and 7 with a third pattern.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 46
Also seen on chemical cleavage analysis of the mRNA (segment IV) 
surrounding exon 16 was the observation that 4 out of 14 samples showed 
the same cleavage product, which could be due to a polymorphism within this 
region. Figure 46 shows lanes 1,4, 12 and 13 with the same sized cleavage 
product on modification with hydroxylamine.
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3.6 SEGREGATION ANALYSIS IN NF-1 FAMILIES USING A 
TETRANUCLEOTIDE REPEAT IN INTRON 27 OF THE NF-1 GENE
Analysis was carried out using an Alu-repeat polymorphic sequence AAAT 
located in intron 27 of the NF-1 gene (Xu et al 1991).
Lazaro et al. (1993) analysed 294 independent normal chromosomes and 
reported the distribution of alleles which were as follows: allele 0 (411 bp: 11 
repeats), allele 1 (407bp:10 repeats), allele 2 (403bp:9 repeats), allele 3 
(399bp:8 repeats) and allele 4 (395bp:7 repeats). This locus was shown to 
have a heterozygosity of 0.50. In this study the different alleles seen on 
analysis of affected patients and their families are shown in Figure 47a.
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Figure 47a
Autoradiograph showing the different alleles in the Scottish population on 
tetranucleotide (AAAT) repeat analysis in intron 27. L represents the 
radiolabelled 1kb ladder.
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Figure 47b
Analysis of the intron 27 tetranucleotide repeats. The unaffected members of 
the family (lanes 2 and 4) show a different pattern from the affected 
members.
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3.7 SCREENING FOR SOMATIC MUTATIONS
Prior to screening for mutations in the NF-1 gene, the tumour samples 
were analysed for mutations within the appropriate ras group of oncogenes 
using SSCP analysis. Two tumour types showed an altered pattern on SSCP 
analysis in the regions surrounding codons 12 and 13 of the K-ras group of 
oncogenes. The tumour types with the alteration were a colonic adenoma 
sample (8549) and a colonic adenocarcinoma sample (8496) (Figure 48a, 
48b). This is in accordance with the fact that up to 40% of colon carcinomas 
harbour a mutant K-ras gene (Bos 1989).
Screening for small alterations within the NF-1 gene was carried out 
by initial screening of exon 24 of the NF-1 gene (Li et al 1992). A pair of 
intron based primers were used to generate a 236bp PCR product, 
containing the FLR exon (159bp). Initial screening was carried out by an 
assay (FLR-Tag assay) designed by Li et al (1992). To detect sensitively and 
rapidly any change in the first nucleotide of Lysine 1423 in exon 24 of the 
NF-1 gene, in which 2 mutations affecting the first base had already been 
reported, Li et al designed a restriction enzyme based assay using the 
restriction enzyme Taq I. Any mutation altering the first A in the AAG Lys- 
1423 codon prevents cutting by Taq I (Figure 49). Using this assay, tumour 
DNA samples were analysed and all the samples showed complete digestion 
with the Taq I restriction endonuclease which indicated no alteration at the 
AAG Lysine 1423 codon. To analyse for mutations in other parts of exon 24, 
these tumour samples were subjected to chemical cleavage analysis, which 
also did not reveal any abnormalities (Figure 50). A positive control was done 
with each chemical cleavage analysis to ensure that the procedure was 
working. A cleavage product was seen in the control, but not in any of the 
tumour samples analysed.
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Figure 48
SSCP analysis of the K-ras group of oncogenes (codons 12-13). 
a)An altered pattern is seen at the level of the single strands (marked by an 
arrow) in tumour sample 8549, which was a colonic adenoma. b)An altered 
SSCP pattern in tumour sample 8496 (marked by an arrow), which is a 
colonic adenocarcinoma.
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FLRTaq Assay for Lys 1423
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Figure 49
FLR-TAQ Assay for Lys 1423 (Lys 1389): The figure shows the upstream 
primer used for amplification, with the modification of one base A to G, in 
order to create the restriction site for Taq I (TCGA), the A being from the first 
base of the codon for Lysine (1423/1389). Modification of the codon for 
Lysine by a mutation in the first base of the codon e.g. A to G transition 
changing Lysine to Glutamine, or an A to C transition changing Lysine to 
Glycine would result in loss of the Taq I site.
The undigested allele of 236bp is shown below. On digestion with an intact 
Lysine codon, the product would show digestion into a 214bp and a 22bp 
fragment (+/+). However, if the codon for Lysine was mutated, it would result 
in digestion into two fragments of 214bp and 22bp from the normal allele and 
an undigested product of 236bp from the mutant allele (+/-). If both alleles 
were mutated, a pattern of no digestion (-/-) would be seen. Electrophoresis 
on an 8% polyacrylamide gel showing lane 1 with the undigested control 
(236bp). Lanes 2,3 and 4 show complete digestion indicating absence of a 
mutation (only the 214 bp band is shown, the 22bp band being much smaller 
runs faster and is not shown). All the tumours were screened using this 
assay and no mutations affecting the codon Lysine (1423/1389) were seen.
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Figure 50
Chemical mismatch cleavage analysis of exon 24 (FLR exon) showing no 
cleavage product in the tumour samples analysed.
Four neuroblastoma samples were screened for large alterations using 
Southern (p5/EcoR I) and Northern blot analysis, none of which revealed any 
abnormalities.
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CHAPTER: 4 
DISCUSSION
CHAPTER 4: DISCUSSION 
4.1 SPECTRUM OF MUTATIONS
The identification and characterisation of mutations within the NF-1 
gene is the first step in addressing a number of important features of NF-1, 
including the possibility of a mutational hotspot, variability of expression and 
the correlation between the genotype and clinical symptoms.
The NF1 gene was cloned in 1990 and until recently very few 
mutations were identified. This could be due to a number of reasons which 
include the large size of the gene, the high mutation rate (up to 50% of cases 
being due to new mutations), the as yet uncharacterised intron-exon 
boundaries and due to the fact that the screening methods used so far may 
have missed mutations.
So far, a total of 68 mutations (June 1994 newsletter-NNFF Mutation 
Analysis Consortium) have been reported in the NF-1 gene. The mutations 
characterised include large and small deletions and insertions, single base 
substitutions which include nonsense, missense, splice junction and silent 
mutations, of which 13 mutations have been characterised in this study 
(Figure 51). Due to the compiling of the mutations by the NF-1 consortium, a 
group of mutations can now be analysed for their spectrum, distribution and 
recurrence.
In this study, a positive screening result was detected in 17 out of 25 
patients analysed, of which 13 have been characterised. Of these, 10 
mutations are potentially pathogenic. The mutations described in the NF-1 
gene so far appear to be heterogeneous and include gene deletions and 
insertions of various sizes as well as single base substitutions. Thus a 
spectrum of changes has been identified and this offers an opportunity to
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compare the relationship between the structure and function of 
neurofibromin.
Table 12 shows the various germline mutations tabulated by their positions 
within the NF-1 gene, including the mutations detected in this study, which 
are marked by an *. Mutations that are underlined have not been reported to 
the Consortium, but have been published elsewhere (Valero et al., 1994). 
Mutations in italics lie within the NF-1 GAP related domain, which extends 
from mRNA positions 1125-1536.
Table 12: Mutations reported within the NF-1 gene
EXON MUTATIONS
3 Deletion of exon 3
11 1721+3G*
13 Q682X
16 partial del of exon 16*
17 2970delAAT, 2875insA, 2851delCTTTT
18 M1035R, 3113+1A*, del exon 18*
21 G1166D*
22 R1276X
23 3974delGTTA, S1311S* L1339R
24 4152delA, 4183delC, 4190delT, K1432E, G1404G*, 
K1419R*
27a R1513X
28 5123delCCAACC, 5077delAAACTGGCTGAGC, 5010delG, 
5108delAG, 4969delTCTATA
29 N1776N*. S1745X. 5451insC. 5468insT. R1748X. Q1754X
30 5678delAC, 5749+2G*
31 5843delAA. R1947(7), 5849insTT, 5816insG, del 5787-5814
32 ins (Alu), 5949delA, 5944-5G (2)
33 del (ex 33), P2056R, 6364+4G
34 6519insG*, L2143M, Y2171R
37 del (ex 37)?
38 6922insGATGAGGTCA
39 7096delAACTTT
42 R2496X*, 7485insGG*
44 7745delTTCTCTTGGA
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FIGURE 51
SPECTRUM OF MUTATIONS
E3 large ins. ■  large del. ■  small ins □  small del. □  nonsense 
□ nissense ■  splice
This chart shows the spectrum of mutations reported within the NF-1 gene in 
the literature and via the NNFF Mutation Analysis Consortium.
A heterogenous group of mutations is seen and 88% of the mutations (i.e. 
excluding the missense mutations) are predicted to cause a disruption of 
neurofibromin.
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From analysis of all the types of mutations identified so far, 88% of mutations 
are predicted to cause disruption of the protein product neurofibromin (Figure 
51). This study has shown that 75% of the mutations characterised are 
predicted to cause disruption of the protein product neurofibromin. The 
reasons for this discrepancy (75% / 88%) could be, the technique of PCR 
amplification of the NF-1 mRNA used in this study is only capable of 
detecting large alterations if the primer pairs used entirely encompass the 
alteration. Also Southern blotting was carried out using only one probe- 
enzyme combination and therefore large alterations may have been missed.
However from all the mutations identified so far and from the spectrum 
of mutations detected in this study, it appears that the majority are small 
sequence alterations causing disruption of the NF-1 gene. This study has 
also identified 3 silent mutations, in addition to the remaining potentially 
pathogenic mutations. A mutation detection method PTT (protein truncation 
test) has been described for rapid detection of translation terminating 
mutations (Roest et al., 1993). This technique is unable to detect missense 
mutations (which may be pathogenic), but has the advantage of not detecting 
silent mutations. This method would be useful in analysing mutations in large 
complex multi-exonic genes, where a large fraction of pathological mutations 
arise from termination of translation. One such example, the dystrophin gene 
was analysed for mutations using PTT (Roest et al., 1993) and this technique 
may be a useful screening method for mutation analysis of the NF-1 gene.
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The mutations characterised within the NF-1 gene that are predicted to 
cause disruption of neurofibromin, i.e. insertions, deletions, duplications, 
splicing errors and nonsense mutations are discussed below.
Insertions
There have been two reports of large insertions, by Wallace et al.,
(1991) who reported insertion of an Alu element in the NF-1 gene and by 
Upadhyaya et al., (1992) who reported insertions of approximately 10kb. 
Small insertions have been reported in the literature by Upadhyaya et al.,
(1992), Zhong et al., (1993) and Ainsworth et al., (1993). Two small 
insertions have been identified as part of this study (6519insG and 
7485insGG).
6519insG: An insertion of a single guanine base was identified in exon 34 at 
position 6519. The mutation causes a shift in the reading frame and is 
predicted to result in the formation of 46 altered amino acids, before 
producing a premature stop codon at position 2220. Thus the predicted 
protein product will contain 2219 amino acids instead of 2818.
7485insGG: An insertion of 2 guanine bases was identified in exon 42 at 
position 7485. The mutation produces a shift in the reading frame and is 
predicted to cause the translation of 5 altered amino acids, before creating a 
premature stop codon at position 2502. A consequence of this mutation will 
be the synthesis of a truncated protein product of 2501 amino acids instead 
of the normal 2818.
Deletions
The deletions reported so far in the NF-1 gene are as follows: 
Viskochil et al., (1990) reported 3 deletions of 190, 40 and 11 kb. Upadhyaya 
et al., (1990), (1992) reported three deletions of 90kb, 40kb and 80kb. Kayes
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et al., (1994) reported 5 patients with deletions of the entire NF-1 gene. 
Weiming et al., (1992) reported a comparatively smaller deletion of 571 bp. 
Small deletions within the NF-1 gene have been reported in the literature by 
Stark et al., (1991), Xu.et al., (1992), Zhong et al., (1993), Shen et al., 
(1993a), Shen et al., (1993b), Colman et al., (1993) and Valero et al., (1994).
In this study two deletions of the NF-1 mRNA were detected, the 
cause of which at the DNA level has not yet been characterised.
The first was a complete deletion of exon 18, detected by RT-PCR and 
direct sequencing. The exclusion of exon 18 from the NF-1 mRNA could be 
due to a splice mutation, a deletion at the DNA level or a nonsense mutation. 
The cause at the DNA level of this mutation remains to be determined.
The second deletion was a partial loss of exon 16 (229 bases) from 
nucleotide positions 2410 to 2639. This loss of 229 residues is predicted to 
result in a shift in the reading frame and creation of a premature stop codon. 
A protein product of 803 residues instead of the normal 2818 amino acids is 
predicted, with loss of the NF-1 GRD. This exclusion of 229 nucleotides from 
exon 16 in the NF-1 mRNA could be due to a deletion at the DNA level or 
due to aberrant splicing (discussed in splice site mutations).
Duplications
A 10 base pair duplication (6922insGATGAGGTCA) was reported in a 
sporadic case of NF-1 with the complication of a neurofibrosarcoma in exon 
38 of the NF-1 gene by Legius et al., (1994b).
A duplication within the NF-1 gene was also reported by Tassabehji et 
al., (1993) in a family with Watson syndrome and features of Noonan's 
syndrome.
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Splice junction mutations
The first splice junction mutation reported within the NF-1 gene was 
reported by Hutter et al., (1994). The mutation was an A to G transition at +4 
of the intron 33 splice donor site and caused exon skipping. The other splice 
mutation was at position - 5 of intron 31, reported independently by 
Rodenheiser et al., (1994) and Legius E. (1994) (NNFF Mutation Analysis 
Consortium newsletter-June1 94).
In this study 3 splice mutations were identified at the splice donor sites of 
introns 11,18 and 30.
1721+3A to G: The first splice mutation detected was an A to G substitution 
at position +3 (nt 1721 +3) of the splice donor site of intron 11. The mutation 
resulted in an error of splicing leading to the skipping of exon 11 from the 
NF-1 mRNA and a shift in the translational reading frame. This is predicted to 
result in the formation of 12 altered amino acids and the creation of a 
premature stop codon at position 560. This would result in the synthesis of a 
protein of 559 amino acids instead of the normal 2818 amino acids. This 
product of translation would lack the NF-1 GAP related domain.
3113+1G to A: The second splice mutation detected was a G to A 
substitution at position +1 (nt 3113 +1) of the invariant GT dinucleotide of the 
splice donor site of intron 18. It resulted in an error of splicing which led to 
the skipping of exon 18 from the NF-1 mRNA. The skipping would result in 
the loss of 41 amino acids from the normal protein product of 2818 amino 
acids, including two cysteine residues at positions 1016 and 1032.
5749+2T to G: The third splice mutation detected was a T to G substitution 
at position +2 (nt 5749 +2) of the invariant GT dinucleotide of the splice 
donor site of intron 30. The mutation resulted in an error of splicing which led 
to skipping of exon 30 from the NF-1 mRNA. The skipping of exon 30 shifts 
the translational reading frame and is predicted to lead to the formation of
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one altered amino acid, before creating a premature stop codon at position 
1851. This would result in a protein of 1850 amino acids instead of the 
normal 2818 amino acids, assuming the predicted neurofibromin is stable.
Nonsense Mutations
Thirteen nonsense mutations have been reported so far within the NF- 
1 gene. Seven of these are the same mutation (R1947X) in exon 31 of the 
NF-1 gene reported by different investigators. The remaining nonsense 
mutations are R1267X, R1523X, R1748X, Q628X, S1745X and Q1745X 
(Cawthon et al., 1990a, Ainsworth et al., 1993, Estivill et al., 1991, Horiuchi 
et al., 1994, Valero et al., 1994 and NNFF Mutation Analysis Consortium 
newsletter, June 1994).
In this study one nonsense mutation was detected in exon 42, 
R2496X. This nonsense mutation resulted due to conversion of C to T at 
position 7486, altering the codon for arginine (CGA) to a premature stop 
codon (TGA). It occurred at a hypermutable CpG dinucleotide and is 
predicted to produce a truncated protein product of 2495 amino acids.
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4.2 DISTRIBUTION OF MUTATIONS
Figure 52 shows the distribution of all the germline mutations identified within 
the NF-1 gene. From analysis of the graph, it appears that most mutations 
are concentrated in exons 20-35 of the NF-1 gene. However this is a biased 
finding, as exons 24 and 28-36 were among the first exons to be screened, 
since the intron sequence at their boundaries was the first to be reported 
(Cawthon et al., 1990a).
4.3 RECURRENCE OF MUTATIONS
There are several examples of recurrent point mutations in disease 
genes. The most striking example is the independent origin of the sickle cell 
mutation in Africa (Antonarakis et al., 1984, Pagnier et al., 1984) and in Asia 
(Kulozic et al., 1986) and the multiple origins of the beta-E-gene (Kazazian et 
al., 1984). Another example is the G6PD Mediterranean C to T at 563 
mutation which has originated independently in Europe and Asia (Beutler and 
Kohl 1990). Within the NF-1 gene, 4 different examples of recurrent 
mutations have been reported which include a nonsense mutation (R1947X) 
which occurs at a CpG dinucleotide reported in seven different studies, a 
single base insertion (5451 insC), a three base deletion (2970delAAT) and a 
splice site mutation (5944-5G) reported by two different investigators.
The mutation R1947X in exon 31 of the NF-1 gene has been 
independently reported by seven investigators. The first report was by 
Cawthon et al., (1990a) who detected this mutation on screening 72 families, 
followed by Estivill et al., (1991) who screened 38 Spanish families and found 
one such mutation. The same mutation was reported by Ainsworth et al.,
(1993) on screening 48 families from South Western Ontario, which is an 
ethnically diverse region. The cases reported above are sporadic cases of 
NF-1 (origin of the mutation reported by Cawthon et al., (1990a) is unknown). 
Horiuchi et al., (1994) reported two familial cases of NF-1 with this mutation, 
on analysis of 25 Japanese families. These cases were the first described in 
an ethnic group other than Caucasian. Valero et al., (1994) also reported the 
R1947X mutation in a familial case of NF-1 on screening 70 unrelated NF-1 
patients.
Therefore of the 253 families screened so far five mutations at this particular 
nucleotide have been detected. The same mutation was also reported by
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Korf et al. (1994) and Vidaud et al. (1994) via the NNFF Mutation Analysis 
Consortium.
Since exon 31 represents 2% of the NF-1 coding region, seven 
independent reports of the same mutation in different populations has 
established this to be a hotspot for mutation in the NF-1 gene and shown that 
this specific cytosine is particularly prone to mutation. The identification of 
the same mutation in seven independent cases also suggests that a specific 
search for this mutation (R1947X) should be made when studying NF-1 
familial or sporadic cases for genetic analysis.
Upadhyaya et al., (1992) reported an insertional mutation 5451 insC in 
exon 29 in two unrelated individuals. The other example is a 3bp deletion, 
2970delAAT, also reported by Upadhyaya et al., (1993) in exon 17 of the NF- 
1 gene in two unrelated individuals. A recurrent splice mutation has been 
reported by Rodenheiser (1994) and independently by Legius (1994), the 
mutation being 5944-5G in intron 31, which results in the shift in the reading 
frame (NNFF newsletter, June 1994). In the above case however, it is not 
known whether the splice mutation represents true recurrence or identity by 
descent.
In the present study, the absence of exon 18 from the NF-1 mRNA 
was detected in two unrelated individuals. In one patient, a familial case of 
NF-1 the absence of exon 18 from the NF-1 mRNA was due to a splice site 
mutation at the donor site of intron 18 (3113+1G to A). In the other patient, 
the absence of exon 18 (shown by RT-PCR and direct sequencing) could be 
due to a splice site mutation or a deletion and this remains to be 
characterised.
188
4.4 NF-1 HOMOLOGOUS SEQUENCES AND PSEUDOGENES
NF-1 related loci have been identified on chromosomes 2, 12, 14, 15, 20, 21 
and 22 (Marchuk et al., 1991). All these show greater than 90% homology 
with some NF-1 exons and intron sequences. A number of the above regions 
have been sequenced and most, if not all represent non-processed 
pseudogenes. Most of the related loci reside on acrocentric chromosomes 
and it was hypothesised that their origin was due to acrocentric chromosome 
pairing during meiosis. These pseudogenes may act as a reservoir of 
mutations that can be crossed on to the NF-1 locus on chromosome 17 by 
gene conversion, which might explain the high mutation rate for the disorder 
(Cummings et al., 1991).
Two groups have further characterised some of the NF-1 homologous 
regions. One of them lies on chromosome 15 and is called the "NF-1 related 
locus" (Legius et al., 1992). Another sequence homologous to exon 24 of the 
NF-1 gene, called the "NF-1 highly homologous sequence" (NF-1HHS) has 
been reported by Gasparini et al. (1993).
The presence of these (and as yet undetected) pseudogenes may 
complicate the genetic analysis of NF-1. In the present study two mutations 
were detected in exon 24, a missense mutation K1419R and a silent mutation 
G1404G. These mutations are likely to be present within the NF-1 gene and 
not in the pseudogenes. The region in which these mutations exist is deleted 
in the "NF-1 related locus" on chromosome 15 and neither of these mutations 
correspond to codon changes in the "NF-1HHS sequence". Furthermore, 
various combinations of intron and exon based primers were used to rule out 
the possibility of amplification from other as yet uncharacterised 
pseudogenes.
The presence of pseudogenes also had to be considered during 
amplification of the regions surrounding exon 18 from genomic DNA.
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IAmplification was carried out using a forward primer in exon 17 (17F) and a 
reverse primer in exon 19 (19R). This region was amplified in the patient who 
had previously shown an altered fragment corresponding to the skipping of 
exon 18 on RT-PCR amplification of the NF-1 mRNA. The above primers 
were used for amplification from genomic DNA to rule out a deletion. Upon 
sequencing the product of amplification, 6 single base substitutions were 
detected in the patient as well as in 14 normal controls (Figure 18). On 
amplification and sequencing of the same region using intronic primers 
immediately flanking exon 18 (18F and 18R), these changes were not 
detected in the patient nor in the controls. Thus on the amplification using 
primers 17F and 19R probably a part of a NF-1 homologous sequence was 
being amplified. This appeared to be an as yet unreported sequence which 
was homologous to exon 18. This homologous sequence was also detected 
by another group who used somatic cell hybrids to map the sequence to 
chromosome 14 (Legius E., personal communication). The presence of 
pseudogenes has thus to be borne in mind when amplifying segments of the 
NF-1 coding sequence and mutations identified should be confirmed to exist 
at the NF-1 locus. Every mutation detected within the NF-1 gene was 
therefore confirmed by repeat amplifications using various combinations of 
intron and exon based PCR primers.
4.5 MECHANISMS OF MUTAGENESIS
Mutations in human genes may arise either as a consequence of 
endogenous error-prone processes such as DNA replication and repair or as 
a result of exposure to exogenous factors such as chemical mutagens or 
ionising /UV irradiation.
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Regarding the endogenous mechanisms of mutagenesis, nucleotide 
substitutions are thought to result from either chemical (e.g. deamination of 
5-methylcytosine or depurination), physical (e.g. DNA slippage) or enzymatic 
(e.g. post-replicative mismatch repair or exonucleolytic proof reading) 
processes. Since the efficiency of all these processes is sequence 
dependent, the distribution of point mutations is seen to be non-random, 
giving rise to "hot spots" of base substitutions. The mutations characterised 
in this study were analysed to understand their mechanism of causation and 
the mechanisms of mutagenesis are discussed.
4.5.1 SINGLE BASE SUBSTITUTIONS
A) Role of CpG dinucleotides
It has been estimated that the CpG dinucleotide within human coding 
sequences is up to 42 times more mutable than is predicted from random 
mutation (Cooper and Krawczak, 1991). One important consequence of the 
hypermutability of CpG dinucleotides is the fact that a substantial proportion 
of intragenic single base pair mutations are the result of C->T or G->A 
transitions. A total of 880 point mutations were studied by Cooper and 
Krawczak, (1993) and their findings showed that 38% of mutations occurred 
in CG dinucleotides, of which 32.8% were C to T or G to A changes due to a 
methylation mediated event.
Evidence of DNA methylation in the NF-1 region was reported by 
Rodenheiser et al. (1993). Southern analyses using isoschizomeric 
methylation sensitive restriction enzyme pairs revealed DNA methylation in 
areas flanking the NF-1 gene, while similar PCR methylation assays showed 
that methylation occurred both on genomic sequences flanking the NF-1 
gene and within the coding region itself. The identification of methylated
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CpGs in and around the NF-1 gene suggests that these are potential sites for 
spontaneous germline and somatic mutations within this gene. In humans 
DNA methylation represents one of the examples of epigenetic modification 
by which several features of NF-1 may be accommodated, such as the fact 
that up to 50% of mutations are the result of new mutations in the NF-1 gene 
and phenotypic expression of the disease is highly variable, even within 
members of the same family.
To find out whether methylated CpG dinucleotides within the highly 
mutable NF-1 gene served as a reservoir, within which C->T or G->A 
transitions contributed to a high frequency of spontaneous germline 
mutations associated with the disease, all the mutations characterised in this 
study and all the single base substitutions reported so far (NNFF Mutation 
Analysis Consortium newsletter-June 1994) were analysed to see if they 
occurred at CpG sites.
In this study 9 single base substitutions were identified which included 
3 splice site mutations. It was seen that only the nonsense mutation at 
position 2496 (R2496X) was due to a C to T transition at a CpG dinucleotide 
(CGA to TGA).
Thirty-one single base substitutions have been reported so far within 
the NF-1 gene which include 13 nonsense mutations, 12 missense and silent 
mutations and 6 splice site mutations. Of these, none of the missense or 
splice site mutations occurred at CpG sites. Of the 13 nonsense mutations, 7 
are the same mutation, (R1947X) which occurred at a CpG site. On analysis 
of the 6 remaining mutations, 3 nonsense mutations occur at CpG sites 
(R1276X, R1513X and R1748X), while the remaining three Q682X, S1745X 
and Q1745X did not.
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B) Other mechanisms responsible for single base substitutions
In this study, 9 single base substitutions were identified. Three of them 
were splice site errors and one was a nonsense mutation that occurred at a 
CpG site. The remaining 5 single base substitutions which did not affect CpG 
sites were analysed for possible mechanisms of causation (Cooper and 
Krawczak, 1993).
The sequence surrounding the 5 single base substitutions is as 
follows: (The affected codon is underlined and the mutated nucleotide is in 
lower case).
1) G1166D in exon 21: GGC to GAC (G to A) 
GCACTCCATAGoCTTAGGTTACCA
2) G1404G in exon 24: GGG to GGA (G to A) 
TATGAAGCAGGoATTTTAGAT
3) S1311S in exon 23: TCC to TCT (C to T)
T GT GAT C AC ATCcTCT GATTGGCAA
4) N1776N in exon 29: AAC to AAT (C toT)
CTAGTAG AT GAGAAcC AGTT C ACCTT
5) K1419R in exon 24: AAG to AGG (A to G)
GGGGCTT G AaGTTAAT GT CAAA
Deoxyadenosine has been found to be the most frequently 
misincorporated base by both prokaryotic and eukaryotic polymerases. 
Besides deamination, if depurination is also a major cause of spontaneous 
mutation in human genes, the observed mutational spectrum would be 
expected to be heavily biased towards substitutions by deoxyadenosine. 
Consistent with this theory, Cooper and Krawczak (1993) found that in their 
sample of 880 point mutations, G to A transitions were the most frequently
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observed, excluding those produced by deamination of CpG sites. In this 
study, 2/5 mutations were G to A transitions.
Analysis of the nearest neighbour (Cooper and Krawczak, 1993) 
showed that after excluding those mutations that were methylation mediated 
at CpG sites, (a)G residues were clearly over represented as 3' flanking 
nucleotides when T was mutated and (b)G residues were clearly over 
represented as 5' flanking nucleotides when G was mutated. So probably the 
relative rates of mutations, are influenced by the nucleotides flanking the 
mutation site. This was detected in both examples of the G to A substitutions 
in the five non-CpG mutations in this study, i.e. G was the flanking 5' 
nucleotide when the adjacent G was mutated.
Analysis of molecular mechanisms of mutagenesis carried out in 
cultured mammalian cells (Kresnick and Davidson, 1992) showed that C to T 
/ G to A transitions occurred preferentially at the 3' guanine residue of a run 
of 2 or more guanines. This was detected in example 2, when the third 
guanine of the codon GGG was mutated to GGA. In fact in example 4, if we 
consider the C to T to be a G to A on the opposite strand, the 3' G in a set of 
2 G's is affected, resulting in a C to T change on the sense strand. This 
example if considered would make the frequency of G to A mutations 3 out of 
5 in the examples detected in this study.
4.5.2 SPLICE JUNCTION MUTATIONS
Mutations that affect mRNA splicing can be assumed to fall into 3 main 
categories:
(a)Mutations within a 5' or 3' splice site: Such lesions usually either abolish 
or at least reduce the amount of mature full length mRNA generated 
with/without activating cryptic (alternative) splice sites in the vicinity of the
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wild-type sites. Exons are recognised and defined as distinct units by the 
initial binding of protein factors to the 3' end of the intron followed by a 
search for a downstream 5' splice site (Robberson et al., 1990). Thus a splice 
site mutation can result in the utilisation of an alternative site, so that an exon 
no longer is recognised as such and as a result be excluded from the mature 
mRNA transcript (exon skipping). The utilisation of an alternative (cryptic) 
splice site results in the production of mRNAs that lack a portion of the 
coding sequence or which contain additional sequence of intronic origin.
(b)Mutations within an intron, which may serve to activate cryptic splice sites, 
leading to the production of aberrant mRNA species.
(c)Mutations within a branch point sequence.
In a review of 101 splice mutations (Krawzcak and Cooper 1991), it 
was observed that of the 5' splice site mutations, 60% involved the invariant 
GT dinucleotide at positions +1 and +2. Of the 3' splice junction mutations, 
87% were seen to involve the AG dinucleotide with an excess at position -2.
In this study, three splice mutations 1721+3A to G in intron 11, 3113 
+1G to A in intron 18 and 5749+2T to G in intron 30 of the NF-1 gene were 
identified (Figure 53). The relative efficiencies of the 5' splice sites (5‘ SS) of 
normal and mutant introns 11, 18 and 30 was calculated on the basis of 
conservation of bases at the eight positions most likely to contribute 5' splice 
recognition determinants (position -2 through to +6). This was done by the 
method of Shapiro and Senapathy (1990), in order to calculate if the mutant 
intron sequences showed a reduction from that of the normal sequence.
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Consensus values (CV) were calculated by the formula below, which 
gave a score between 0 and 100.
CV = 100(t-min t) / (max t-min t)
where 'min t' and 'max t' are the sums of the lowest and highest possible total 
of percentages in each of the eight positions (-2 to +6) at the splice donor 
site, 't' is the total of percentages for the same eight positions observed in the 
splice donor sequence in question.
Two sets of calculations were done for estimating the consensus values of 
the three splice mutations found in this study:
1)By calculating the 'min t' and 'max t' values for the NF-1 gene from the 
published splice donor sequences of 49 of its introns (Appendix 2 & 3).
2)Using the 'min t' and 'max t' values used by Shapiro and Senapathy for the 
various Genebank files (vertebrates) (Appendix 4).
1) Using the values calculated for the NF-1 gene (positions -2 to +6),
min t= 2+0+0+0+4+2+2+13=23
max t= 74+86+100+100+74+81+67+50=632
The consensus sequence determined for positions -2 to +6 of the splice 
donor sites of the NF-1 gene is (Appendix 3):
~2 —1 +1 +2 +3 +4 +5 +6
a 74 g 8 6 1g 100 T l0 0  A 74 A 81 G67 T5 0 / A22
1)Consensus values (CV) for the three splice mutations 1721+3A to G in 
intron 11, 3113 +1G to A in intron 18 and 5749+2T to G in intron 30, using 
the calculations for the NF-1 consensus sequence are as follows:
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't' values for the normal (wild type) introns 11,18 and 30 (the mutated bases
are underlined'
INT -2 -1 +1 +2 +3 +4 +5 +6 't'
11 A74 G86 G100 T100 A74 T15 A20 T50 519
18 A74 G86 G100 T100 G11 A81 G67 T50 569
30 T16 A10 G100 T100 A74 A81 G67 T50 498
T values for the mutant introns 11, 18 and 30 (the mutant bases are 
underlined) _____________ ________________________________ _ _
INT -2 -1 +1 +2 +3 +4 +5 +6 t
11 A74 G86 G100 T100 G13 T15 A20 T50 ^  5£
18 A74 G86 A0 T100 G11 A81 G67 T50 he*1
30 T16 A10 G100 GO A74 A81 G67 T50
Therefore the consensus Values the various normal (CVn) and mutant (CVm) 
5' splice sites were as follows:
NORMAL CVn MUTANT CVm
intron 11 81.4 intron 11 71.4
intron 18 89.7 intron 18 73.2
intron 30 78.0 intron 30 62.0
2)Similarly values were calculated using the 'min t' and 'max t' values 
calculated for 542 vertebrate 5' SS sequences by Shapiro and Senapathy 
(1990), which were 'min t'= 47 and 'max t' = 595.
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T he 't' values were calculated using consensus values in vertebrates for 
positions -2 to +6 and were as follows:
Normal t Mutant t
intron 11 454 436
intron 18 577 477
intron 30 514 414
Using the above T values, the consensus value (CV) for the normal and 
mutant introns was as follows:
NORMAL CVn MUTANT CVm
intron 11 74.0 intron 11 70.0
intron 18 96.0 intron 18 78.0
intron 30 85.0 intron 30 66.0
Thus it can be seen that using the consensus values described by 
Shapiro and Senapathy (1990) the mutations at the splice sites of introns 11 
18 and 30 reduce the consensus values by 4%, 18% and 19% respectively. 
This is similar to the values calculated specifically for the NF-1 gene, where 
the mutations in introns 11, 18 and 30 cause reduction in consensus values 
of 10%, 17% and 16% respectively. The relatively larger difference in CV for 
intron 11 using the values calculated for the NF-1 gene may indicate the 
importance of calculating values specifically for the NF-1 gene, as this is a 
more significant reduction (10%) in comparison with the reduction observed 
using general values for vertebrates (4%).
Therefore these results show that the mutations at the donor splice 
sites in introns 11, 18 and 30 would be expected to reduce their efficiency, 
thus causing the skipping of exons 11,18 and 30 respectively, as was shown 
earlier.
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Figure 53
M u ta t io n  C V n *  C V m *
1721 + 3A -*• G 81.44 71.42
3113+1G -*• A 89.65 73.23
5749 + 2T — G 77.99 61.57
?lntron 15 splice
acceptor mutation 79.3 (15) 84.9
* C V  as Shapiro & Senapath y  (1990)
The three spl ice donor mutations (A,B,C) and 
one possible ut i l isat ion of a c ryp t ic  spl ice site 
(D) are depicted. The splice mutations are l isted 
along with  the normal and mutant consensus values 
(CVn and CVm). In (D) the CVn represents the value 
for the splice acceptor of intron 15 and CVm that 
of the deletion junct ion si tuated 229bp into exon 
16, as a potent ial  spl ice acceptor. The exons 
skipped from the NF-1 mRNA are indicated in each 
case in between f i l led boxes that represent intact 
exons.
Possible utilisation of a cryptic splice site due to a splice acceptor 
mutation
An interesting feature was identified in a patient who showed partial 
loss of exon 16 from the NF-1 mRNA. The nucleotides missing included 
positions 2410 to 2639 i.e. from the first base of exon 16 extending for 229 
nucleotides into exon 16. When the sequence around the deletion junction 
was analysed, it appeared to be that of a splice acceptor site.
The sequence at the deletion junction was:
t t c t a t g a t t t c a g It
where | denotes the deletion junction.
b)The consensus sequence at a splice acceptor site, derived by Padgett et 
al., (1986) who scanned approximately 400 vertebrate genes was as follows: 
Y Y Y Y Y Y Y Y Y Y N C A G G
from positions -14 to +1 where Y is a pyrimidine and N is any base.
The sequence of the normal splice acceptor site of intron 15 (from -14 to +1) 
was as follows:
A A T T T T G T G T T T A G G
On detailed analysis this was confirmed to be a potential splice 
acceptor site by calculating the consensus values for splice acceptor sites by 
the method of Shapiro and Senapathy (1990). On analysis, the sequence at 
the deletion junction had a consensus value of 84.9. This was found to be 
higher than the consensus value of the normal intron 15 splice acceptor site 
which was 79.3 which is normally utilised and may reduce even further if this 
normal intron 15 site was mutated. Hence the utilisation of a potential cryptic 
splice site in this case was considered to be a possibility.
The choice between cryptic splice site usage and exon skipping may 
be visualised as a decision whether to utilise the next available splice site or,
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the next best although illegitimate sequence in the immediate vicinity. Cryptic 
splice site usage is favoured under conditions where a number of such sites 
are present in the vicinity and these sites exhibit sufficient homology to the 
splice consensus sequence for them to be able to compete successfully with 
the mutated splice site (Cooper and Krawczak 1991, 1993).
The partial loss of exon 16 thus could have two explanations at the 
DNA level. One possibility could be a deletion which involves intron 15 and 
part of exon 16. The other possibility could be a mutation at the splice 
acceptor site of intron 15, in which case the next most suitable splice 
acceptor site, which happens to lie in the first half of exon 16 (seen at the 
deletion junction) would be utilised leading to partial skipping of exon 16. As 
DNA from the patient was unavailable for analysis characterisation at only 
the RNA level was possible. Whatever the cause of this loss of 229 
nucleotides from exon 16, the mutant allele has a premature termination 
codon following the deletion junction and so a truncated protein product of 
803 amino acid residues instead of the normal 2818 amino acids is 
predicted.
4.5.3 INSERTIONS
The majority of insertion type mutations are consistent with an 
explanation which involves an endogenous replication associated 
mechanism of mutagenesis. This may be explained either in terms of 
(a)direct repeats/runs of single bases causing slipped mispairing, (b)inverted 
repeats or (c)symmetric elements facilitating the formation of secondary 
structure intermediates (Cooper and Krawczak, 1991).
In this study two insertions, 6519insG in exon 34 and 7485insGG in 
exon 42 were identified within the NF-1 gene.
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The mechanism of insertion 6519insG may be explained by the 
theoretical model of 'slipped mispairing mediated by direct repeats' (Cooper 
and Krawczak 1991). The sequence surrounding the insertion is shown and 
the five direct GA repeats surrounding the site of insertion are underlined (A). 
The insertion is indicated in lower case (B).
(A) TCTCCTGGCTCCTATGAGAGAGAGACTTTTGCTTTTGA
(B) TCTCCTGGCTCCTATGAGAGAaGAGACTTTTGCTTTTGA
In principle, slipped mispairing at the replication fork can account for 
deletion and insertion type mutations. An insertion takes place when the 
newly synthesised strand disconnects from the primer strand during 
replication synthesis and slips or folds back so that pairing between different 
direct repeat copies becomes possible. If synthesis is resumed so as to 
stabilise this mispairing, DNA sequence from between the direct repeats is 
inserted. In 6519insG, the single guanine base has been inserted in a series 
of five GA repeats and the insertion of G has occurred at the level of A in the 
third GA repeat.
On the other hand, the insertion of 7485insGG can be explained by a 
more complex mechanism. Cooper and Krawcak (1991) have seen in their 
studies of the sequence context of short gene deletions and insertions, a 
significant excess of symmetric elements (e.g. CTGAAGTC). On analysis of 
the sequence surrounding the 2 base insertion, the following was identified 
(the insertion is indicated in lower case letters): 
AAAGGACCGAGCCCCTGACC 
AAAGGACCGAGaaCCCCTGACC
A symmetric element CCGAGCC (underlined) is seen within the sequence 
where the insertion has occurred. Its relevance can be explained by 
predicting a stemloop formation within the sequence. Imperfect self
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complementarity among the stemloops can mediate the formation of partially 
misaligned secondary structures. The non-palindromic portions of this 
structure then provide a template putatively for insertions by gap repair. The 
DNA sequence flanking the insertion correctly predicts the insertion of the 
appropriate base at the appropriate site.
The stemloop formed in the sequence surrounding the insertion was 
predicted using a sequence analysis program "STEMLOOP" (Genetics 
Computers Group GCG), which is shown in Figure 54.
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6 T T
A T G------C G------C
C C A C A C
C C C C------G < -
A C C C------G <r~
G------C A C A C
A G G------C G------C
C A A G A G
C------G C A C A
G------C C------G C------G
G------C G------C G------C
G------C G------C
(A ) (B ) (C )
Figure 54
(A) shows the predicted stemloop pattern prior to the GG insertion. The insertion 
of GG is templated by the base sequence within the hairpin (stemloop).
(B) shows the formation of a partially misaligned secondary structure due to 
imperfect self complementarity within the stem loop.
(C) shows the prediction of 2 bases (GG) complementary to the two C residues. 
These sequence changes (insertion of GG) (indicated by arrows) would be 
predicted to result in increased stability of the hairpin loop.
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4.6 CORRELATION OF THE GENOTYPE WITH THE PHENOTYPE
Inherited traits are defined by their ability to be passed from one 
generation to the next in a predictable manner. Visible or otherwise 
measurable properties are called the phenotype, while the genetic factors 
responsible for creating the phenotype are called the genotype. The 
phenotypic results of mutations vary from the undetectable (no defect 
appears to result from the absence of the protein), to lethal (the organism 
cannot survive without the protein).
Table 13 compares the clinical features and complications of NF-1 in 
all the patients in this study whose mutations were fully characterised and 
predicted to be pathogenic, thus allowing a comparison of the genotype with 
the phenotype.
Figure 55 shows a diagrammatic representation of the predicted 
products of translation in these mutations.
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TABLE 13 GENOTYPE-PHENOTYPE CORRELATION
Age, sex, 
type
Mutation 1 2 3 4 5 6 7 Complications
30 yrs, 
female 
familial
1721+3A-»G 
intron 11
+ + + + + plexiform 
neurofibroma left 
arm, parasthesia 
L-arm, i  power R- 
arm, f  reflexes R- 
leg, abnormal gait
41 yrs, 
female 
familial
3113+1G-+A 
intron 18
+ + + grand mal 
epilepsy, sciatica, 
macrocephaly
29 yrs,
male
sporadic
5749+2 T->G 
intron 30
+ + + sensorineural
deafness,
abnormal EEG, rt 
sided deviation of 
palate, left 
convergent squint, 
pes cavus
11 yrs, male 
familial
G1166D 
exon 21
+ - + - + - - short stature
19yrs, male 
sporadic
K1419R 
exon 24
+ + + - - - - none
34yrs,
female
familial
6519insG 
exon 34
+ + + + none
8yrs, male 
sporadic
7486insGG 
exon 42
+ + + + - - - learning difficulties
23yrs,
female
sporadic
R2486X 
exon 42
+ + + + none
12yrs, male 
sporadic
partial loss of 
exon 16 
? splice/del
+ + macrocephaly, 
precocious 
puberty, CT scan 
showing 
intracranial 
calcification and 
dysplastic 
cerebellum
59yrs, male 
familial
exon 18 
? splice/del
+ + + - + - - leiomyosarcoma of 
colon at 34 yrs
1=cafe au lait patches, 2=neurofibromas, 3=axillary freck 
nodules, 5=NF-1 relative 6=glioma 7=osseous dysplasia
ing, 4=Lisch
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Figure 55
PREDICTION OF PRODUCTS OF TRANSLATION
1125-1536 
NF-1 GRD
559 a.a (1721+3AtoG)
I 803 a.a (partial deletion of exon 16)
2818 a.a
(3113+1G) 
loss of 41 a.a
1850 a.a (5749+2TtoG)
■  2219 a.a (6519 insG)
2495 a.a (R2498X) 
2501 a.a (7486 insGG)
Figure 55 shows the prediction of products of translation in each of the 
mutations, predicted to cause disruption of the product of translation. A 
diagrammatic representation of normal and mutant neurofibromins is seen in 
relation to the NF-1 GAP related domain which extends from positions 1125- 
1536 (indicated by the hatched box). The sizes of the products of translation 
are predicted presuming the predicted mutant neurofibromins are stable.The 
causative mutation and the size of the product of translation is indicated on 
the right
4.6.1 PREDICTION OF THE PRODUCTS OF TRANSLATION
Seven patients were identified with mutations that were predicted to 
result in either loss of amino acids or truncation of neurofibromin (Figure 55). 
The mutations were as follows:
The mutation at the splice donor sequence of intron 11 (1721+3A to 
G) caused skipping of exon 11 from the NF-1 mRNA in the proband, who was 
the first case of NF-1 in her family. However, she had an affected son, who 
was shown to inherit the mutation from his mother by analysis of his DNA and 
RNA. The skipping of exon 11 caused a shift in the reading frame and a 
premature termination of translation, resulting in the synthesis of a shorter 
protein product of 559 amino acids. The mutant neurofibromin predicted in 
this case would not be expected to stimulate the GTPase, as it would not 
possess the NF-1 GAP related domain. As the microtubule binding domain 
also lies distal to the site of premature termination, this mutant neurofibromin 
would also not have the putative microtubule mediated signal transduction 
function. The patient does not have any evidence of malignancy, but has 
neurological complications of NF-1 which include parasthesia of the left 
hand, decreased power and increased reflexes in the right arm and leg and 
abnormal gait. The patient had plexiform neurofibromatosis of the left arm for 
which surgery was undertaken. Her affected son has pseudarthrosis of the 
left tibia.
The partial loss of exon 16 was detected in a sporadic 12 year old 
male with NF-1. The loss of 229 bases from exon 16 is predicted to shift the 
translational reading frame and result in the formation of a premature stop 
codon and a shortened protein product of 803 amino acids which would lack 
the NF-1 GRD. In addition to NF-1, the patient has precocious puberty, an 
abnormal CT scan showing intracranial calcification, dysplastic cerebellum 
and complications of NF-1 including an optic glioma.
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Thus, two patients have been detected in whom the loss of the NF-1 
GRD is predicted due to truncation of their protein products. Due to predicted 
loss of the NF-1 GRD, malignancies would be expected in these patients as 
the NF-1 GRD is involved in ras regulatory pathways controlling cell 
proliferation and differentiation. The patient with the intron 11 splice donor 
mutation has, as yet no evidence of malignancy. However it should be taken 
into account that this patient had a plexiform neurofibroma and it is known 
that some plexiform neurofibromas may progress to malignant 
neurofibrosarcoma. This risk could not be assessed as the plexiform 
neurofibroma had been operated upon and removed in this patient. The 
patient with the partial loss of exon 16 does have a malignant complication of 
NF-1 (optic glioma).
Disease causing mutations within the GAP related domain of the NF-1 
gene have been reported in patients with NF-1 and include an A to G 
transition at codon 1423 in a familial case of NF-1 (no details about the 
presence/absence of malignancy were published) reported by Li et al., 
(1992). The same mutation was also identified in two different tumour types 
unrelated to NF-1. A single base deletion of thymidine at position 4190 has 
also been reported by Anglani et al., (1993) in a sporadic case of NF-1 (no 
details about the presence/absence of malignancy in this patient were 
published).
In the present study, analysis of the GAP related domain revealed four 
characterised and two partially characterised mutations. The 4 characterised 
mutations are all single base substitutions, (two missense G1166D & 
K1419R and two silent mutations G1404G & S1311S) which are not 
predicted to cause truncation of neurofibromin. The two patients with the
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missense mutations within the NF-1 GRD (G1166D and K1419R) did not 
have any evidence of malignancy.
The other two mutations include a chemical cleavage result in exon 
27a of the NF-1 gene and a possible deletion of exon 23 of the NF-1 gene. 
The patient with the chemical cleavage result in 27a (which lies within the 
GAP related domain) herself did not have any malignancy, but had a positive 
family history of NF-1 and cancer. The proband's mother with NF-1 died of 
oesophageal cancer and her maternal uncle with NF-1 died of a brain 
tumour.
The patient with a possible deletion of exon 23 within the NF-1 GRD 
also has a positive family history of NF-1 and malignancy. The patient is a 17 
year old familial case of NF-1. The deletion was suspected due to loss of 
heterozygosity at a newly detected rare sequence variant in exon 23. The 
patient does not as yet have any evidence of malignancy, but had an affected 
mother who died of malignant complications of NF-1 (brain tumour).
It is interesting to note that the 5 patients in the study reported by 
Kayes et al. (1993, 1994) have complete deletions of the NF-1 gene (which 
would include loss of its GAP related domain) and have no evidence of 
malignancy.
The loss of exon 18 from the NF-1 mRNA was detected in two 
unrelated patients. In one the cause was identified to be a splice mutation 
causing skipping of exon 18 and in the other case, the cause at the DNA 
level (splice mutation/deletion) remains to be determined. Both patients 
would have an identical predicted protein product with the loss of 41 amino 
acids including two cysteine residues at positions 1016 and 1032. Cysteine 
residues are important in covalent bonding by the formation of S-S disulphide 
bridges, which are important for the maintenance of conformation of
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polypeptide chains. Loss of the two cysteine residues (1016, 1032) may 
result in an altered conformation of neurofibromin, which could result in 
reduced stability/function.
The splice mutation (3113+1G to A) in intron 18 causing skipping of 
exon 18 was detected in a familial case of NF-1 and in her affected son. The 
proband is a 41 year old Caucasian female, who was first diagnosed with 
neurofibromatosis at the age of 28 years, when she was admitted to the 
hospital for grand mal seizures. The patient has short stature and several 
cafe au lait spots and widespread neurofibromas on her trunk and limbs 
which appeared in early childhood and a head circumference of 56cm 
(+1S.D.). The proband has seven unaffected sisters and one son who is 
affected. He has cafe au lait spots and neurofibromas which were noticed on 
his back, at the age of 2 years. The son has a head circumference of +2
S.D., his height is around the 25th centile for his age and has been treated 
for squint.
The other patient who was shown to have exon 18 missing from his 
mRNA by RT-PCR and direct sequencing, is a 59 year old Caucasian male, 
with cafe au lait macules, neurofibromas, axillary freckling and has a history 
of two unrelated malignancies in the family. The proband had a 
leiomyosarcoma of the colon which was diagnosed at 31 years of age and an 
affected son who died of gliobalstoma, which is a malignant complication of 
NF-1.
A splice mutation was identified in the splice donor site of intron 30 
(5749+2T to G) in a sporadic case of NF-1. The mutation caused an error of 
splicing which resulted in the skipping of exon 30. The patient's unaffected 
mother, father and brother were screened and shown not to have the same 
mutation. Thirty normal controls were similarly screened by SSCP and were
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shown not to have this mutation. The patient has neurological complications 
of NF-1 which include sensorineural deafness, right sided deviation of the 
palate, left convergent squint and an abnormal EEG. In addition the patient 
also has skeletal deformities which include pes cavus.
A single base insertion of guanine (6519insG) was identified in exon 
34 of the NF-1 gene. The proband is a 40 year old Caucasian female with 
four affected children and a family history of NF-1 involving four generations. 
The patient shows typical skin stigmata of NF-1 and has no complications of 
NF-1.
An interesting feature presented in two cases involving exon 42, 
where a nonsense mutation and an insertion of 2 guanine bases were seen 
to affect the same codon (Arginine 2496) in two unrelated sporadic cases. 
The patient with the nonsense mutation had a predicted protein product of 
2495 amino acids and the patient with the two base insertion had a predicted 
product of 2501 amino acids. The clinical features in the two cases were 
compared. Both patients showed typical features of NF-1 including multiple 
cafe au lait patches, neurofibromas, axillary freckling and Lisch nodules. The 
patient with the nonsense mutation had no complications of NF-1, but the 
patient with the 2 base insertion had specific learning difficulties. He has an 
IQ of 110, but has problems with complex visual data. This was a cognitive 
problem, as there was no abnormality in visual acuity. The patient has 
marked grapho-motor difficulties, high activity impulsivity and a short 
attention span.
A study of the neuropsychological profile in 45 children with NF-1 was 
carried out by Legius et al., (1994a). Mental retardation (total IQ<70) was 
noted in 5% of the children. The mean IQ of the entire group was 90, with a 
significantly higher verbal IQ than performal IQ. A weaker score was seen on
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perceptual organisation as compared to verbal comprehension. Legius et al., 
(1994a) concluded that learning disabilities were frequent in the children 
analysed and nonverbal learning disabilities were the predominant type 
identified in 40% of the children. The cognitive phenotype in NF-1 was also 
assessed by Hofman et al., (1994) who studied 12 families each comprising 
an affected child with NF-1 (6-16 years), an unaffected sibling of the same 
age and the biological parents using neurocognitive testing and magnetic 
resonance imaging (MRI). The full scale IQ ranged from 70-130 among 
children with NF-1 and 99-139 in unaffected siblings. Children with NF-1 
were seen to have significant learning disabilities in written language, 
reading and neuromotor dysfunction. Hofman et al., (1994) concluded that 
NF-1 is associated with a significantly lower full scale IQ, multifocal cognitive 
deficits, reading disability and neuromotor deficit and the cognitive 
differences correlated with the number of brain lesions on magnetic 
resonance imaging.
4.6.2 PATHOGENICITY OF MISSENSE MUTATIONS
While it is clear how insertions and deletions cause disease, missense 
mutations have to be evaluated for their pathogenicity. This can be done in 
the following ways:
1. Segregation analysis: the novel appearance and subsequent co- 
segregation of the gene lesion and disease phenotype through a family 
pedigree.
2. Population studies: the failure to observe such a mutation in a sufficiently 
large sample of normal controls.
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3. Occurrence of the mutation in a region of known structure or function: by 
analysis of commonly occurring functional domains.
4. Occurrence of the lesion in an evolutionarily conserved residue: 
conservation among other homologous proteins and across species.
5. The previous independent occurrence of the mutation in an unrelated 
patient, the mutation being the only change on screening the entire 
coding sequence and other regions important for efficient expression.
6. Functional studies to determine the effect of the mutation on the protein: 
by demonstrating the pathological phenotype in the cultured cells by 
expression of the mutant gene/protein and its wild-type counterpart.
In the case of the two missense mutations detected in this study, 
G1166D in exon 21 and K1419R in exon 24, the following analyses were 
carried out:
1)G1166D: This mutation was identified in a familial case of NF-1 
where the mutation in the proband was transmitted from his affected mother. 
The mutation affected a rare restriction site and this single base substitution 
could not be detected by heteroduplex analysis, hence CCM was used to 
screen normal controls, none of whom showed this mutation.
The mutation results in the conversion of glycine, which is a neutral 
and polar amino acid to aspartate which is acidic. The amino acid glycine 
lacks a (3-carbon and can assume many backbone dihedral angles not 
possible by other amino acids. Due to this, glycine can be used in certain 
types of reverse turns where other amino acids are not suitable. Replacing 
glycines in such turns with any other residue would be expected to be 
destabilising, unless the protein could form an alternative type of turn (Pakula 
and Sauer, 1989). However due to lack of structural information for the NF-1 
protein, it is not possible to determine if the glycine 1166 residue is used in
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this manner, hence the effect of the substitution of this residue by aspartate 
cannot be predicted.
2)K1419R: This mutation was identified in a sporadic case of NF-1. 
Fifty normal controls were screened by restriction analysis with the restriction 
enzyme Mnl I (the mutation created a new Mnl I site) and none of the controls 
were shown to have this mutation. The mutation causes conversion of lysine 
to arginine, both amino acids being basic in nature and this change would 
normally be considered to be a conservative one. However, there are known 
examples of conservative missense mutations that can result in a disease 
phenotype if they occupy sites in the protein that are key determinants of 
stability or function (Pakula and Sauer, 1989).
The NF-1 GRD spans exons 20-27a of the NF-1 gene and both 
mutations lie within this region. These missense mutations were also 
analysed for their involvement with common functional domains mapped on 
the human NF-1 sequence, using the 'MOTIF' sequence analysis program 
(GCG) (Smith et al., 1990). This program searches for sequence motifs by 
scanning through a protein sequence for patterns catalogued and defined in 
the PROSITE dictionary of protein sites and patterns (Bairoch et al., 1991). 
The two missense mutations were found not to lie within important functional 
sites. All the important sites within the NF-1 gene according to the 'MOTIF' 
sequence analysis program, are described in Appendix 5.
Attribution of these missense mutations to disease can thus only be 
confirmed by (a)screening the remainder of the coding sequence and other 
regions important for gene expression to exclude other causative mutations 
and (b)by functional studies.
215
4.6.3 OVEREXPRESSION OF THE NEUROFIBROMIN ISOFORM NF-1 
GRD-II
An interesting feature was detected in a case of a variant form of 
neurofibromatosis, in a 44 year old female patient with segmental 
neurofibromatosis affecting the right upper arm. The mutation arose de novo 
in this patient, as there was no family history of the disease. The patient had 
a plexiform neurofibroma affecting her right ulnar nerve. She also has some 
permanent loss of function of that nerve and several small neurofibromas 
along the line of the ulnar nerve. Two neurofibromas in her right upper arm 
were confirmed histologically to be neurofibromas. The patient had no other 
cutaneous manifestations and was also examined for the presence of Lisch 
nodules which she did not have.
Upon RT-PCR amplification of RNA segment VI spanning part of the 
NF-1 GRD agarose gel electrophoresis showed the presence of an 
approximately sixty base pair insertion. This was confirmed by CCM analysis 
and shown to be an insertion of 63bp which has been described by Marchuk 
et al., (1991). This 63 base pair insertion represents the alternatively spliced 
isoform of the NF-1 gene called the NF-GRD II. This insertion is present in 
block 2 of the NF-1 GRD which is a region of strong homology between GAP, 
IRA1, IRA2 and neurofibromin (Andersen et al., 1993a). This insertion 
significantly weakens the statistical significance of this homology block. 
(Andersen et al., 1993a).
A study by Nishi et al., (1991), demonstrated that the type I transcript 
(NF-GRD I) is predominantly expressed in undifferentiated cells, while the 
type II transcript (NF-GRD II) predominates in differentiated cells.
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Suzuki et al., (1991) have shown that the type I transcript (NF-GRD I) 
is predominantly expressed in normal brain tissue, while the type II transcript 
(NF-GRD II) predominates in brain tumours.
Using RT-PCR analysis Andersen et al., (1993a) were not able to 
detect evidence of consistent tissue specificity differences of NF-GRD I and 
NF-GRD II, in a variety of normal and abnormal tissues. The authors found at 
least some evidence of both forms in all tissues analysed.
The additional 63bp insertion in the type II transcript reflects the 
insertion of a separate exon by alternative splicing. The evolutionary 
conservation of the type II form supports the conclusion that both the forms 
are important for neurofibromin function. However in in vitro biochemical 
assays, type II transcripts lack apparent GTPase stimulating activity with H- 
ras. This suggests that the 21-amino acid insertion results in the reduction of 
the catalytic activity of NF-GRD II.
Using primers designed in this study, only amplification of the type I 
transcript was detected in the remaining patients with NF-1. Expression of 
both type I and type II transcripts (with the 63bp insertion) was detected in 
only the above mentioned patient. This would mean that in this assay, using 
these sets of primers, either only the smaller product (NF-GRD I) was being 
preferentially amplified in all other patients examined, or that the 
amplification from the type II transcript was in very small quantities, which 
would not be visible on agarose gel electrophoresis. However, the 
reproducible (three RT-PCR amplifications) detection of NF-GRD II transcript 
in the above patient would indicate that at least for this assay, the patient 
was producing equal quantities of type I and type II transcripts in comparison 
with other patients who produced only type I transcripts.
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Thus this observation is an interesting finding in a patient with 
segmental neurofibromatosis. In this patient, a somatic mutation in that 
particular tissue which would lead to the manifestations of localised 
neurofibromatosis is expected instead of a germline mutation. This finding 
cannot yet be attributed to disease but was the only finding detected in this 
patient after screening 78% of her NF-1 coding sequence.
4.6.4 UNEQUAL EXPRESSION OF NF-1 ALLELES
An interesting finding was detected as a chemical cleavage result of 
RNA segment VI in a familial case of NF-1. Direct sequencing revealed this 
to be a C to T substitution, maintaining serine at position 1311 (S1311S). 
Upon direct sequencing, only the altered allele was seen. This was detected 
on sequencing both strands and on restriction analysis. The mutation also 
causes loss of a Fok I restriction site. Upon digestion of the PCR product, 
only the allele with the silent mutation (undigested due to loss of the 
restriction site was seen). This could be accounted for by one of the 
following:
(a)One possibility is that this could be a common polymorphism and this 
patient is homozygous for it. This could not be confirmed by family studies, 
as the father of the patient was unavailable for analysis and her affected 
mother had died due to a malignant brain tumour. Thirty other individuals 
screened in this region did not show a similar chemical cleavage result, i.e. 
this was probably a rare sequence variant and not a common polymorphism. 
Thus homozygosity due to a polymorphism does not appear likely.
(b)The second possibility and probably the most likely, is that the patient has 
a large deletion in this region on one allele and a silent mutation on the other 
allele, hence there was no amplification from the allele with the deletion. This
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mutation causes the loss of a Fok I site. On amplification and digestion with 
Fok I and electrophoresis on an agarose gel, only the allele with the silent 
mutation, which was undigested due to loss of the restriction site was 
detected. Ideally there should have been digestion of the PCR product from 
the normal allele (showing complete digestion) and the mutant allele showing 
no digestion due to loss of the restriction site (Figure 31). Thus in this case it 
appeared that the other allele in this patient had a large deletion that 
involved at least one primer binding site and therefore was not being 
amplified.
(c)Another reason could be unequal expression of the two NF-1 alleles: 
Disproportionately low amounts of mRNA from mutant alleles in patients 
heterozygous for stop mutations has been reported in the literature, (Jones et 
al., 1992). A transcribed polymorphism in exon 32 of the NF-1 gene was 
reported by Hoffmeyer et al. (1994). Using the polymorphic Rsa I restriction 
site in exon 32 of the NF-1 gene (in patients heterozygous for the 
polymorphism) the relative abundance of mRNAs transcribed from both 
alleles was evaluated by Hoffmeyer et al., (1994). Putative mutations lying 
outside the coding region but in regions essential for gene expression will not 
have a direct effect on the NF-1 protein, but may affect the expression of the 
mutant allele or the stability of the mutant messengers. This may therefore 
lead to the unequal representation of wild type and mutant messengers in the 
cells of NF-1 patients.
Thus S1311S is a silent mutation on the allele being expressed. The 
other allele may not be expressed due to a deletion or a mutation causing 
decreased expression or increased instability of the NF-1 mRNA.
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In conclusion, the strategy of using both DNA and RNA as templates 
for PCR amplification and use of chemical mismatch cleavage analysis as the 
main screening method, has proved to be a useful screening strategy for 
detection of mutations within the NF-1 gene.
The advantages of using both RNA and DNA as templates for PCR in 
mutation analysis in the NF-1 gene are as follows:
The NF-1 gene is ubiquitiously expressed and the NF-1 mRNA can be easily 
obtained from peripheral blood leukocytes and used for analysis after 
conversion to cDNA by reverse transcription. Using NF-1 mRNA as a 
template allowed the amplification of large areas of the coding sequence. 
Using mRNA as a template it was possible to begin screening for mutations 
in the NF-1 gene before the complete genomic organisation was known 
(initially intron-exon boundaries for only 9 of the 49+ exons were published, 
Cawthon et al., 1990a). Amplification using RNA segments readily allowed 
the detection of large alterations within the NF-1 coding sequence (five large 
alterations were detected in this study).
Amplification of DNA allowed the easy and rapid screening of 
relatively smaller fragments comprising individual exons of the NF-1 gene. 
Genomic DNA amplification was necessary for the characterisation of splice 
site mutations after detection of an altered transcript on RT-PCR. Genomic 
DNA was useful in the complete characterisation of deletions or insertions 
which were also seen as alterations on amplification of the NF-1 cDNA. 
Genomic DNA allows equal amplification of both alleles. This is useful in 
those cases where mutations cause unequal levels of mRNA production on 
amplification from mRNA.
In this study most mutations were confirmed by amplification of both 
DNA and cDNA. This was done in order to rule out amplification from NF-1
220
homologous sequences. Various combinations of intron and exon based 
primers were used for this purpose. In this study, a novel NF-1 homologous 
sequence was identified. Direct sequencing revealed the sequence to be 
homologous to exon 18 and the flanking introns.
The screening methods used in this study included SSCP and 
chemical cleavage analysis. Initially, SSCP analysis was used to screen 
exons 28-36. However the sensitivity of SSCP falls to < 50% in products of 
400bp or higher, (Grompe M., 1993) and it is possible that using this 
technique some mutations were missed. Therefore all the products of DNA 
PCR were eventually analysed using chemical cleavage analysis. The 
segments amplified using RNA as a template ranged from 400bp - 1kb and 
chemical mismatch cleavage was used directly for screening these 
fragments.
Chemical mismatch cleavage analysis allows the analysis of relatively 
large fragments of up to 1.7 kb in length (Grompe,M., 1993). CCM detects 
greater than 95% of mutations when only the probe is labelled and almost 
100% of mutations when both the wild-type probe and the mutant samples 
are labelled in separate reactions (Forrest et al., 1992). Chemical cleavage 
allowed accurate localisation of the mutation, as mismatches reduce the size 
of the end labelled probe after cleavage, thus enabling sequencing of a 
limited area instead of the whole product. Chemical cleavage also detects 
the nature of the altered base depending on the modifying chemical i.e. C 
and G residues using modification with hydroxylamine and A and T residues 
using osmium tetroxide, which further confirms the nature of the mutation on 
sequencing. In this study chemical cleavage analysis was also useful in 
determining the boundaries of deletions and insertions in the case of gross 
RNA rearrangements. CCM analysis also has to some extent the advantage
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of exclusion of mutations in a region that has been screened and found 
negative for mutations, provided suitable controls are done with each 
analysis. Thus CCM analysis was a useful screening method in detection of 
mutations within the NF-1 gene and was used as the main screening method.
Nine tumour types unrelated to NF-1 (a total of 29 samples) were 
analysed for somatic mutations within the NF-1 gene. No small alterations 
were detected on screening the tumours for mutations in exon 24 (FLR exon) 
within the NF-1 GRD by CCM analysis. Four neuroblastoma samples were 
screened for large alterations by Southern (p5/EcoR I) and Northern blotting 
and they did not reveal any alterations.
This study has been able to identify a positive screening result in 17 
out of 25 patients on analysis of 78% of the NF-1 coding sequence. Thirteen 
of these have been characterised, demonstrating a range of mutations 
including deletions, insertions and single base substitutions. Ten of these 
mutations are potentially disease causing and eight of them are predicted to 
cause disruption of neurofibromin.
Most of the mutations detected within the NF-1 gene (this study as 
well as other reported mutations) appear to be small sequence alterations 
resulting in disruption of the protein product neurofibromin.
Nine single base substitutions were detected including 3 splice site 
mutations, 1 nonsense mutation, 2 missense and 3 silent mutations. Only 
one of these 9 mutations (R2486X) affected a CpG site.
Except R1947X in exon 31 (seven independent reports of the same 
mutation) no mutational hotspot has been observed. However since 22% of 
the coding sequence and regions important for efficient gene expression 
have not yet been analysed in this study, a clustering of mutations in the yet 
unanalysed part of the NF-1 gene cannot be ruled out.
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This study compares the genotype with the phenotype in a 
heterogeneous group of mutations affecting the NF-1 gene. No definitive 
correlation can be made based on these observations and a multicentre 
study, facilitating the analysis of a large number of mutations would be 
helpful.
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APPENDIX 1
Solutions used for extraction of DNA from peripheral blood
a)Lysis mix
b)Nuclei lysis mix (pH 7.8)
c)T.E. buffer
d)Proteinase K (10mg/ml)
Solutions used for extraction of
a)Proteinase K buffer
Solutions used for extraction of
a)Lysis buffer
b)Proteinase K (100pg/ml)
Solutions for extraction of RNA
a)Solution D
b)2M sodium acetate (pH 4.0)
c)Phenol
dJChloroform: isoamyl alcohol
e)Histopaque '1077'
0.32 M Sucrose 
10mM Tris-HCI (pH 7.5)
5mM MgCl2 
1% Triton X-100
10mM Tris-HCI 
0.4M NaCI 
2mM EDTA
10mM Tris-HCI (pH 7.5)
1mM EDTA
Boehringer Mannheim
from parrafin embedded tissue
50mM Tris-HCI pH 8.7 
10mM NaCI 
0.1% Triton-X 100
from tissue culture cells
100mM Tris-HCI pH 8.5 
5mM EDTA 
0.2% SDS 
200mM NaCI
Boehringer Mannheim
4M guanidinium thiocyanate (Fluka) 
25mM sodium citrate 
0.5% sarcosyl (Sigma)
0.1 mM p-mercaptoethanol (Sigma)
water saturated
49:1
Sigma
f)Phosphate buffered saline (pH 7.2) 0.14M NaCI
3mM KCI
0.1 mM sodium hydrogen phosphate 
1mM potassium dihydrogen phosphate 
alternatively PBS (Gibco BRL) was used
Solutions for the preparation of the RNA sample
a)10 X MOPS 200mM MOPS
50mM sodium acetate pH 7.0 
10mM EDTA
b)Formamide
c)37% formaldehyde solution
d)Loading mix 2g Ficoll
1ml 2.5% bromophenol blue 
1ml 2.5% xylene cyanol 
0.2ml 0.5M EDTA 
8 ml water
Solutions used in PCR
(All reagents were obtained from Boehringer Mannheim)
a)10 X PCR buffer 500mM KCI
100mM Tris-HCI (pH 8.4) 
15mM MgCI2 
1000pg/ml gelatin
b)dNTP (dTTP, dCTP, dGTP, dATP) 100mM each
c) Taq DNA polymerase 5U/pl
Solutions used for reverse transcription
(All solutions were from Gibco BRL)
a)Reverse transcriptase buffer (5X) 250mM Tris-HCI (pH 8.0)
375mM KCI 
15mM MgCl2
b)DTT (dithiothreitol 0.1M)
c)MMLV reverse transcriptase 200 units/pl
Solutions used for chemical mismatch cleavage analysis (CCM)
a)Geneclean II kit (BIO 101)
b)T4 kinase buffer (10 X)
c)Annealing buffer (10 X)
d)Stop/precipitation mix
1)6M sodium iodide (Nal)
2)NEW wash (pH 7.5-8.0).
14 mis of the NEW concentrate, 280 
mis of distilled water, 310 mis of 100% 
ethanol.
3)Glassmilk
500mM Tris-HCI pH 7.6
0.1MDTT
0.1MMgCI2
3M NaCI
1M Tris-HCI pH 8.0
63mM sodium acetate 
20pM EDTA 
80% ethanol
Details of chemical reagents used for CCM analysis
1)T4 polynucleotide kinase
2)Glycogen
3)Hydroxylamine hydrochloride
4)Diethylamine
5)Osmium tetroxide
6)Pyridine
7)Piperidine
8U/fil (NBL)
Boehringer Mannheim
BDH
BDH
4% solution in water, Aldrich
BDH
Fluka
Solutions used for sequencing
(All solutions were supplied by USB - Sequenase version 2.0 kit)
a)Sequenase buffer (5 X )
b)Dithiothreitol (DTT)
c)Labelling mix (dGTP) (5 X)
d)Labelling mix (dITP) (5 X)
200 mM Tris-HCI pH7.5 
100mM MgCI2 
250mM NaCI
0.1M
7.5pM dGTP 
7.5pM dCTP 
7.5pM dTTP
15pM dITP 
7.5pM dCTP 
7.5pM dTTP
e)Termination mix (ddG.T.C or A) 8|liM  ddG,T,C or ATP
80|iM dNTP 
50mM NaCI
f)Enzyme dilution buffer 10mM Tris-HCI pH 7.5 
5mM DTT 
0.5mg/ml BSA
g)Stop solution
Plamid solutions
a)Luria broth (L-broth 1 litre pH 7.5)
b)Circleprep kit
c)lnstaprep kit
d)STE buffer
Solutions used for Southern blotting
a)Denaturation solution
^Neutralisation solution (pH 7.5)
c)Depurination solution
d)Prehybridisation solution
95% formamide 
20mM EDTA 
0.05% bromophenol blue 
0.05% xylene cyanol
10g Bactotryptone 
5g Bactotryptone yeast extract 
5g NaCI
alternatively L-Broth (BRL) was used
Pre-lysis buffer: Tris/EDTA/glucose 
lysis reagent: 0.2%NaOH, 1 %SDS. 
Neutralisation solution: 3M potassium 
acetate
Lithium chloride solution 
glassmilk
Binding buffer: KBr/Nal/Tris mixture 
Wash solution 
Sieve material
Insta-Mini-Prep tubes
Phenol: Chloroform: Isoamyl alcohol
(50:49:1)
Chloroform: Isoamyl alcohol (49:1)
TE (10mM Tris, 1mM EDTA, pH 8)
100mM NaCI 
10mM Tris 
1mM EDTA pH 8
0.5M NaOH 
1.5M NaCI
0.5M Tris-HCI 
3M NaCI
0.25M HCI
50% Formamide 
5 X Denhardt's solution 
5XSSC 
2% SDS
Solutions used for Northern blotting
a)Pre hybridisation solution 5 X SSC
1 X Denhardts solution 
100|ig/ml salmon sperm DNA 
0.5% SDS 
50% formamide
b)Hybridisation solution 5 X SSC
1 X Denhardt's solution 
10% Dextran sulphate 
100(ig/ml salmon sperm DNA 
50% formamide
0.5% SDS
2 X 106 counts/ml labelled probe
APPENDIX 2
SEQUENCE AT 5'SS POSITIONS -4 TO +6 IN INTRONS OF THE NF-1 
GENE
exon -4 - 3 -2 - 1 +1 +2 +3 +4 +5 +6
1 G C A G
2 T A T G G T G A G T
3 T G G G G T A A G T
4 A A A G G T A A G T
5 G C T G G T A A G G
6 T A A G
7 T A A G G T A A T A
8 T A A G G T G A G G
9 C A A T G T A A G T
10 G G A G
11 T T A G G T A T A T
12A T A A G G T A A G C
12B T A T G G T C A G C
13 A C A G G T C A A A
14 T G A G G T A T G C
15 C C A G G T A A G T
16 A C A G G T A A A G
17 T C A G G T A A G C
18 T T A G G T G A G T
19 T T A A G T A A A T
20 A T A G G T G A G A
21 G T G G G T A A G T
22 C A A G G T T T G T
23 C C A G G T A T G C
24 A A A G G T G A A T
25 G C A G G T A A T T
26 A C A G G T A A G A
21A C T A G
27B G G A G G T A A G A
28 T A A A G T A A G T
29 T A C G G T A G G T
30 T C T A G T A A G T
31 G C A G G T A T T G
32 C A A G G T A A T C
33 A G T G G T A A G T
34 G G A G G T A T A G
35 A A A G G T A T G T
36 C A A G G T A C C T
37 T A A G G T A A T T
38 C A A G G T A A G C
39 A A A G G T A A A A
40 G C A G G T A A A A
41 A T A G G T A A G T
42 C T T G G T T A G T
43 A T G G G T G A G A
44 T C T A G T A A G G
45 T T G T G T A A G T
46 C A A A G T C A A A
47 A A A G G T A A G A
48 C C A G G T C A G T
APPENDIX 3
CALCULATION OF CONSENSUS SEQUENCES FOR POSITIONS -4 TO 
+6 OF THE NF-1 GENE
POSITION TOTAL NUMBER OF T/C/G/A % CONSENSUS
- 4 T=18 /51 36% T=36%
C=12/51 23% C/A=23%
0 =9 /51 18% THEREFORE
A=12/51 23% T /C /A  OR N
- 3 T =10 /51 19% A
C=14/51 27%
0=7 /51 14%
A=30/51 59%
-2 T=8/51 16% A
C = l / 5 1 2%
G=4/51 8%
A=38/51 74%
- 1 T=2/5 1 4% 6
C - 0 /5 1 0%
G=4 4 /51 86%
A=5/51 10%
+ 1 T = 0 / 46 0% 6
C = 0 /46 0%
G=46/46 100%
A = 0 / 46 0%
+2 T=46 /46 100% T
C = 0 /46 0%
G=0 /46 0%
A=0/46 0%
+3 T=2/ 4  6 4% A
C = 4 /46 9%
G =6/46 13%
A=34/46 74%
+4 T=7 /4 6 15% A
C = l / 4 6 2%
G = l /4 6 2%
A = 3 7 /46 81%
+5 T = 5 / 46 11% G
C = l / 4 6 2%
G=31/46 67%
A = 9 / 46 20%
+6 T=2 3 /4 6 50% T/A
C=7/46 15%
G=6/46 13%
A = 1 0 / 46 22%
APPENDIX 4
Consensus nucleotide frequency patterns at 8 positions within 5' and 
3'splice sites (Data from Shapiro and Senapathy, 1990).
Position A C G T
5’ splice sites
- 2 0.58 (24) 0.12 ( 9) 0.15 ( 4) 0.15 (10)
- 1 0.10 ( 5) 0.04 ( 4) 0.78 (33) 0.08 ( 5)
+ 1 0.00 ( 0) 0.00 ( 0) 1.00 (47) 0.00 ( 0)
+ 2 0.00 ( 0) 0.00 ( 0) 0.00 ( 0) 1.00 (47)
+  3 0.57 (26) 0.02 ( 1) 0.39 (16) 0.02 ( 4)
+  4 0.71 (35) 0.08 ( 1) 0.12 ( 5) 0.09 ( 6)
+  5 0.05 ( 1) 0.06 ( 2) 0.84 (40) 0.05 ( 4)
+  6 0.16 ( 5) 0.15 ( 9) 0.22 ( 5) 0.47 (28)
3’ splice sites
- 6 0.06 ( 0) 0.39 ( 7) 0.06 ( 1) 0.47 (11)
- 5 0.06 ( 5) 0.40 ( 8) 0.08 ( 0) 0.46 ( 6)
- 4 0.23 ( 7) 0.29 ( 2) 0.23 ( 2) 0.23 ( 8)
- 3 0.03 ( 1) 0.74 (11) 0.01 ( 0) 0.22 ( 7)
- 2 1.00 (19) 0.00 ( 0) 0.00 ( 0) 0.00 ( 0)
- 1 0.00 ( 0) 0.00 ( 0) 1.00 (19) 0.00 ( 0)
+ 1 0.28 ( 5) 0.13 ( 2) 0.49 (10) 0.10 ( 2)
+  2 * 0.17 ( 1) 0.22 ( 3) 0.24 ( 6) 0.37 ( 9)
APPENDIX 5
Analysis of functional domains within neurofibromin using 
programme 'MOTIF' (GCG; Smith et al. 1991)
r* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
inase II phosphorylation site *
> * * *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * *
naSe II (CK-2) is a protein serine/threonine kinase that has activity 
t of cyclic nucleotides and of calcium. CK-2 phosphorylates many 
! proteins. The substrate specificity [1] of this enzyme can be 
;d aS follows:
0r comparable conditions Ser is favoured over Thr. 
acidic residue (either Asp or Glu) must be present three residues to 
C-terminal of the phosphate acceptor site.
tional acidic residues in positions +1, +2, +4, and +5 increase the
phorylation rate. Most physiological substrates have at least one
jic residue in these positions.
Js preferred to Glu as the provider of acidic determinants, 
asic residue to the N-terminal of the acceptor site decreases the
phorylation rate, while an acidic one will increase it.
u s  pattern: [ST]-x(2)-[DE]
[S or T is the phosphorylation site]
his pattern is found most, but not all, of the known physiological 
ates.
CK2 PHOSPHO SITE
15: VQAW
( S , T ) x 2 ( D , E ) 
(S)x{2}(D) 
SRFD EQLPI
(T)x{2)(E)
12 3: CHFLH TCRE GNQHA
421: RIITN
467: MAPSL
482: FKEKP
(S)x{2)(D) 
SALD
(T)X{2}(E)
TFKE
( T ) X { 2 } ( E ) 
TDLE
WWPKI
KVTSL
TRSYK
(S)x{2)(E)
521: PETQG STAE LITGL
569:
592:
665:
685: 
737: 
829: 
833 : 
1,118: 
1,178: 
1,191: 
1,195:
1,234:
1,245:
1,310:
1,324:
1,331:
1,353:
1,399:
1,435:
DAPVE
SHQML
KGKGN
CRQAQ
LPNYN
GSIDL
LSDTD
LLNDC
LQTRA
ILQQG
GTEFD
NWPC
ARVLV
LRIVI
FEVDP
LEPSE
HAIIS
NPAIV
NHVLF
T)X{2} 
TFWE
S ) X  { 2 } 
SSTE
S ) X  { 2 } 
SSMD
T)x{2} 
TKLE
T)x{2} 
TFME
S)x{2} 
SDTD
S)x{2)
SLQE
S ) X  { 2  } 
SEVE
T)x{2} 
TFME
T)x{2} 
TEFD
T)x{2} 
TLAE
S)x(2} 
SQWD
T)x{ 2} 
TLFD
T)x{2} 
TSSD
T)x{2} 
TRLE
S)x{2)
SLEE
S)x{2}
SSSE
S)X{2}
SPYE
T)x{2} 
TKEE
E]
E)
D]
E]
E]
D]
e :
e :
e :
d ;
e ;
d ;
d ;
d
e ;
e
E
E
E
ISSQM
ILKWL
SAAGC
VALYM
FASVS
SLQEW
WINMT
DESAQ
VLTKI
TLAET
TVLAD
ELARV
SRHLL
WQHVS
PSESL
NQRNL
FPPQL
AGILD
HMRPF
1,449: NDFVK
(S x{2)
SNFD
D)
AARRF
1,503: GQYLS
(S x{2}
SNRD
D)
HKAVG
1,546: LNLTS
(s x{ 2} 
SKFE
E)
EFMTR
1,744: TAVQV
(T x{ 2} 
TSAE
E)
RTKVL
1,765: DIYYA
(s X  { 2 } 
SEIE
E)
EICLV
1,808: IIHIR
(T x{ 2} 
TRWE
E)
LSQPD
1,813: TRWEL
(S
(s
X { 2 } 
SQPD
x{ 2}
D)
E)
SIPQH
1,916: SGFSK SSIE LKHLC
1,961: KLITM
(T x{ 2} 
TINE
E)
KQMYP
2,131: QVLRL
(s X {  2 } 
SLTE
E)
FSLPK
2,160: IAFRS
(S x{ 2} 
SYRD
D)
RSFSP
2,179: ETFAL
(T x (2} 
TSLE
E)
TVTEA
2,183: LTSLE
(T X  ( 2 } 
TVTE
E)
ALLEI
2,334: IFNDK
(s x {2} 
SPEE
E)
VFMAI
2,423: LAALL
(T x {2} 
TVSE
E)
EVRSR
2,466: DPSYR
(T x{ 2} 
TLKE
E)
TQPWS
2,554: RRVAE
(T x{ 2} 
TDYE
E)
METQR
2,576: HLRKV
(s x{ 2} 
SVSE
E)
SNVLL
2,609: TLVKY
(T x {2} 
TTDE
E)
FDQRI
2,729: GIDEE
(T x{ 2} 
TSEE
E)
SLLTP
* * * * * * * * * * * * * * * * * *
LStoylation site *
* * * * * * * * * * * * * * * * * *
reciable number of eukaryotic proteins are acylated by the covalent 
i of myristate (a C14-saturated fatty acid) to their N-terminal residue 
imide linkage [1,2]. The specificity of the enzyme responsible for 
iification, myristoyl CoA:protein N-myristoyl transferase (NMT), has 
rived from the sequence of known N-myristoylated proteins and from 
using synthetic peptides. The sequence specificity seems to be the 
lg:
^-terminal residue must be glycine.
)sition 2, uncharged residues are allowed. Charged residues, proline 
Large hydrophobic residues are not allowed.
>sitions 3 and 4, most, if not all, residues are allowed.
)sition 5, small uncharged residues are all allowed (Ala, Ser, Thr, 
Asn and Gly). Serine is favored, 
jsition 6, proline is not allowed.
5us pattern: G-{EDRKHPFYW)-x(2)-[STAGCN]-{P)
[G is the N-myristoylation site]
</e deliberately include as potential myristoylated glycine residues 
tfhich are internal to a sequence, for it could well be that the 
:e under study represents a viral polyprotein precursor and that 
aent proteolytic processing could expose an internal glycine as the fi­
ll of a mature protein.
L G~(E,D,R,K,H,P,F,Y,W)x2(S,T,A,G,C,N)~(P)
26: LPIKT
G~(E,D,R,K,H,P,F,Y,W)x{2)(T)~P 
GQQNTH TKVST
127: HTCRE
G~(E,D,R,K,H,P,F,Y,W)x(2)(A)~P 
GNQHAA ELRNS
140: RNSAS
G~(E,D,R,K,H,P,F,Y,W)x{2)(S)~P 
GVLFSL SCNNF
367: KPFSR
G~(E,D,R,K,H,P,F,Y,W)x(2}(A)~P 
GSQPAD VDLMI
455: AVQGC
G~ E,D,R,K,H,P,F,Y,W)x{2
GAHPAI
(A) ~P
RMAPS
772: EHPTA
G~ E,D,R,K,H,P,F,Y,W)x{2
GNTEAW
(A) ~P
EDTHA
875: VSERK
G~ E,D,R,K,H,P,F,Y,W)x{2
GSMISV
(S)~P
MSSEG
1,160: ANVDS
G~ E,D,R,K,H,P,F,Y,W)x{2
GLMHSI
(S)~P
GLGYH
1,277: QTLFR
G~ E,D,R,K,H,P,F,Y,W)x{2
GNSLAS
(A) ~P
KIMTF
1,382: PQNSI
G~ E,D,R,K,H,P,F,Y,W)x{2
GAVGSA
(S)~P
MFLRF
1,481: SFISD
G~
G~
E,D,R,K,H,P,F,Y,W)x{2
GNVLAL
E,D,R,K,H,P,F,Y,W)x{2
(A) ~P 
(S)~P
HRLLW
1,498: NQEKI GQYLSS NRDHK
1,576: IFYQA
G~ E,D,R,K,H,P,F,Y,W)x{2
GTSKAG
(A) ~P
NPIFY
1,595: RRFKT
G~ E,D,R,K,H,P,F,Y,W)x{2
GQINGD
(G) ~P
LLIYH
1,678: ERLLT
G~ E,D,R,K,H,P,F,Y,W)x{2
GLKGSK
(S)~P
RLVFI
1,786: TIANQ
G~ E,D,R,K,H,P,F,Y,W)x{2
GTPLTF
(T) ~P
MHQEC
1,831: PKDVP
G~ E,D,R,K,H,P,F,Y,W)x{2
GTLLNI
(N) ~P
ALLNL
2,000: KTSAT
G~ E,D,R,K,H,P,F,Y,W)x{2
GGLGSI
(S)~P
KAEVM
2,003: ATGGL
G~ E,D,R,K,H,P,F,Y,W)x(2
GSIKAE
(A) ~P
VMADT
2,103: RASTH
G~(E,D,R,K,H,P,F,Y,W)x{2)(N) ~P 
GLVINI IHSLC
2,358: MDHFV
G~(E,D,R,K,H,P,F,Y,W)x {2)(N)~P 
GLNFNS NFNFA
2,518: TKKLL
G~(E,D,R,K,H,P,F,Y,W)x{2)(S)~P 
GTRKSF DHLIS
2,662: LNPIH
G~(E,D,R,K,H,P,F,Y,W)x{2)(S)~P 
GIVQSV VYHEE
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
•in kinase C phosphorylation site *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
— (81%)[Hit space to continue, Del to abort]
>, protein kinase C exhibits a preference for the phosphorylation of 
or threonine residues close to a C-terminal basic residue [1,2]. The 
:e of additional basic residues at the N- or C-terminal of the target 
icid enhances the Vmax and Km of the phosphorylation reaction.
isus pattern: [ST]-x-[RK]
[S or T is the phosphorylation site]
SPHO SITE
101: GQPKD
(S,T)x(R,K)
(T)x(R)
TMR LDETM
123: CHFLH
(T)x(R)
TCR EGNQH
158: VFSRI
(S)x(R)
STR LQELT
259: DGFAE
(S)x(K)
STK RKAAV
260: GFAES
(T)x(R)
TKR KAAVW
302: KLFLD
(S)x(R)
SLR KALAG
467: MAPSL
(T)x(K)
TFK EKVTS
474: KEKVT
(S)x(K)
SLK FKEKP
488: DLETR
(S)x(K)
SYK YLLLS
657: RTPGA
(S)x(R)
SLR KGKGN
750: SNMMS
(T)x(R)
TGR AALQK
871: PMGPV
(S)x(R)
SER KGSMI
1,135: RKRGM
(S)x(R)
SRR LASLR
(S)x(R)
1,140: SRRLA 
1,343: NLLQM 
1,373: LYQW 
1,503: GQYLS 
1,545: SLNLT 
1,577: FYQAG 
1,609: YHVLL 
1,630: THTGP
1,682: TGLKG 
1,733: KDTKV 
1,847: GSSDP 
2,004: TGGLG 
2,026: NVKLV 
2,096: ATGPL 
2,160: IAFRS 
2,201: MRDIP
2,235: VFGCI 
2,326: LHTLD 
2,388: AIVAR 
2,433: VRSRC
SLR
T)x(K
TEK
S)x(R
SQR
S)x(R
SNR
S)x(K
SSK
T)x(K
TSK
T) x(K 
TLK
S)x(R
SNR
S)x(R
SKR
S)x(K
SIK
S)x(R
SLR
S)x(K
SIK
S)x(K
SSK
S)x(R
SLR
S)x(R
SYR
T)x(K
TCK
S)x(R
SKR
S)x(R
SLR
T)x(R
TVR
S)x(K
SLK
HCTVL
FFHAI
FPQNS
DHKAV
FEEFM
AGNPI
PYYAK
FKTDF
LVFID
VGSTA
SAAYN
AEVMA
VIGRM
ASTHG
DRSFS
WLDQW
VSHGQ
IFNDK
ILHTL
HRKSL
2 , 4 6 3 :
2 , 4 6 6 :
2 , 4 7 5 :
2 , 4 9 4 :
2 , 5 1 3 :
2 , 5 1 9 :
2 , 5 6 0 :
2 , 7 8 9 :
2 , 8 0 8 :
2 , 8 1 3 :
HHGDP
DPSYR
TQPWS
TVGQT
PSQAN
KKLLG
DYEME
TGHCN
QRSAG
SFKRN
S)x(R
SYR
T)x(K
TLK
S)x(K
SPK
S)x(R
SPR
T)x(K
TKK
T)x(K
TRK
T)x(R
TQR
S)x(R
SGR
S)x(K
SFK
S)x(K
SIK
TLKET
ETQPW
GSEGY
ARKSM
LLGTR
SFDHL
ISSSQ
TRHGS
RNSIK
KIV*
* * * * * * * * * * * * * * * * * * *
ilycosylation site *
* * * * * * * * * * * * * * * * * * *
s been known for a long time [1] that potential N-glycosylation sites are 
fic to the consensus sequence Asn-Xaa-Ser/Thr. It must be noted that the 
nee of the consensus tripeptide is not sufficient to conclude that an 
agine residue is glycosylated, due to the fact that the folding of the 
in plays an important role in the regulation of N-glycosylation [2]. It 
ieen shown [3] that the presence of proline between Asn and Ser/Thr will 
it N-glycosylation; this has been confirmed by a recent [4] statistical 
sis of glycosylation sites, which also shows that about 50% of the sites 
have a proline C-terminal to Ser/Thr are not glycosylated.
st also be noted that there are a few reported cases of glycosylation 
with the pattern Asn-Xaa-Cys; an experimentally demonstrated occurrence 
e— (12%)[Hit space to continue, Del to abort] 
ch non-standard site is found in the plasma protein C [5].
ensus pattern: N-{P)-[ST]-{P)
[N is the glycosylation site]
jYCOSYLATION N~(P)(S,T)~(P)
N~P(S)~P 
45: KECLI NISK YKFSL
639: IPSSG
N~P(S)~P
NTSQ MSMDH
664: RKGKG
N~P(S)~P 
NSSM DSAAG
839: LQEWI
N~P(T)~P 
NMTG FLCAL
974: KNLLD
N~P(T)~P 
NHTE GSSEH
1,472: TSDAV 
1,542: HWSSL 
1,652: GFAYD 
1,882: LCIPA
N~P(S)~P 
NHSL
N~P(T)~P 
NLTS
N~P(S)~P
NVSA
N~P(T)~P 
NNTL
SFISD
SKFEE
VYIYN
FIVSI
N~P(S)~P 
2,070: LMLSF NNSL DVAAH
2,756: ITANL
N~P(S)~P
NLSN SMTSL
* * * * * * * * * * * * * * * * * *
e zipper pattern *
* * * * * * * * * * * * * * * * * *
ure, referred to as the 'leucine zipper' [ 1 , 2 ] ,  has been proposed to
how some eukaryotic gene regulatory proteins work. The leucine zipper
of a periodic repetition of leucine residues at every seventh 
i over a distance covering eight helical turns. The segments containing 
>eriodic arrays of leucine residues seem to exist in an alpha-helical 
ition. The leucine side chains extending from one alpha-helix interact 
>se from a similar alpha helix of a second polypeptide, facilitating 
ition; the structure formed by cooperation of these two regions forms a
:oil [3]. The leucine zipper pattern is present in many gene regulatory 
», such as:
XATT-box and enhancer binding protein (C/EBP).
:AMP response element (CRE) binding proteins (CREB, CRE-BP1, ATFs). 
Tun/APl family of transcription factors, 
feast general control protein GCN4.
Eos oncogene, and the fos-related proteins fra-1 and fos B.
2-myc, L-myc and N-myc oncogenes.
Dctamer-binding transcription factor 2 (Oct-2/OTF-2). 
sus pattern: L-x(6)-L-x(6)-L-x(6)-L
ces known to belong to this class detected by the pattern: All those 
ned in the original paper, with the exception of L-myc which has a Met 
d of the second Leu.
sequence(s) detected in SWISS-PROT: some 600 other sequences from every 
ry of protein families.
as this is far from being a specific pattern you should be cautious in 
the presence of such pattern in a protein if it has not been shown to 
uclear DNA-binding protein.
I_ZIPPER Lx6Lx6Lx6L
Lx{6}Lx{6)Lx(6)L 
1 83 4: VPGTL LNIALLNLGSSDPSLRSAAYNL LCALT
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
saminoglycan attachment site *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
lycans [1] are complex glycoconjugates consisting of a core protein to 
variable number of glycosaminoglycan chains (such as heparin sulfate, 
i t m  sulfate, etc.) are covalently attached. The glycosaminoglycans are 
d to the core proteins through a xyloside residue which is in turn is 
to a serine residue of the protein. A consensus sequence for the 
ent site seems to exist [2], However, it must be noted that this 
us is only based on the sequence of three proteoglycans core proteins.
sus pattern: S-G-x-G
[S is the attachment site] 
onal rule: There must be at least two acidic amino acids from —2 to -4 
relative to the serine.
^MINOGLYCAN SGxG
821: RMSHV SGGG SIDLS
sine kinase phosphorylation site *
l r *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ites of tyrosine protein kinases are generally characterized by a lysine 
irginine seven residues to the N-terminal side of the phosphorylated 
le. An acidic residue (Asp or Glu) is often found at either three or 
ssidues to the N-terminal side of the tyrosine [1,2,3]. There are a 
of exceptions to this rule such as the tyrosine phosphorylation sites 
Lase and lipocortin II.
isus pattern: [RK]-x(2)-[DE]-x(3)-Y 
or [RK]-x(3)-[DE]-x(2)-Y
[Y is the phosphorylation site!
)SPHO SITE
2.549: TPPKM
(R,K)x{2,3)(D,E)x(2,3)Y 
(R)x{3)(E)x{2)Y 
RRVAETDY EMETQ
2,550: PPKMR
(R)x{2)(E)x{2}Y
RVAETDY EMETQ
r * * * * * * * * * * * *
lation site * -Consensus pattern: x-G-[RK]-[RK]
,************ tx 1S amidation site]
-ecursor of hormones and other active peptides which are C-terminally 
:ed is always directly followed [1,2] by a glycine residue which provides
lide group, ana most often by at least two consecutive basic residues 
>r Lys) which generally function as an active peptide precursor cleavage 
Although all amino acids can be amidated, neutral hydrophobic residues 
is Val or Phe are good substrates, while charged residues such as Asp or 
ire much less reactive. C-terminal amidation has not yet been shown to 
in unicellular organisms or in plants.
EION xG(R,K)(R,K)
xG(R)(K)
1,128: ESAQT GGRK RGMSR
xG(R)(R)
1,510: RDHKA VGRR PFDKM
GTPase-activating proteins signature *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
oteins are membrane-associated molecular switches that bind GTP and GDP 
owly hydrolyze GTP to GDP [1]. This intrinsic GTPase activity of ras is 
ated by a family of proteins collectively known as 'GAP' or GTPase- 
ting proteins [2]. As it is the GTP bound form of ras which is active, 
proteins are said to be down-regulators of ras. Proteins known to
s such activity are listed below:
malian GAP. GAP can down-regulate wild-type ras, but fails to do so with 
ogenic, mutated ras.
1 and IRA2, the functional equivalents of GAP in yeast. They regulate
RAS-cyclic AMP pathway, controlling cell growth.
1, the fission yeast protein that regulates rasl in that organism.
2, a yeast protein that activates BUD1/RSR1 and which participates in 
regulation of bud-site selection [3].
an neurofibromin (gene NF1) [4]. NF1 is associated with type 1 
rofibromatosis, one of the most frequently inherited genetic diseases 
racterized, in part, by multiple neural tumors. NF1 has been shown 
etically and biochemically to interact with and stimulate the GTPase 
ivity of h-ras.
sophila Gapl [5], which acts as a negative regulator of signalling by 
Sevenless receptor tyrosine kinase involved in eye development.
e above proteins are quite large (from 765 residues for sari to 3079 
es for IRA2) but share only a limited (about 250 residues) region of 
ce similarity, referred to as the 'catalytic domain'. The most conserved 
within this domain contains a 12 residue motif which seems to be 
teristic of this family of proteins [2].
nsus pattern: F-L-R-x(3)-P-[AV]-x(3)-P
nces known to belong to this class detected by the pattern: ALL. 
sequence(s) detected in SWISS-PROT: NONE.
di!f?rent GAPs for the rap and rho/rac subfamilies
in  [si1 a° • w S
PASE_ACTIV FLRx3P(A,V)x3P
FLRx{3}P(A)x{3}P 
1,389: VGSAM FLRFINPAIVSP YEAGI
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
- and cGMP-dependent protein kinase phosphorylation site * 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
las been a number of studies relative to the specificity of cAMP- and 
spendent protein kinases [1,2,3]. Both types of kinases appear to share 
srence for the phosphorylation of serine or threonine residues close to
st two consecutive N-terminal basic residues. It is important to note 
lere are quite a number of exceptions to this rule.
nsus pattern: [RK](2)-x-[ST]
[S or T is the phosphorylation site]
»HOSPHO_SITE (R,K)2x(S,T)
(K){2}x(T)
583: LFYIC KKLT SHQML
( R ) (2}x(S)
815: KTIVK RRMS HVSGG
(R,K)(2}x(S)
873: GPVSE RKGS MISVM
(R,K){2}x(S)
2,236: FGCIS KRVS HGQIK
(R,K) (2}x(S)
2,573: QHPHL RKVS VSESN
(R,K){2}X(S)
2,810: SAGSF KRNS IKKIV
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